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Strength training (ST) is considered an intervention of choice for the prevention
and treatment of the adverse consequences of sarcopenia. Our group previously reported
that the CA dinucleotide repeat polymorphism in the promoter region of the insulin-like
growth factor 1 (IGF1) gene influenced the muscle strength response to ST in
Caucasians. Other studies have shown that the insulin-like growth factor binding protein-
3 (IGFBP-3) is a modulator of IGF-1 in circulation and is present in skeletal muscle. The
-202 polymorphism in the promoter region of the IGFBP3 gene has been shown to
influence IGFBP-3 levels. In addition, there have been reports that IGF-1 and calcineurin
are linked in a common pathway to induce skeletal muscle cell hypertrophy. A previous
study has shown that an insertion/deletion (I/D) polymorphism in the gene encoding the
regulatory subunit of calcineurin, calcineurin B, influences cardiac hypertrophy. To
examine the influence of these IGF pathway gene polymorphisms on muscle mass and
strength responses to ST, we studied 128 Caucasian and African American men and
women before and after a 10-wk single-leg knee extension ST program. One repetition
maximum strength (1 RM), muscle volume (MV), and muscle quality (MQ) were
assessed at baseline and after 10 wk of ST.
There was a significant combined gene effect, including both IGF1 main effect
and IGF1 by calcineurin B (PPP3R1) gene by gene interaction effect, for change in
strength with ST (P < 0.01). There was also a significant combined gene effect for IGF1
on change in MQ (P < 0.05). The gene by gene interaction of IGF1 and PPP3R1 by
itself, approached significance for change in strength with ST (P = 0.07) and was right on
the border of significance for change in MQ (P = 0.05). Moreover, PPP3R1 II
homozygotes approached significance for a greater increase in MV with ST than PPP3R1
D-allele carriers (P = 0.06). There were no significant combined gene effect for PPP3R1
(i.e., PPP3R1 main effect combined with PPP3R1 by IGF1 interaction effect) for change
in strength or MQ with ST. Also, there were no significant influences of the IGFBP3
polymorphism on muscle phenotypic responses to ST. These data extend our previous
findings for IGF1 by indicating that IGF pathway gene polymorphisms may influence
muscle phenotypic responses to ST in Caucasian and African American older men and
women.
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Losses of muscle mass and strength with aging, referred to as sarcopenia, have been
well-documented (141, 147) and have been associated with many adverse health
consequences, including increased mortality (159). Strength training (ST) has been
shown to be an effective intervention for the prevention and treatment of sarcopenia with
few side effects (101, 224). Nevertheless, increases in muscle mass and strength are
highly variable among individuals (107, 135), suggesting a genetic influence. Further
support for a genetic influence on muscle phenotypes comes from twin studies which
have shown that up to 90% of the variance in baseline muscle mass and ~ 60% of the
variance in baseline muscle strength is heritable (103). Though accounting for a smaller
percent of the variance, the response of these muscle phenotypes to ST also appear to be
heritable (260). However, there have been few candidate genes identified as playing a
role in influencing muscle responses to ST (41, 69, 107, 127, 211), and there are no
reports, that we are aware of, on the influence of candidate genes that are linked in a
common biological pathway.
Insulin-like growth factor-1 (IGF-1) is a potent mitogen and anabolic agent
important in the growth of various body tissues, including skeletal muscle (67, 254). The
decline of circulating levels of IGF-1 with advancing age is related to the loss of muscle
mass and strength that occurs with age (264). ST increases skeletal muscle IGF-1 levels,
even in the elderly (64, 90) and this locally produced IGF-1 can stimulate muscle
hypertrophy through activation of satellite cells and increased protein synthesis rates (1,
98, 240, 289). Nevertheless, significant variability in skeletal muscle IGF-1 and muscle
phenotype responses with ST have been reported (64, 91).
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Some of this variability in response to ST may be accounted for by a CA
dinucleotide repeat polymorphism in the promoter region of the IGF1 gene, which
encodes for the IGF-1 protein (127). Other polymorphisms within the insulin-like growth
factor pathway of genes are thought to be involved in muscle hypertrophy and strength
response to ST, but no studies have been reported, to our knowledge, concerning their
influence on muscle phenotypic response to ST. Two examples of such genes within the
insulin-like growth factor pathway, are insulin-like growth factor binding protein 3
(IGFBP3) and calcineurin B (PPP3R1) genes.
Most circulating IGF-1 is bound by IGFBP-3 (22). IGFBP-3 can potentiate or
inhibit the action of IGF-1 on skeletal muscle (63). Although it is unclear whether
IGFBP-3 is the primary carrier of IGF-1 in skeletal muscle, there is evidence that it does
exist in skeletal muscle (70, 238, 249) and that increased secretion of IGFBP-3 in primary
adult human skeletal muscle cells is stimulated by IGF-1 (70). There have been several
reports that the -202 polymorphism in the promoter region of the IGFBP3 gene can
influence the levels of this protein in circulation (47, 111, 246), which may in turn
modulate the activity of IGF-1. Deal et al. (47) showed that this polymorphism was
directly related to promoter activity of the IGFBP3 gene, suggesting a functional
association that potentially affects protein levels of IGFBP-3.
IGF-1-induced muscle hypertrophy in skeletal muscle cells is at least partially
mediated by a Ca2+-dependent calcineurin signaling pathway (172, 240). Calcineurin is a
Ca2+/calmodulin-dependent protein phosphatase, which consists of a catalytic subunit,
designated as calcineurin A, and a regulatory Ca2+-binding subunit, designated as
calcineurin B (281). Calcineurin plays a role in both cardiac (166, 214) and skeletal
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muscle hypertrophy (54, 55, 163, 172, 240, 257). Tang et al. (258) suggested that the 5-
base pair (bp) insertion/deletion (I/D) polymorphism in the promoter region of the
PPP3R1 gene was associated with the incidence of inappropriately high left ventricular
mass in severe hypertensives (258). Due to the influence that this polymorphism may
have on hypertrophy in cardiac muscle, and the fact that cardiac and skeletal muscle
share common hypertrophic pathways (182), it is possible that this polymorphism may
influence hypertrophic responses in skeletal muscle as well.
The purpose of this study was to test the hypothesis that polymorphisms in the
promoter regions of the IGF1, IGFBP3, and PPP3R1 genes, which may be linked in a
common biological pathway, will significantly influence the changes in muscle volume,
strength, and MQ with ST in older Caucasian and African American men and women.
To test this association, the CA dinucleotide repeat polymorphism in the promoter region
of the IGF1 gene, the -202 locus polymorphism in the promoter region of the IGFBP3
gene, and the 5-bp I/D polymorphism in the promoter region of the PPP3R1 gene will be
studied.
METHODS
Subjects. One hundred twenty-eight previously physically inactive, relatively
healthy men (n = 58) and women (n = 70) between the ages of 50 and 85 years
volunteered to participate in this study. A small portion of the subjects (n = 10) were
from a previous study cohort in our laboratory who underwent the identical strength
training (ST) intervention program (107). Another portion (n = 57) were from the same
cohort, but used in a previous manuscript (127). Prior to participation, all subjects
underwent a phone-screening interview, received medical clearance from their primary
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care physician, and completed a detailed medical history. They were nonsmokers, free of
significant cardiovascular disease and metabolic or musculoskeletal disorders that would
affect their ability to safely perform heavy resistance exercise. Subjects who were
already taking medications for at least three weeks prior to the start of the study were
permitted into the study as long as they did not change their medications or dosages at
any time throughout the study. After all methods and procedures were explained,
subjects read and signed a written consent form which was approved by the Institutional
Review Board of the University of Maryland, College Park. All subjects were
continually reminded throughout the study not to alter physical activity levels or dietary
habits for the duration of the study. Body weight was monitored weekly throughout the
study to ensure compliance in maintaining a stable diet.
Body composition assessment. Body composition was estimated by dual-energy
X-ray absorptiometry (DXA) using the fan-beam technology (Hologic, model QDR
4500A, version 8.21 software, Waltham, MA). A total body scan was performed at
baseline and again after the ST program to assess total body and thigh fat-free mass
(FFM), fat mass, and percent body fat. A standardized procedure for patient positioning,
apparel, and utilization of the QDR software was used. Total body FFM was defined as
lean soft tissue mass plus total body bone mineral content (BMC). The coefficients of
variation (CV) for all DXA measures of body composition were calculated from repeated
scans of 10 subjects who were scanned three consecutive times with repositioning. The
CV was 0.6% for FFM and 1.0% for percent body fat. The scanner was calibrated daily
against a spine calibration block and step phantom block supplied by the manufacturer.
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In addition, a whole body phantom was scanned weekly to assess any machine drift over
time.
Strength testing. One repetition maximum (1 RM) strength tests were performed
before and after the ST program using an air-powered knee-extension resistance machine
(Keiser A-300 Leg Extension machine). The 1 RM test was defined as the maximal
resistance that could be successfully moved through the full range of motion with proper
form one time. Approximately the same number of trials (6-8) and the same rest periods
between the last few trials (~ 60 sec) were used to reach the 1 RM both before and after
training. Before the regular ST program and the 1 RM testing were performed, subjects
underwent at least three familiarization sessions in which the participants completed the
training program exercise with little or no resistance and were instructed on proper warm-
up, stretching and exercise technique. These low-resistance training sessions were
conducted in order to familiarize the subjects with the equipment, to help control for the
large 1 RM strength gains that commonly result from skill (motor learning) acquisition
during the initial stages of training, and to help prevent injuries and reduce muscle
soreness following the strength training protocol. The same investigator conducted
strength tests for each subject both before and after training using standardized
procedures with consistency of seat adjustment, body position, and level of vocal
encouragement. All subjects were positioned with a pelvis strap (seat belt) to minimize
the involvement of other muscle groups. The 1 RM was achieved by gradually
increasing the resistance after each successful repetition from an estimated sub-maximal
load until the maximal load was obtained, which resulted in failure to successfully
complete a repetition when a higher load was introduced.
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Training program. The training program consisted of unilateral (one-legged)
training of the knee extensors of the dominant leg, three times per week, for ~ 10 weeks.
Training was performed on a Keiser A-300 air powered leg extension machine, which
allowed for ease of changing the resistance without interrupting the cadence of the
exercise. The untrained control leg was kept in a relaxed position throughout the training
program.
Following the warm-up, the training consisted of five sets of knee extension
exercise for those < 75 yrs of age and four sets for those ≥ 75 yrs of age, to avoid
overtraining for this age group. The protocol was designed to combine heavy resistance
with high volume exercise, while eliciting near maximal effort on all repetitions. The
first set was considered a warm-up set and consisted of five repetitions at 50% of the
previously determined 1 RM strength value. The second set consisted of five repetitions
at the current 5 RM value. The 5 RM value was increased continually throughout the
training program to reflect increases in strength. The first four or five repetitions of the
third set were performed at the current 5 RM value, then the resistance was lowered just
enough to complete one or two more repetitions before reaching muscular fatigue. This
process was repeated until a total of 10 repetitions were completed. This same procedure
was used for the fourth and fifth sets, but the total number of repetitions was increased in
these sets to 15 and 20, respectively. The second, third, fourth, and fifth sets were
preceded by rest periods lasting 30, 90, 150, and 180 seconds, respectively. The muscle
shortening phase (formerly called concentric phase) of the exercise was performed in ~
two seconds, and the lengthening phase (formerly called eccentric phase) (135) of each
repetition took ~ three seconds.
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Muscle volume. To quantify quadriceps muscle volume (MV), computed
tomography (CT) imaging of the trained and untrained thighs was performed (GE
Lightspeed Qxi, General Electric, Milwaukee) at baseline and during the last week of the
10-week unilateral ST program. Axial sections of both thighs were obtained from the
most distal point of the ischial tuberosity to the most proximal part of the patella, while
subjects were in a supine position. Measurements of MV in the untrained leg served as a
control for seasonal, methodological, and biological variation of MV, by subtracting the
changes in the control leg from the training-induced changes in the trained leg. Section
thickness was set at 10 mm, with 40 mm separating each section, based on previous work
in our laboratory with slight modifications (266). Quadriceps MV was estimated based
on using a 4 cm interval between the center of each section. Each CT image was
obtained at 120 kVp with the scanning time set of 1 s at 40 mA. A 48-cm field of view
and a 512 X 512 matrix was used to obtain a pixel resolution of 0.94 mm. Using Medical
Image Processing, Analysis, and Visualization (MIPAV) software (NIH, Bethesda), two
technicians performed analyses of all images for each subject. Briefly, for each axial
section, the cross-sectional area (CSA) of the quadriceps muscle group was manually
outlined as a region of interest. The quadriceps CSA was outlined in each 10 mm axial
image from the first section closest to the superior border of the patella to a point where
the quadriceps muscle group is no longer reliably distinguishable from the adductor and
hip flexor muscle groups. The technicians were blinded to subject identification, date of
scan, and training status, for both baseline and after training analysis. Repeated
measurement coefficient of variation (CV) was calculated for each investigator based on
repeated measures of selected axial sections of one subject on two separate days.
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Average intra-investigator CV was 1.7% and 2.3% for investigator one and two,
respectively. The average inter-investigator CV was < 1%. The final MV was calculated
using the truncated cone formula as we described previously (266).
In addition, data was used in this analysis from 10 subjects from a previous cohort.
All methods for testing and training these subjects were the same as in the current cohort,
except that MV was measured by magnetic resonance imaging (MRI). However,
Mitsiopoulos et al. (164) have shown a correlation of 0.99 between CT and MRI for the
measurement of skeletal MV.
Genotyping. Genomic DNA was prepared from EDTA-anticoagulated whole
blood samples by standard salting-out procedures (Puregene DNS Extraction, Gentra
Systems). The CA microsatellite of IGF1 was amplified by polymerase chain reaction
(PCR) of genomic DNA using fluorescence-tagged primers (222). An ABI 3100 DNA
sequencer (PE Applied Biosystems) and the ABI Genescan/Genotyper 2.5 software
program (PE Applied Biosystems) were used to determine the genotype of the CA repeat
microsatellite in the promoter region of the IGF1 gene. Genotype assignment was based
on the method described by Rosen et al. (e.g., 19 CA repeats = 192 base pairs), in which
these authors found the 192 allele to be the most common, and thus compared it with
other alleles for this microsatellite (222). Therefore the genotype assignments in the
present study were 192 homozygotes, 192 heterozygotes, and noncarriers of the 192
allele. Genotyping of the IGFBP3 -202 polymorphism was performed using PCR and
restriction digest of the PCR product with Alw21I as described by Deal et al. (47) with
genotype groups designated as AA homozygotes, AC heterozygotes, and CC
homozygotes. The 5-base pair (bp) insertion/deletion (I/D) polymorphism located at the -
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1059 to -1063 loci relative to the transcription start site of the PPP3R1 gene was
genotyped using standard PCR and AseI restriction digest as described by Tang et al.
(258) with genotype groups designated as II homozygotes, ID heterozygotes, and DD
homozygotes. Direct sequencing was used to confirm the accuracy of all genotyping
methods.
Statistical analyses. All statistical analyses were performed using SAS software
(SAS version 9.1, SAS Institute, Cary, NC). Changes in body weight, percent body fat,
and fat-free mass (FFM) with strength training (ST) within each sex, race, and genotype
group were tested using paired t-tests. Fixed effect linear models were used to test
differences in baseline muscle phenotypes (1 RM strength, MV, and MQ) among the
categorical variables: sex, race, and genotype groups and to test for differences in the
change in muscle phenotypes with ST among sex, race, and genotype groups. Initial
linear models for each muscle phenotype (dependent variable) included the main effect of
the following independent variables: the CA dinucleotide repeat polymorphism of IGF1,
the -202 locus polymorphism in the promoter region of IGFBP3, and the 5-bp I/D
polymorphism of calcineurin B (PPP3R1). The initial models also included their two-
way interactions with each other, as well as with race (Caucasian and African American)
and with sex and hormone replacement therapy status (male, female on hormone
replacement therapy, or female not on hormone replacement therapy), when sufficient
data existed (n ≥ 5). The only exception was for the PPP3R1 by IGFBP3 gene by gene
interaction, in which there were only four subjects who were both PPP3R1 D-allele
carriers and IGFBP3 CC homozygotes, and for the IGF1 by IGFBP3 gene by gene
interaction, in which there were only four subjects who were both IGF1 non-carriers of
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the 192 allele and IGFBP3 AA homozygotes. It was not possible to combine both of
these groups with IGFBP3 AC heterozygotes in order to have a genotype group with n ≥
5. Therefore, these interactions were tested in the model with n = 4.
Because sample sizes for each genotype were a function of different allelic
frequencies, the experiment was unbalanced. Therefore, non-independent sources of
variation were removed using a backward elimination process similar to that previously
described (97). The continuous variables age, height, body weight, body mass index, and
baseline muscle phenotypes for models testing differences in change in muscle
phenotypes were included in the models as covariates. For those final models in which
interaction terms were present, the significance of the contribution for the total gene
effects, including interaction and main effects, was tested by comparing the error term
sums of squares for the full model (all gene effects and error term) with the error term
sums of squares for the model in which the gene effects of interest were removed from
the model. Results are presented as means (SD) for age, height, body weight, percent
body fat and FFM, and as least squares means ± SE for muscle phenotypes.
For all analyses the initial threshold of significance was set to P < 0.05. Mean
comparisons were made using t-tests, with P-values adjusted using a Bonferroni
correction to reduce the chance of a Type I error. The P-values calculated from the linear
models were multiplied by the number of comparisons for the effect of interest to
determine the P-value with Bonferroni correction.
Race by genotype. To determine whether data for change in muscle phenotypes
with ST for African Americans and Caucasians could be pooled, gene by race
interactions were tested in each linear model for the IGF1, IGFBP3, and PPP3R1 gene
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polymorphisms. For the IGF1 gene polymorphism there was insufficient data for the
IGF1 192-allele homozygotic African Americans. Therefore, initially for each of the
linear models IGF1 192-allele homozygotes and 192-allele heterozygotes were combined
so that sufficient data existed to test the IGF1 by race interaction. However, once this
interaction term was no longer significant in the model, and removed from the model, the
IGF1 gene effects were tested with all IGF1 genotype groups (192-allele homozygotes,
192-allele heterozygotes, and noncarriers of the 192-allele). In addition, to control for the
potential influence of race on muscle phenotype responses to ST, race was used as a
covariate in all linear models.
Percent variability explained by genotype. To estimate the percent variability for
the change in strength, MV, and MQ with ST attributable to IGF1, IGFBP3, and PPP3R1
genotypes and any relevant gene by gene interactions, the sums of squares of the gene or
gene by gene interaction of interest was divided by the sums of squares of all gene effects
present in the model and the sums of squares of the error. With this procedure, it was
assumed that each gene involved in a gene by gene interaction contributes an equal
portion to the percent variability.
Power analyses. Statistical power for the three primary comparisons was
estimated for the IGF1, IGFBP3, and PPP3R1 genotype effect on each variable using all
data from the present study. Statistical power for the changes in strength was estimated




Allele and genotype frequencies. Tables 1-3 show the allele and genotype
frequencies for the IGF1, IGFBP3, and PPP3R1 promoter polymorphisms. These
frequencies were similar to those reported previously (47, 49, 222, 258). Data for
PPP3R1 DD genotype group was combined with the PPP3R1 ID genotype group, as D-
allele carriers, and were compared with data from PPP3R1 II homozygotes because there
was only one subject who was a PPP3R1 carrier.
Physical characteristics. Tables 4 and 5 show that there were no significant
changes in body weight, percent body fat, or fat-free mass (FFM) with ST within sex or
race groups. Tables 7-9 and 11-15 of Appendix I show that there were no significant
within genotype group differences for change in body weight, percent body fat, or FFM
with ST, except those with MV data who were IGF1 noncarriers of the 192 allele, who
had a significant decrease in percent body fat with ST (P < 0.001) as shown in Table 10
of Appendix I. Table 4 shows that men had greater mean values than women for baseline
1 RM strength (P < 0.001), MV (P < 0.001), and MQ (P < 0.01). Table 5 shows that
African Americans had greater MV than Caucasians at baseline (P < 0.001). However,
there was a trend for a significant race by IGFBP3 interaction for baseline strength and a
significant race by IGFBP3 interaction for baseline MQ as shown in Figures 5-6 of
Appendix I. Therefore, it was difficult to interpret if there were significant racial
differences in these baseline muscle phenotypes because the racial difference was
inconsistent across IGFBP3 genotype groups.
Genotype associations with muscle phenotypes at baseline. Tables 7-9 of
Appendix I show that there were no significant differences in baseline muscle phenotypes
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among genotype groups. The IGFBP3 by race interaction for baseline 1 RM strength
approached significance (P = 0.06) as shown in Figure 5 of Appendix I. Although
IGFBP3 CC homozygotic African Americans had a significantly greater baseline 1 RM
strength than Caucasians who were IGFBP3 CC homozygotes (32 ± 2.5 vs 24 ± 1.3 kg, P
= 0.04), this difference was not consistent across IGFBP3 genotypes (24 ± 1.8 vs 24 ± 1.2
kg, P = 1.00 for AA homozygotes, 26 ± 1.5 vs 23 ± 1.0 kg, P = 1.00 for AC
heterozygotes), due to the IGFBP3 by race interaction. There was also a significant
IGFBP3 by race interaction for baseline MQ (P < 0.05) as shown in Figure 6 of
Appendix I. Thus, differences between IGFBP3 genotype groups for MQ were not
consistent between race groups, making it difficult to interpret the influence of IGFBP3
on baseline MQ.
Muscle phenotype responses to ST for sex and race groups. Men had
significantly greater absolute (8.9 ± 0.84 vs 5.7 ± 0.72 kg, P < 0.01) and relative (%)
increases (38 ± 3.6 vs 27 ± 3.1%, P < 0.05) in knee extension 1 RM strength with ST
than women. It was not possible to determine if there was a significant difference among
races for absolute and relative change in knee extension 1 RM strength because of an
IGFBP3 by race interaction as shown in Figure 2 and Figure 7 of Appendix I. There was
no significant difference between the absolute (140 ± 16 vs 110 ± 14 cm3, P = 0.10) or
relative (10 ± 1.1 vs 7.1 ± 0.99 %, P = 0.08) changes in MV with ST between men and
women. In addition, there were no significant differences between African Americans
and Caucasians for changes in absolute (130 ± 14 vs 110 ± 11 cm3, P = 0.31) or relative
change (8.5 ± 0.97 vs 7.6 ± 0.78%, P = 0.39) in MV with ST. Likewise, there was no
significant difference in the absolute (3.5 ± 0.39 vs 2.8 ± 0.42 kg/cm3 *10-3, P = 0.23) or
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relative (22 ± 2.1 vs 14 ± 2.3 %, P = 0.30) changes in MQ for men compared to women.
Also, there was a borderline significant difference in the absolute change in MQ in
African Americans compared to Caucasians (3.5 ± 0.41 vs 2.6 ± 0.33 kg/cm3 *10-3, P =
0.05). The relative difference in MQ between African Americans and Caucasians could
not be determined due to an IGFBP3 by race interaction for this phenotype as shown in
Figure 8 of Appendix I.
Race by gene interaction for change in muscle phenotypes with ST. There were
no significant gene by race interactions for the changes in 1 RM strength, MV, or MQ
with ST. There was a trend however, for a significant IGFBP3 gene by race interaction
for change in 1 RM strength with ST (P = 0.09). Because of the absence of a significant
gene by race interaction, data from African Americans and Caucasians were averaged
across races for all other genotype analyses.
IGF1 influence on 1 RM strength, MV and MQ responses to ST.
1 RM response: Table 10 of Appendix I shows that there was no significant
influence of the IGF1 main effect on the change in muscle strength with ST (P = 0.51).
Figure 1 shows that the gene by gene interaction between IGF1 and PPP3R1 approached
significance for change in strength with ST (P = 0.07). In this case, IGF1 192
homozygotes and heterozygotes responded similarly, while IGF1 noncarriers of the 192
allele responded differently with respect to PPP3R1 genotype groups. In fact, PPP3R1 II
homozygotes who were also 192-allele heterozygotes for IGF1, had significantly greater
increases in strength with ST than PPP3R1 II homozygotes, who were also noncarriers of
the 192 allele for IGF1 (8.4 ± 0.66 vs 4.7 ± 0.89 kg, P < 0.01). However, there were no
significant differences between PPP3R1 II homozygotes who were IGF1 192
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homozygotes and either PPP3R1 II homozygotes who were IGF1 192 heterozygotes (6.9
± 0.81 vs 8.4 ± 0.66 kg, P > 0.05) or PPP3R1 II homozygotes who were noncarriers of
the 192 allele (6.9 ± 0.81 vs 4.7 ± 0.89 kg, P > 0.05). Also, Table 19 of Appendix I
shows that for PPP3R1 D-allele carriers there was no significant difference in change in
strength with ST among IGF1 genotype groups. The IGF1 by IGFBP3 and IGF1 by race
interactions for change in muscle strength with ST were not significant. Table 20 of
Appendix I shows that for all relevant comparisons, there were no significant differences
among genotype groups for change in strength with ST for the IGF1 by IGFBP3
interaction. The IGF1 by sex and hormone replacement therapy status interaction could
not be tested due to insufficient sample size. There was a significant combined gene
effect, including both IGF1 main effect and IGF1 by PPP3R1 gene by gene interaction
effect, on change in strength with ST (P < 0.01). Table 6 shows that this total gene effect
accounted for 3.41% of the variability in change in muscle strength with ST.
MV response: Table 13 and Figure 9 of Appendix I show that there was no
significant influence of the IGF1 main effect on the change in MV with ST (P = 0.36).
There were no significant interactions for IGF1 with either IGFBP3 or PPP3R1 for
change in MV with ST. For all relevant comparisons, there were no significant
differences among genotype groups change in MV (Tables 22-23 of Appendix I) with ST
for these gene by gene interactions. Also there was no significant interaction between
IGF1 and race for change in MV with ST. The IGF1 by sex and hormone replacement
therapy status interaction could not be tested due to insufficient sample size. Due to the
lack of at least a trend for a significant gene by gene or gene by race interaction involving
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IGF1 for change in MV, a combined gene effect for IGF1 for change in MV was not
determined.
MQ response: Table 16 of Appendix I shows that there was no significant
influence of the IGF1 main effect on the change in MQ with ST (P = 0.69). Figure 4
shows that the gene by gene interaction between IGF1 and PPP3R1 was right on the
borderline for being significant for the change in MQ with ST (P = 0.05). There was no
consistent MQ response to ST of PPP3R1 genotype groups across IGF1 genotype
groups. Those who were both PPP3R1 II homozygotes and IGF1 192-allele
heterozygotes had a significantly greater increase in MQ with ST than PPP3R1 II
homozygotes who were IGF1 noncarriers of the 192 allele (3.7 ± 0.37 vs 1.8 ± 0.48
kg/cm3 *10-3, P < 0.01). PPP3R1 II homozygotes who were 192 homozygotes had
increases in MQ with ST that were not significantly different than either PPP3R1 II
homozygotes who were 192 heterozygotes (3.3 ± 0.45 vs 3.7 ± 0.37 kg/cm3 *10-3, P =
1.00) or PPP3R1 II homozygotes who were IGF1 noncarriers of the 192 allele (3.3 ±
0.45 vs 1.8 ± 0.48 kg/cm3 *10-3, P = 0.14). In addition, Table 19 of Appendix I shows
that for PPP3R1 D-allele carriers there were no significant differences in the change in
MQ with ST among IGF1 genotype groups. There was no significant gene by gene
interaction for IGF1 with IGFBP3 for change in MQ with ST. For all relevant
comparisons, there were no significant differences among genotype groups for change in
MQ with ST (Tables 26 of Appendix I) for this interaction. Also there was no significant
IGF1 by race interaction for change in MQ with ST. The IGF1 by sex and hormone
replacement therapy status interaction could not be tested due to insufficient sample size.
There was a significant combined gene effect for IGF1, including both IGF1 main effect
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and IGF1 by PPP3R1 gene by gene interaction effect, for change in MQ with ST (P <
0.05).
IGFBP3 influence on 1 RM strength, MV, and MQ responses to ST.
1 RM response to ST: Table 11 of Appendix I shows that there was no significant
influence of the IGFBP3 main effect on the change in muscle strength with ST (P =
0.18). However, Figure 2 shows a gene by race interaction that approached significance
for the change in strength with ST for the -202 gene polymorphism for IGFBP3 (P =
0.09). For the IGFBP3 AA genotype group there was a larger difference in response
between races than for the other IGFBP3 genotype groups. African Americans who were
AA homozygotes had a significantly greater increase in strength with ST than AA
homozygotic Caucasians (10 ± 1.2 vs 5.3 ± 0.84 kg, P < 0.01), while there was no
significant differences between races for the change in strength for the IGFBP3 AC (7.2
± 0.98 vs 5.9 ± 0.69 kg, P = 1.00) and CC genotype groups (6.6 ± 1.71 vs 4.9 ± 0.83 kg,
P = 1.00). There were no significant gene by gene interactions for IGFBP3 with IGF1 or
PPP3R1 for change in strength with ST. Also for all relevant comparisons, there were no
significant differences among genotype groups for change in strength (Tables 26-27 of
Appendix I) with ST for these gene by gene interactions. The IGFBP3 by sex and
hormone replacement therapy status interaction could not be tested due to insufficient
sample size. The combined gene effect for IGFBP3, which included both the IGFBP3
main effect and the IGFBP3 by race interaction effect, was not significant (P > 0.05).
MV response to ST: Table 14 and Figure 10 of Appendix I show that there was
no significant influence of the IGFBP3 gene polymorphism on the changes in MV with
ST (P = 0.91). Moreover, there were no significant gene by gene interactions for
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IGFBP3 with IGF1 or PPP3R1 nor was there a significant IGFBP3 by race intearaction
for change in MV with ST. Also for all relevant comparisons, there were no significant
differences among genotype groups for change in MV (Tables 23-24 of Appendix I) with
ST for IGFBP3 by IGF1 or IGFBP3 by PPP3R1 gene by gene interactions. The IGFBP3
by sex and hormone replacement therapy status interaction could not be tested due to
insufficient sample size. Due to the lack of at least a trend for a significant gene by gene
or gene by race interaction involving IGFBP3 for change in MV, a combined gene effect
for IGFBP3 for change in MV was not determined.
MQ response to ST: Table 17 and Figure 11 of Appendix I show that there was no
significant difference among IGFBP3 genotype groups for change in MQ with ST (P =
0.66). Similarly, there was no significant gene by gene interaction between IGFBP3 and
either IGF1 or PPP3R1 for change in MQ with ST. For all relevant comparisons, there
were no significant differences among genotype groups for change in MQ with ST
(Tables 26-27 of Appendix I). Also, there was no significant IGFBP3 by race interaction
for change in MQ with ST. The IGFBP3 by sex and hormone replacement therapy status
interaction could not be tested due to insufficient sample size. Due to the lack of at least
a trend for a significant gene by gene or gene by race interaction involving IGFBP3 for
change in MQ, a combined gene effect for IGFBP3 for change in MQ was not
determined.
PPP3R1 influence on 1 RM strength, MV, and MQ responses to ST.
1 RM response: Table 12 of Appendix I shows that there was no significant
influence of the PPP3R1 main effect on the change in muscle strength with ST (P =
0.90). However, there was a trend for a significant interaction between PPP3R1 and
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IGF1 for the change in strength with ST (P = 0.07), as shown in Figure 1. There was no
significant interaction between PPP3R1 and IGFBP3 nor between PPP3R1 and race for
change in strength with ST. For all relevant comparisons, there were no significant
differences among genotype groups for change in strength (Tables 21 of Appendix I)
with ST for the PPP3R1 by IGFBP3 gene by gene interaction. The PPP3R1 by sex and
hormone replacement therapy status interaction could not be tested due to insufficient
sample size. The combined gene effect for PPP3R1, including both PPP3R1 main effect
and PPP3R1 by IGF1 gene by gene interaction effect, on the change in strength with ST
did not reach significance (P > 0.05). Figure 3 shows there was a trend for II
homozygotes of the I/D polymorphism in the promoter region of the PPP3R1 gene to
have a greater increase in MV with ST than D-allele carriers (130 ± 10 vs 100 ± 14 cm3,
P = 0.06). There were no significant gene by gene interactions between PPP3R1 and
either IGF1 or IGFBP3 for change in MV with ST. For all relevant comparisons, there
were no significant differences among genotype groups for change in MV (Table 22 and
24 of Appendix I) with ST for these gene by gene interactions. Also there was no
significant PPP3R1 by race interaction for change in MV with ST. The PPP3R1 by sex
and hormone replacement therapy status interaction could not be tested due to insufficient
sample size. Due to the lack of at least a trend for a significant gene by gene or gene by
race interaction involving PPP3R1 for change in MV, a combined gene effect for
PPP3R1 for change in MV was not determined.
MQ response: Table 18 of Appendix I shows that there was no significant
difference among PPP3R1 genotype groups for change in MQ with ST (P = 0.70).
Figure 4 shows that the gene by gene interaction between PPP3R1 and IGF1 was right
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on the borderline for being significant for the change in MQ with ST (P = 0.05). There
was no consistent MQ response to ST of PPP3R1 genotype groups across IGF1 genotype
groups. Those who were both PPP3R1 II homozygotes and IGF1 192-allele
heterozygotes had a significantly greater increase in MQ with ST than PPP3R1 II
homozygotes who were IGF1 noncarriers of the 192 allele (3.7 ± 0.37 vs 1.8 ± 0.48
kg/cm3 *10-3, P < 0.01). PPP3R1 II homozygotes who were 192 homozygotes had
increases in MQ with ST that were not significantly different than either PPP3R1 II
homozygotes who were 192 heterozygotes (3.3 ± 0.45 vs 3.7 ± 0.37 kg/cm3 *10-3, P =
1.00) or PPP3R1 II homozygotes who were IGF1 noncarriers of the 192 allele (3.3 ±
0.45 vs 1.8 ± 0.48 kg/cm3 *10-3, P = 0.14). In addition, Table 19 of Appendix I shows
that for PPP3R1 D-allele carriers there were no significant differences in the change in
MQ with ST among IGF1 genotype groups. There was no significant gene by gene
interaction for PPP3R1 with IGFBP3 for change in MQ with ST. For all relevant
comparisons, there were no significant differences among genotype groups for change in
MQ with ST (Tables 27 of Appendix I) for this interaction. Also there was no significant
PPP3R1 by race interaction for change in MQ with ST. The PPP3R1 by sex and
hormone replacement therapy status interaction could not be tested due to insufficient
sample size. There was not a significant combined gene effect for PPP3R1, including
both PPP3R1 main effect and IGF1 by PPP3R1 gene by gene interaction effect, for
change in MQ with ST (P > 0.05).
Gene polymorphism contribution to each muscle phenotype. Table 6 shows the
estimated percent of variability attributable to IGF1, IGFBP3, and PPP3R1 genotypes
and to each relevant gene by gene interaction for the changes in strength, MV, and MQ
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with ST. The contributions to the percent variability for the change in strength and MQ
with ST for the IGF1 and PPP3R1 gene by gene interactions was ~4.5 and 5.9%,
respectively. The single gene contributions of IGF1, IGFBP3, and PPP3R1 to percent
variability for change in strength and MQ were ~2-5% and 1-4%, respectively. For
change in MV with ST the single contributions were 2-3% for IGF1 and PPP3R1, while
the contribution of IGFBP3 was less than 1%.
DISCUSSION
To our knowledge, this is the first report that has investigated the influence of
genes linked in a common biological pathway on muscle phenotypic responses to
strength training (ST). The results offer partial support to the hypothesis that insulin-like
growth factor pathway genotypes influence changes in muscle phenotypes with ST, and
suggest that the IGF1 and PPP3R1 genes may be linked to influence muscle strength and
muscle quality (MQ) responses to ST.
The major finding of this study was that there was a significant combined gene effect
for IGF1, including both IGF1 main effect and IGF1 by PPP3R1 gene by gene
interaction effect, for change in strength with ST (P < 0.01). There was also a significant
combined gene effect for IGF1 on change in MQ (P < 0.05). The gene by gene
interaction for IGF1 by PPP3R1 approached significance for both the change in strength
and MQ with ST. The findings of this study complement those of a previous study from
our laboratory, which used some of the same subjects that were enrolled in this
investigation, and found significant IGF1 main effects on the change in muscle strength
response to ST (127). However, the present study extends these findings by showing that
combined gene effects for IGF1, including both IGF1 main effect and IGF1 by PPP3R1
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interaction effect, influence the strength and MQ responses to ST. In addition, although
our results showed only a trend towards statistical significance for gene by gene
interactions, they are novel in that they are the first, that we are aware of, which suggest a
possible interaction between genes in a common biological pathway to influence skeletal
muscle phenotypic responses to ST. Two previous studies, which investigated individual
genes of this biological pathway, have shown an individual influence of the IGF1
dinucleotide repeat polymorphism (127) and the PPP3R1 5-base pair (bp)
insertion/deletion (I/D) polymorphism (258) on muscle phenotypes.
We had anticipated significant gene influences on muscle phenotypic responses to
ST because previous studies have shown an influence of IGF-1 on calcineurin to promote
skeletal muscle cell hypertrophy (172, 240). However, these studies did not test the
influence of insulin-like growth factor pathway genes on responses to ST. The muscle
phenotypes that we investigated are complex phenotypes and would likely be influenced
by several genes in several different pathways. Thus, the contribution of two genes, even
linked in a pathway, may not be enough to significantly influence a muscle phenotype.
However, we found that the contribution to percent variability attributable to the IGF1
and PPP3R1 interaction was ~ 4.5% and 5.9%, respectively for the change in strength
and MQ with ST. These contributions are larger than the contributions of single genes
(~2%) reported to influence other muscle phenotypic responses to ST (41).
Another unexpected result was that there were no significant combined gene effects
for PPP3R1, including both PPP3R1 main effects and PPP3R1 by IGF1 interaction
effects, on the changes in strength and MQ with ST, despite our findings suggesting a
potential interaction with IGF1 to influence these phenotypic responses to ST. Tang et
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al. (258) reported that the 5-bp I/D polymorphism of the PPP3R1 gene influenced left
ventricular muscle mass in Caucasians and African Americans who were severely
hypertensive (258). They reported that those possessing at least one D-allele were
associated with greater risk of developing inappropriately high left ventricular mass than
those possessing two copies of the I allele. The functional significance of the variant (D)
allele of the PPP3R1 polymorphism is unknown. However, these authors suggested that
this variant eliminates a transcription factor binding site, and they hypothesized that this
is an important binding site for a repressor or inhibitor of PPP3R1 transcription. Our
results differed from those of Tang et al. (258) in that II homozygotes tended to increase
their skeletal muscle mass with overload more than D-allele carriers. These
discrepancies could be due to, 1) differences in the function of calcineurin B, especially
for the variant allele, in different tissues, 2) the nature of the load (ST vs hemodynamic
overload) inducing hypertrophy, 3) differences in population being studied, or 4) a
combination of two or more of these factors. We are unaware of any other studies that
have compared variations at this locus to the response of interventions designed to
change muscle mass or strength.
Contrary to our hypotheses, our results showed no significant influence of the
IGFBP3 genotype on changes in muscle phenotypes with ST, although we did observe a
trend for a significant race by IGFBP3 interaction to influence change in strength. We
hypothesized a significant influence of IGFBP3 because previous studies have shown
that levels of IGFBP-3, a major carrier of IGF-1 in circulation (22), can be influenced by
IGF-1 (278) and several studies have shown IGFBP-3 to be present in skeletal muscle. In
addition, Foulstone et al. (70) have shown that increased secretion of IGFBP-3 in primary
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adult human skeletal muscle cells is stimulated by IGF-1 (70). Moreover, previous
studies have shown that the -202 polymorphism in the promoter region of the IGFBP3
gene influences levels of the IGFBP-3 protein (47, 111, 246), although these studies have
shown that several factors can interact with this polymorphism to influence protein
levels, including female hormone levels, height, and BMI (47, 111, 246). In an in vitro
study, Deal et al. (47) showed that the -202 polymorphism influenced the promoter
activity of the gene, suggesting the possibility that this polymorphism could influence the
levels of the protein in skeletal muscle. However, it is also possible that the isoforms of
IGF-1 in skeletal muscle may be carried by a different binding protein than IGFBP-3.
Therefore, even though the -202 locus of the IGFBP3 gene may influence the levels of
IGFBP-3 in skeletal muscle, this protein may not be the major potentiator of IGF-1 action
in skeletal muscle.
In light of the trend for a significant IGFBP3 by race interaction for influencing
change in strength with ST, the influence of insulin-like growth factor pathway gene
polymorphisms on the muscle phenotypic responses to ST should be studied more
extensively in African Americans. Based on the different frequencies for the IGF1,
IGFBP3, and PPP3R1 genes between African Americans and Caucasians, it is possible
that race effects may have played a greater role than genotype effects for the findings we
observed. For example, African Americans had a higher frequency of the non-192 allele
for the IGF1 gene polymorphism compared with Caucasians. In contrast, Caucasians had
a higher frequency of the variant (C) allele for the IGFBP3 gene polymorphism
compared with African Americans. Finally, African Americans had a higher frequency
of the deletion allele for the PPP3R1 gene polymorphism compared with Caucasians.
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Similar differences between African Americans and Caucasians in allele frequencies for
the IGF1 and PPP3R1 gene polymorphisms have been observed in previous studies (49,
110, 120, 258). There are no reports that we are aware of on the frequency difference
between races for the IGFBP3 polymorphism. To determine if there was a difference in
response among races we tested for all possible genotype by race interactions and our
results suggested there was no difference, except for the IGFBP3 gene polymorphism for
change in strength with ST.
There are several limitations of the present study, but the major limitation is the low
statistical power for MV and MQ assessments. The lower statistical power for detecting
differences among genotype groups for changes in MV and MQ with ST was, in part, due
to smaller effect sizes projected for these phenotypes compared with changes in muscle
strength. Additionally, the use of an untrained control leg in the design of the present
study may have reduced the effect size needed for MV. However, the use of a control leg
allowed for a better assurance that the results represent the independent effects of ST by
controlling for variation due to methodological, biological, or seasonal factors. Thus,
future studies should consider changes in MV and MQ with larger sample sizes to test for
gene by gene interactions, as well as to investigate other genes in this biological pathway.
Another possible limitation was that race by environment effects may have influenced
our results. Nevertheless, we covaried for race in all analyses and tried to control for all
possible race by environment interactions that could have potentially contributed a race
effect to our results. One final limitation was that we assumed that each gene involved in
a gene by gene interaction contributed equally to muscle phenotype variability. This
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assumption was made because it was not possible to calculate the contributions of each
gene involved in the interaction.
Future studies should be performed using larger sample sizes to better determine
the influence of IGF1, IGFBP3, and PPP3R1, especially for gene by gene interactions,
on muscle phenotypic responses and to investigate if other polymorphisms in the insulin-
like growth factor pathway play a larger role in influencing muscle phenotypes. For
example, it is possible that other polymorphisms in the PPP3R1 gene, or a polymorphism
in the catalytic subunit of calcineurin may be more responsible for influencing muscle
phenotypic responses to ST. Secondly, there is a need to investigate other IGF-1-
dependent mechanical signaling pathways that influence muscle phenotypic responses to
ST. For example, it is conceivable that the IGF1-PI3K/Akt/mTOR pathway (186) may
compensate for some of the effects of a potentially detrimental allele for the PPP3R1
gene polymorphism. Finally, measurements should be made on transcription and protein
levels of the insulin-like growth factor pathway gene polymorphisms investigated in the
current study to better understand how they may influence muscle phenotype responses to
ST.
In conclusion, this is the first study to examine the effects of insulin-like growth
factor pathway gene polymorphisms on muscle phenotypic responses to ST in older
adults. The results suggest that combined IGF1 effects, i.e., the main effect for IGF1
combined with the interaction effect with PPP3R1, will significantly influence muscle
phenotypic responses. Although the results from IGF1 by PPP3R1 interactions should be
interpreted with caution due to limited sample size for some of the combined genotype
groups, they do provide support for the generation of new hypotheses involving IGF1 by
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PPP3R1 interactions that should be tested in future studies. Such studies will provide a
better understanding of the role of gene polymorphisms on the responses to ST.
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Table 1. IGF1 CA promoter allele and genotype frequency for all subjects
Allele Total (%) Caucasians African
Americans
192 141 (55) 115 (61) 26 (39)
Non-192 115 (45) 75 (39) 40 (61)
Genotype
192/192 39 (30) 34 (36) 5 (15)




26 (20) 14 (15) 12 (36)
CA = cytosine adenine
192 allele is equivalent to 19 CA repeats
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Table 2. IGFBP3 A-202C promoter allele and genotype frequency for all subjects
Allele Total (%) Caucasians African
Americans
A 128 (50) 90 (47) 38 (58)
C 128 (50) 100 (53) 28 (42)
Genotype
A/A 33 (26) 22 (23) 11 (33)
A/C 62 (48) 46 (48) 16 (48)
C/C 33 (26) 27 (28) 6 (18)
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Table 3. PPP3R1 5-base pair I/D promoter allele and genotype frequency for all
subjects
Allele Total (%) Caucasians African
Americans
I 227 (89) 177 (93) 50 (76)
D 29 (11) 13 (7) 16 (24)
Genotype
I/I 100 (78) 82 (86) 18 (55)
I/D 27 (21) 13 (14) 14 (42)









Baseline After ST Baseline After ST
Age 65 (8) -- 63 (9) --
Height (cm) 174 (7) -- 162 (7) --
Weight (kg) 85.8 (13.5) 86.0 (13.4) 72.1 (12.6) 72.3 (13.2)
Body Fat (%) 28.0 (4.9) 27.6 (4.6) 38.6 (5.7) 38.1 (5.7)
FFM (kg) 61.2 (8.1) 61.7 (7.9) 43.8 (5.7) 44.2 (5.9)
1 RM (kg) 32 ± 1.0† 22 ± 1.0
MV (cm3) 1740 ± 32† 1340 ± 35
MQ (kg/cm3)*10-3 18.8 ± 0.56* 16.1 ± 0.61
Values are means (SD)
Values for 1 RM, MV, and MQ are least square means ± SE
† Significantly greater than women, P < 0.001
*Significantly greater than women, P < 0.01
FFM = Fat Free Mass
1 RM = Knee extension one repetition maximum
MV = Muscle Volume
MQ = Muscle Quality
1Sample size variability was due to missing data for muscle phenotypes
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Baseline After ST Baseline After ST
Age 65 (8) -- 62 (8) --
Height (cm) 168 (9) -- 166 (7) --
Weight (kg) 78.2 (15.3) 78.4 (15.6) 78.5 (12.7) 78.9 (12.8)
Body Fat (%) 34.1 (7.6) 33.7 (7.5) 33.0 (7.3) 32.5 (7.2)
FFM (kg) 51.4 (11.3) 51.8 (11.3) 52.6 (10.5) 53.3 (10.6)
1 RM (kg) 24 ± 0.9 27 ± 1.2
MV (cm3) 1380 ± 28 1560 ± 35†
MQ (kg/cm3)*10-3 17.0 ± 0.48 17.1 ± 0.65
Values are means (SD)
Values for 1 RM, MV, and MQ are least square means ± SE
† Significantly greater than Caucasians, P < 0.001
FFM = Fat Free Mass
1 RM = Knee extension one repetition maximum
MV = Muscle Volume
MQ = Muscle Quality
1Sample size variability was due to missing data for muscle phenotypes
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Table 6. Percent Variability for Muscle Phenotypes Attributable to
IGF1, IGFBP3, and PPP3R1
Percent Variability for Genotypes for Change in Muscle





IGF1 1.14 3.41 = 1.14 + ½ (4.54) < 0.01
IGFBP3 2.93 4.97 = 2.93 + ½ (4.07) > 0.05
PPP3R1 0.01 2.28 = 0.01 + ½ (4.54) > 0.05
IGF1*PPP3R1 4.54 0.07
IGFBP3*Race 4.07 0.09
Percent Variability for Genotypes for Change in Muscle





IGF1 1.86 1.86 0.36
IGFBP3 0.16 0.16 0.91
PPP3R1 3.21 3.21 0.06
Percent Variability for Genotypes for Change





IGF1 0.70 3.63 = 0.70 + ½ (5.86) < 0.05
IGFBP3 0.79 0.79 0.66
PPP3R1 0.14 3.07 = 0.14 + ½ (5.86) > 0.05
IGF1*PPP3R1 5.86 0.05
Note: The “Total Gene” effect was computed as the main effect plus one-half of any gene
by gene interaction or gene by race interaction. For example for IGF1, “Total Gene”
effect is the IGF1 main effect (1.14) plus one half of the IGF1 by PPP3R1 gene by gene




Figure 1. Influence of calcineurin B (PPP3R1) by insulin-like growth factor 1 (IGF1)
genotype groups on change in one repetition maximum (1 RM) strength with strength
training (ST). There was a trend for a significant gene by gene interaction between IGF1
and PPP3R1 (P = 0.072). PPP3R1 II homozygotes who were also IGF1
192-allele heterozygotes had significantly greater increases in 1 RM strength with ST
than PPP3R1 II homozygotes who were also IGF1 noncarriers of the 192 allele
(* P = 0.004). Values are covaried for age, hormone replacement therapy status and sex,
race, height, body weight, body mass index, and baseline 1 RM strength. Values are
means ± SE.
Figure 2. Influence of insulin-like growth factor binding protein 3 (IGFBP3) genotype
by race groups on change in 1 RM strength with strength training (ST). There was a
trend for a significant IGFBP3 gene by race interaction (P = 0.094). African American
IGFBP3 AA homozygotes had significantly greater increases in 1 RM strength with ST
than Caucasian IGFBP3 AA homozygotes (* P = 0.005). Values are covaried for age,
hormone replacement therapy status and sex, race, height, body weight, body mass index,
and baseline 1 RM strength. Values are means ± SE.
Figure 3. Influence of calcineurin B (PPP3R1) genotype groups on change in muscle
volume (MV) with strength training (ST). There was a trend for PPP3R1 II homozygotes
to have greater increases in MV with ST than the PPP3R1 D-allele carriers (P = 0.061).
Values are covaried for age, hormone replacement therapy status and sex, race, height,
body weight, body mass index, and baseline MV. Values are means ± SE.
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Figure 4. Influence of calcineurin B (PPP3R1) by insulin-like growth factor 1 (IGF1)
genotype groups on change in muscle quality (MQ) with strength training (ST). There
was a borderline significant gene by gene interaction between IGF1 and PPP3R1 (P =
0.051). PPP3R1 II homozygotes who were also IGF1 192-allele heterozygotes
had significantly greater increases in 1 RM strength with ST than PPP3R1 II
homozygotes who were also IGF1 noncarriers of the 192 allele (* P = 0.005). Values
are covaried for age, hormone replacement therapy status and sex, race, height, body













































Figure 1 Change in Muscle Strength with Strength Training for Calcineurin
B (PPP3R1) and Insulin-like Growth Factor 1 (IGF1) Genotype Groups



















PPP3R1 and IGF1 Genotype Groups


































Figure 2 Change in Muscle Strength with Strength Training for Race and
Insulin-like Growth Factor Binding Protein 3 (IGFBP3) Genotype Group



















P = 0.094 for interaction















Figure 3 Change in Muscle Volume with Strength Training for


























































Figure 4 Change in Muscle Quality with Strength Training for Calcineurin
B (PPP3R1) and Insulin-like Growth Factor 1 (IGF1) Genotype Groups
























* P = 0.005









Research Hypotheses, Delimitations, Limitations, and Operational Definitions
Research Hypotheses
1. Carriers of the 192 allele of the CA dinucleotide repeat polymorphism in the
promoter region of the insulin-like growth factor 1 (IGF1) gene will have
greater increases in muscle strength and muscle volume with strength training
than noncarriers of the 192 allele.
2. AA homozygotes at the -202 locus in the promoter region of the insulin-like
growth factor binding protein 3 (IGFBP3) gene will have greater increases in
muscle strength and muscle volume with strength training than C-allele
carriers.
3. D-allele carriers of the 5-base pair (bp) insertion deletion polymorphism of the
calcineurin B (PPP3R1) gene will have greater increases in muscle strength
and muscle volume with strength training than II homozygotes.
Delimitations
1. The scope of this study will be delimited to ~130 men and women between
the ages of 50 and 85 who volunteer as participants and complete the study
protocol.
2. Participation in the study will be limited to healthy participants free of
musculoskeletal or cardiovascular disease.
3. Based on previous research, subjects will be divided into three groups for the
IGF1 and IGFBP3 genes and into two groups for the PPP3R1 gene in
determining the effect of these genotypes. The groups will be based on homo-
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and heterozygosity for the 192 allele for the CA dinucleotide repeat
polymorphism for the IGF1 gene and for the promoter region polymorphism at
the -202 locus in the IGFBP3 gene. For the PPP3R1 gene grouping will be
based on the presence or absence of at least one deletion allele for the 5 bp
insertion/deletion polymorphism.
Limitations
1. The participants will be volunteers and not randomly selected from the
general population. Therefore, the results of this study cannot be generalized
to individuals who do not possess characteristics such as age, body size,
physical activity, etc. similar to those of subjects in the study.
2. Subjects will self-report many factors related to health and lifestyle such
as physical activity habits, dietary habits, medication regimens, and medical
conditions and they will be asked to keep such lifestyle components constant
during the training program. The accuracy of these components will not be
verified, therefore it is possible that inaccurate self-reports may occur, which
could adversely affect the results of this study.
3. Genotypes other than the IGF1 promoter, IGFBP3 promoter, and PPP3R1 5
bp insertion/deletion sites will not be considered in the proposed study. It
is possible that the effects of these polymorphisms are present only in the
presence of a specific, but unknown, genetic background (epistasis). Also
these polymorphisms may be in linkage disequilibrium with the
polymorphism that actually affects the phenotype of interest.
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Operational Definitions:
5-RM: Refers to the maximal amount of resistance an individual can move
through a complete range of motion only five times.
192 polymorphism (IGF1 gene): This polymorphism is identified by the length
of a CA dinucleotide repeat found in the promoter region of the IGF1 gene. It can
be 16 to 22 dinucleotides in length (99% of the population) and is located at
nucleotide position 1087-1127 in the human IGF1 DNA sequence in the original
human IGF1 DNA sequence Genbank accession number AY260957.
RS# 10665874
-202 polymorphism (IGFBP3 gene): This polymorphism is identified by an A
or C nucleotide base at the -202 locus or at position 1704 in the promoter region
of the IGFBP3 gene. The Genbank position number is M35878.
Calcineurin B (PPP3R1) gene (protein phosphatase 3, regulatory subunit B,
alpha isoform 1): A gene spanning approximately 12 kb located on chromosome
2p16-p15 containing 4 introns of lengths >4.6, 1.1, 0.6, and 1.4 kb (282).
Calcineurin B protein: A 19 kDa Ca (2+)-binding regulatory subunit making up
calcineurin (calmodulin-regulated protein phosphatase), which plays a critical role
in transcriptional regulation and growth control in T lymphocytes by a mechanism
believed to involve dephosphorylation of the nuclear factor NF-AT, which is
essential for transcription of the interleukin-2 gene.
Combined gene effect: Gene effect which includes both the main effect for that
gene and either a gene by race interaction with that gene, or a gene by gene
interaction, including that gene and another gene.
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Computed tomography (CT): A technique for assessing regional muscle size
based on the examination of axial scans of the thigh. Visual images are created
from the measurement of the intensity of x-rays and analyzed to measure cross-
sectional area. The images are based on the attenuation of x-rays as they pass
through the body. Attenuation scores are measured in Hounsfield units, which
depend upon the level of absorption of emitted x-ray beams, -1000 in air to +1000
in bone. Skeletal muscle is typically 0 to 100 Hounsfield units while adipose
tissue is usually -190 to -30 Hounsfield units.
Dual-energy x-ray absorptiometry (DXA): A technique for assessing whole
and regional body composition that considers the body to be composed of three
compartments: bone mineral mass, soft tissue, and lean tissue. Tissue amounts
are based on the attenuation of x-rays as they pass through the body.
IGF1 gene: A gene of at least 45 kb containing six exons and five introns (247).
The location of the human IGF1 gene is 12q22-q23 (28, 271).
IGF-1 protein: A polypeptide similar in structure to insulin with
autocrine/paracrine effects on muscle during growth and differentiation and in
adult life.
IGFBP3 gene: A gene spanning 8.9 kb containing 4 exons with a 5th exon
containing the 3’-untranslated region. The location of the human IGFBP3 gene is
on human chromosome 7p14-p12 (58).
IGFBP-3 protein: A polypeptide which functions as the major carrier of IGF-1
in the circulation, as a modulator of IGF-1 bioactivity, and as a direct growth
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inhibitor in the extravascular tissue compartment, where it is expressed in a highly
regulated manner.
Insertion/deletion polymorphism (PPP3R1 gene): This polymorphism is
identified by the insertion or deletion of a 5-base pair (bp) sequence located at the
-1063 to -1059 position. The Genbank accession number is NT022184-12. RS#
3039851
Muscle quality: Also known as specific tension or specific force, it is the
strength of a muscle divided by muscle volume (the amount of force production
per unit area of muscle tissue).
Muscle volume: Muscle volume will be determined by the MIPAV software and
equations used by Tracy et al. (266). Briefly, this involves an equation that
utilizes the 8-10 axial thigh slices that are obtained from the CT scan.
Sarcopenia: A condition characterized by the loss of muscle size, quality, and
function that occurs with aging. This typically leads to or exacerbates ailments
such as osteoporosis and loss of functional independence.
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APPENDIX B











CONSENT TO PARTICIPATE IN A RESEARCH PROJECT
Project Title: Effects of Gene Variations on Age- and Strength Training-Induced
Changes in Muscular Strength, Body Composition, Blood Pressure, Glucose Metabolism,
and Lipoprotein-lipid Profiles
I state that I am over 18 years of age, in good physical health, and have elected to
participate in a program of research being conducted by Dr. Ben Hurley in the
Department of Kinesiology at the University of Maryland, College Park, MD 20742.
I understand that the primary purpose of this study is to assess the role that genetics
may play in causing losses of muscular strength and muscle mass with age and gains in
strength and muscle mass as a result of strength training. I understand that another
purpose of the study will be to assess the influence of genes on changes in body
composition, blood pressure, blood sugar metabolism, blood fats muscle power, and
performance of common physical tasks with age and strength training.
I understand that the procedures involve three phases. During the first phase, I will undergo
testing, which will include a blood draw to analyze my DNA (genetic material), blood sugar and
fats, and other blood proteins. My blood pressure, body composition, bone mineral density, leg
muscle volume, muscle strength, muscle power, and ability to complete selected tasks similar to
common activities of daily living will also be assessed during this first phase. The second phase
of the study involves my participation in a strength training program three times a week for
approximately six months. The third and final phase will be a repeat of all previously taken
measures, except analysis of my DNA, which will not need to be repeated. Some of the tests
will be repeated both after ~ 10 weeks of training and again after the entire training program.
These repeat tests will include blood pressure, strength, power, muscle volume and body
composition. Other tests will be repeated only after the entire training program.
I understand that the blood draw will require providing about 2 to 3 tablespoons of blood. I
understand that there is a risk of bruising, pain and, in rare cases, infection or fainting as a result
of blood sampling. However, these risks to me will be minimized by allowing only qualified
people to draw my blood. A portion of this blood sample will be sent to the University of
Pittsburgh to analyze my DNA. I understand that the remainder will be stored at the University
of Maryland for later analysis of my blood sugar, the hormone that regulates my blood sugar
(insulin), blood fats, and other blood proteins. I understand that a portion of this sample may
also be used for potential future studies, but only as such studies examine strength, body
composition (i.e., fat, muscle & bone), metabolism of blood sugar, and blood pressure. I
understand that I may contact the principal investigator at any future point in time to request that
any stored blood sample be destroyed immediately.
I understand that while I am lying on a padded table, my leg muscle and fat mass will be
measured by computed tomography (CT). The CT scan will be performed at Washington
Adventist Hospital. My percent body fat and bone mineral density measurements will be
performed at the United States Department of Agriculture in Beltsville, Maryland by dual-energy
x-ray absorptiometry (DXA). This will require my lying still on a padded exam table wearing
metal-free clothing for about 10 minutes at a time, totaling less than 30 total minutes for the
entire procedure.
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I understand that there will be a total radiation dose of no more than 1 Rem to the
whole body (effective dose equivalent) from each CT scan. This amount is well below
the maximal annual radiation dose (5 Rems) allowed for exposure in the workplace. The
body composition and bone density testing completed by DXA involves a small radiation
exposure. The radiation exposure I will receive from DXA is equal t to an exposure of
less than 50 millirems to the whole body. Naturally occurring radiation (cosmic
radiation, radon, etc.) produces whole body radiation of about 300 millirems per year.
Therefore, the total dose of radiation exposure due to the DXA measurement is minimal
and the combined dose of DXA and CT is considered low.
I understand that strength and power assessments will be performed on machines that
measure how much force and how fast I can exert force through a typical range of knee
extension motion. Strength testing will also be performed on the same exercise machines
used for training by measuring the maximal amount of force that I can move through the
full range of an exercise. During each strength training session I will be asked to exercise
on machines which offer resistance against extending and flexing my arms, legs, and
trunk region for approximately 40 minutes or less a day, three times a week for up to six
months. I understand that I may experience some temporary muscle soreness as a result
of the testing sessions. There is also a risk of muscle or skeletal injury from strength and
power testing, as well as from strength training. The investigators of this study will use
procedures designed to minimize this risk.
I understand that I will be asked to complete some tasks to measure my ability to
carry out normal daily activities. These tasks include rising from a chair, short brisk walks
and climbing a flight of stairs. Any risk of injury during the completion of these tasks will
be minimized by having all sessions supervised by an exercise physiologist qualified to
direct this type of testing and wearing a safety harness during the short brisk walks and
climbing a flight of stairs.
I understand that it is also possible that heart or blood vessel problems could arise
during my participation in the testing or training involved in this study. Although
unusual, it is possible that these problems could lead to a heart attack or even death.
Therefore, prior evaluation and permission from my physician at my expense will be
required to participate in this study. I also understand that it is possible that these risks
will not be eliminated completely, even with a medical evaluation prior to participation in
the study.
I understand that this study is not designed to help me personally, but may help the
investigators better understand who is likely to be most and least susceptible to losing
strength, power, and muscle mass with advanced age and who is most and least likely to
benefit from strength training.
I understand that my decision of whether or not to participate in this study is
voluntary. I understand that I am free to ask questions about this study before I decide
whether or not to participate in the study. I understand that if I consent to participate in
the study I am free to withdraw from participation at any time without penalty or
coercion, or without any requirement that I provide an explanation to anyone of my
decision to withdraw. In addition, I understand that refusal to participate will not involve
a penalty or loss of benefit to which a volunteer would ordinarily be entitled to at that
time. If I am on hormone replacement therapy (HRT) prior to the study, I must remain
on them and if I am not on HRT prior to the study, I must remain off them throughout the
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study to qualify for continued participation. If I am taking other medications prior to the
study, I will be permitted to participate as long as I had been on these mediations for at
least 4 weeks prior to the study and do not stop taking them prior to the end of the study.
I understand that all information collected in this study is confidential. For my
participation in the study I will receive information after the study is completed about my
blood pressure, blood test results, bone mineral density, body composition, and functional
ability upon request, free of charge. However, I understand that I will not receive any
financial compensation in exchange for my participation in this study.
In the event of physical injury resulting from participation in this study, upon my
consent, emergency treatment will be available at the medical center of Washington
Adventist Hospital with the understanding that any injury that requires medical attention
becomes my financial responsibility. I understand that the University of Maryland at
College Park will not provide any medical or hospitalization insurance coverage for
participants in this research study, nor will they provide compensation for any injury
sustained as a result of this research study, except as required by law.
I understand that I can discuss this research study at any time with the
principal investigator, Dr. Ben Hurley at (301) 405-2457 or with the study
coordinator of this project at (301) 405-2569.
I have read and understand the above information and have been given an
adequate opportunity to ask the investigators any questions I have about the study.
My questions, if any, have been answered by the investigators to my satisfaction. By
my signature I am indicating my decision to consent to participate voluntarily in
this study.
Principal investigator: Ben Hurley, Ph.D., Dept of Kinesiology, HLHP Building,
University of Maryland, College Park, MD 20742-2611, Ph: (301) 405-2486.
Printed Name of Subject___________________________
Signature of Subject__________________________ Date_____________
Contact information of Institutional Review Board: If you have questions about
your rights as a research subject or wish to report a research-related injury, please
contact:
Institutional Review Board Office, University of Maryland, College Park, MD
20742;

























APPENDIX C: IGF1 GENOTYPING
HUR127 genotype confirmed by direct sequencing as 188/196 (add 4 base pairs to peaks
above due to primer)
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HUR210 genotype confirmed by direct sequencing as 192/192 (add 4 base pairs to peaks

























Final Statistical Models and Results for Baseline Muscle Phenotypes
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APPENDIX E: FINAL STATISTICAL MODELS AND RESULTS FOR
BASELINE MUSCLE PHENOTYPES
Model for comparison in muscle strength baseline among sex, race, and genotype
groups:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race: 1 is Caucasians or 2 is African American
Age is subject’s age
hrt_sex is hormone replacement status variable: MN is male, FN is females not on
hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
RMTLPREKG is subject’s baseline muscle strength for training leg
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proc mixed data=one covtest;












/ outp=resides ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'females vs males' hrt_sex 0.5 0.5 -1/E;
estimate 'mean for females' height 167.62 age 64.11 bwpre 78.21
bmipre 27.79 intercept 1 hrt_sex 0.5 0.5 0/E;






Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
Race 1 107 6.79 0.0105
Height 1 107 0.67 0.4150
IGF1 2 107 1.50 0.2276
IGFBP3 2 107 3.19 0.0452
Calbb 1 107 3.38 0.0689
Age 1 107 24.00 <.0001
bwpre 1 107 3.02 0.0850
hrt_sex 2 107 29.96 <.0001
bmipre 1 107 2.20 0.1411




Label Estimate Error DF t Value Pr > |t|
females vs males -10.3709 1.4450 107 -7.18 <.0001
mean for females 22.0469 1.0456 107 21.09 <.0001
Least Squares Means
Standard
Effect hrt_sex IGF1 IGFBP3 Calbb Race Estimate Error DF t Value Pr > |t|
Race 1 23.7579 0.8504 107 27.94 <.0001
Race 2 27.2388 1.1900 107 22.89 <.0001
hrt_sex FN 21.8164 0.9539 107 22.87 <.0001
hrt_sex FY 22.2663 1.6658 107 13.37 <.0001
hrt_sex MN 32.4123 1.0371 107 31.25 <.0001
IGF1 1 24.1648 1.1152 107 21.67 <.0001
IGF1 2 25.7870 0.9475 107 27.22 <.0001
IGF1 3 26.5432 1.2481 107 21.27 <.0001
IGFBP3 11 24.1906 1.1234 107 21.53 <.0001
IGFBP3 12 24.3286 0.9840 107 24.72 <.0001
IGFBP3 22 27.9758 1.4250 107 19.63 <.0001
Calbb 11 24.3518 0.8206 107 29.67 <.0001
Calbb 12 26.6449 1.1627 107 22.92 <.0001
IGFBP3*Race 11 1 24.2424 1.2484 107 19.42 <.0001
IGFBP3*Race 11 2 24.1388 1.8066 107 13.36 <.0001
IGFBP3*Race 12 1 23.1419 1.0309 107 22.45 <.0001
IGFBP3*Race 12 2 25.5154 1.4793 107 17.25 <.0001
IGFBP3*Race 22 1 23.8894 1.2604 107 18.95 <.0001
IGFBP3*Race 22 2 32.0622 2.5121 107 12.76 <.0001
96
Differences of Least Squares Means
Calb _ _ _ _ _ Standard
Effect hrt_sex IGF1 IGFBP3 b Race hrt_sex IGF1 IGFBP3 Calbb Race Estimate Error P1
Race 1 2 -3.4809 1.3362 0.0105
hrt_sex FN FY -0.4499 1.7313 1.0000
hrt_sex FN MN -10.5959 1.4066 <.0001
hrt_sex FY MN -10.1459 1.9225 <.0001
IGF1 1 2 -1.6223 1.1701 0.5055
IGF1 1 3 -2.3785 1.4972 0.3453
IGF1 2 3 -0.7562 1.3706 1.0000
IGFBP3 11 12 -0.1380 1.3648 1.0000
IGFBP3 11 22 -3.7852 1.7155 0.0885
IGFBP3 12 22 -3.6472 1.5387 0.0558
Calbb 11 12 -2.2932 1.2481 0.0689
IGFBP3*Race 11 1 11 2 0.1036 2.1440 1.0000
IGFBP3*Race 11 1 12 1 1.1006 1.4061 1.0000
IGFBP3*Race 11 1 22 1 0.3530 1.5504 1.0000
IGFBP3*Race 11 2 12 2 -1.3765 2.2629 1.0000
IGFBP3*Race 11 2 22 2 -7.9233 3.0819 0.1035
IGFBP3*Race 12 1 12 2 -2.3735 1.6216 1.0000
IGFBP3*Race 12 1 22 1 -0.7476 1.3193 1.0000
IGFBP3*Race 12 2 22 2 -6.5468 2.8153 0.1971
IGFBP3*Race 22 1 22 2 -8.1728 2.7706 0.0351
1 With 107 df
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Model for comparison in muscle volume baseline among sex, race, and genotype
groups:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11
is CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele
carriers
Race: 1 is Caucasian or 2 is African American
Age is subject’s age
hrt_sex is hormone replacement status variable: MN is male, FN is females not on
hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
MVTB is subject’s baseline muscle volume for training (exercising) leg
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proc mixed data=one;












*hrt_sex FN FY MN;
estimate 'females vs males' hrt_sex 0.5 0.5 -1;
estimate 'mean for females' height 167.57 age 64.14 bwpre 78.62 bmipre 27.89
intercept 1 hrt_sex 0.5 0.5 0;






Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
IGF1 2 107 0.98 0.3804
IGFBP3 2 107 0.88 0.4187
CalbB 1 107 0.58 0.4492
Age 1 107 12.49 0.0006
Race 1 107 21.20 <.0001
hrt_sex 2 107 41.42 <.0001
bmipre 1 107 11.18 0.0011
Height 1 107 3.83 0.0530




Label Estimate Error DF t Value Pr > |t|
females vs males -400.36 48.0958 107 -8.32 <.0001
mean for females 1338.08 34.9550 107 38.28 <.0001
Least Squares Means
Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B Estimate Error DF t Value Pr > |t|
Race 1 1381.24 28.0867 107 49.18 <.0001
Race 2 1561.39 35.3901 107 44.12 <.0001
hrt_sex FN 1335.54 30.3115 107 44.06 <.0001
hrt_sex FY 1340.19 57.1854 107 23.44 <.0001
hrt_sex MN 1738.23 31.8235 107 54.62 <.0001
IGF1 1 1437.40 36.2803 107 39.62 <.0001
IGF1 2 1484.62 28.7487 107 51.64 <.0001
IGF1 3 1491.93 38.8077 107 38.44 <.0001
IGFBP3 11 1466.79 34.9485 107 41.97 <.0001
IGFBP3 12 1448.23 29.7480 107 48.68 <.0001
IGFBP3 22 1498.94 38.5739 107 38.86 <.0001
CalbB 11 1456.35 26.9719 107 53.99 <.0001
CalbB 12 1486.29 36.4080 107 40.82 <.0001
Differences of Least Squares Means
Calb _ _ _ _ _ Standard
Effect hrt_sex Race IGF1 IGFBP3 B hrt_sex Race IGF1 IGFBP3 CalbB Estimate Error P1
Race 1 2 -180.15 39.1243 <.0001
hrt_sex FN FY -4.6484 59.0864 1.0000
hrt_sex FN MN -402.69 45.3823 <.0001
hrt_sex FY MN -398.04 65.6694 <.0001
IGF1 1 2 -47.2179 37.2314 0.6225
IGF1 1 3 -54.5280 46.3371 0.7257
IGF1 2 3 -7.3102 40.8802 1.0000
IGFBP3 11 12 18.5626 38.6627 1.0000
IGFBP3 11 22 -32.1474 45.5530 1.0000
IGFBP3 12 22 -50.7101 38.3552 0.5667
CalbB 11 12 -29.9402 39.4222 0.4492
1 With 107 df.
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Model for comparison in muscle quality baseline among sex, race, and genotype
groups:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race: 1 is Caucasian or 2 is African American
Age is subject’s age
hrt_sex is hormone replacement status variable: MN is male, FN is females not on
hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is subjects’ baseline body weight
bmipre is subject’s baseline body mass index
mqb is subject’s baseline muscle quality (strength per muscle volume) for training leg
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proc mixed data=one covtest scoring=10 convh=1E-5 covtest;












/outp=resids ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'females vs males' hrt_sex 0.5 0.5 -1/E;
estimate 'mean for females' height 167.62 age 64.51 bwpre 78.59 bmipre 27.92 intercept
1 hrt_sex 0.5 0.5 0/E;






Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
Age 1 98 16.44 0.0001
Race 1 98 0.02 0.8862
Height 1 98 0.36 0.5473
bwpre 1 98 0.49 0.4877
IGF1 2 98 1.77 0.1753
IGFBP3 2 98 3.89 0.0237
CalbB 1 98 1.45 0.2308
hrt_sex 2 98 7.98 0.0006
bmipre 1 98 0.20 0.6522




Label Estimate Error DF t Value Pr > |t|
females vs males -2.6907 0.8309 98 -3.24 0.0016
mean for females 16.1215 0.6070 98 26.56 <.0001
Least Squares Means
Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B Estimate Error DF t Value Pr > |t|
Race 1 16.9665 0.4823 98 35.18 <.0001
Race 2 17.0694 0.6455 98 26.44 <.0001
hrt_sex FN 15.7085 0.5322 98 29.52 <.0001
hrt_sex FY 16.5337 0.9901 98 16.70 <.0001
hrt_sex MN 18.8117 0.5579 98 33.72 <.0001
IGF1 1 16.2361 0.6291 98 25.81 <.0001
IGF1 2 17.3004 0.5214 98 33.18 <.0001
IGF1 3 17.5174 0.6674 98 26.25 <.0001
IGFBP3 11 16.0605 0.6139 98 26.16 <.0001
IGFBP3 12 16.5198 0.5510 98 29.98 <.0001
IGFBP3 22 18.4736 0.7734 98 23.89 <.0001
CalbB 11 16.6106 0.4656 98 35.67 <.0001
CalbB 12 17.4254 0.6353 98 27.43 <.0001
Race*IGFBP3 1 11 17.5893 0.7232 98 24.32 <.0001
Race*IGFBP3 1 12 16.4017 0.5612 98 29.22 <.0001
Race*IGFBP3 1 22 16.9086 0.7025 98 24.07 <.0001
Race*IGFBP3 2 11 14.5318 0.9593 98 15.15 <.0001
Race*IGFBP3 2 12 16.6379 0.8354 98 19.92 <.0001
Race*IGFBP3 2 22 20.0386 1.3320 98 15.04 <.0001
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Differences of Least Squares Means
Calb _ _ _ _ _ Standard
Effect hrt_sex Race IGF1 IGFBP3 B hrt_sex Race IGF1 IGFBP3 CalbB Estimate Error P1
Race 1 2 -0.1029 0.7172 0.8862
hrt_sex FN FY -0.8252 1.0261 1.0000
hrt_sex FN MN -3.1032 0.7768 0.0003
hrt_sex FY MN -2.2781 1.1418 0.1464
IGF1 1 2 -1.0643 0.6377 0.2949
IGF1 1 3 -1.2812 0.8006 0.3381
IGF1 2 3 -0.2170 0.7263 1.0000
IGFBP3 11 12 -0.4593 0.7466 1.0000
IGFBP3 11 22 -2.4130 0.9141 0.0291
IGFBP3 12 22 -1.9537 0.8239 0.0197
CalbB 11 12 -0.8148 0.6758 1.0000
Race*IGFBP3 1 11 1 12 1.1875 0.7836 1.0000
Race*IGFBP3 1 11 1 22 0.6807 0.8750 1.0000
Race*IGFBP3 1 11 2 11 3.0575 1.1743 0.1773
Race*IGFBP3 1 12 1 22 -0.5068 0.7225 1.0000
Race*IGFBP3 1 12 2 12 -0.2362 0.9008 1.0000
Race*IGFBP3 1 22 2 22 -3.1300 1.4638 0.3150
Race*IGFBP3 2 11 2 12 -2.1061 1.2379 0.8280
Race*IGFBP3 2 11 2 22 -5.5068 1.6278 0.0090
Race*IGFBP3 2 12 2 22 -3.4007 1.4982 0.2286
1 With 98 df.
104
APPENDIX F
Final Statistical Models and Results for Muscle Phenotype Changes with Strength
Training
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APPENDIX F: FINAL STATISTICAL MODELS AND RESULTS FOR MUSCLE
PHENOTYPE CHANGES WITH STRENGTH TRAINING
Model for change in muscle strength with strength training:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race: 1 is Caucasian or 2 is African American
Age is subject’s age
sex: 1 male or 2 female
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
rmtlprekg is subject’s baseline muscle strength for training leg
rmdkg is the change in muscle strength with strength training
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proc mixed data=one covtest;













/ outp=resids ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'females vs males ' hrt_sex 0.5 0.5 -1/E;
estimate 'mean for females ' rmtlprekg 24.77 height 167.62 age 64.11 bwpre 78.21
bmipre 27.79 intercept 1 hrt_sex 0.5 0.5 0/E;






Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
RMTLPREKG 1 104 0.31 0.5789
Race 1 104 8.57 0.0042
Height 1 104 0.74 0.3912
IGF1 2 104 0.68 0.5101
IGFBP3 2 104 1.75 0.1796
Calbb 1 104 0.02 0.8961
Age 1 104 1.40 0.2388
bwpre 1 104 0.14 0.7080
hrt_sex 2 104 4.33 0.0157
bmipre 1 104 0.17 0.6821
Race*IGFBP3 2 104 2.42 0.0935




Estimate Error DF t Value Pr > |t|
females vs males -3.1988 1.1580 104 -2.76 0.0068
mean for females 5.6628 0.7208 104 7.86 <.0001
Least Squares Means
Standard
Effect hrt_sex Race IGF1 IGFBP3 Calbb Estimate Error DF t Value Pr > |t|
Race 1 5.3969 0.5715 104 9.44 <.0001
Race 2 8.0610 0.8077 104 9.98 <.0001
hrt_sex FN 5.5325 0.6658 104 8.31 <.0001
hrt_sex FY 5.7929 1.1154 104 5.19 <.0001
hrt_sex MN 8.8614 0.8382 104 10.57 <.0001
IGF1 1 6.5863 0.8108 104 8.12 <.0001
IGF1 2 7.3696 0.6590 104 11.18 <.0001
IGF1 3 6.2310 0.9653 104 6.45 <.0001
IGFBP3 11 7.8620 0.7802 104 10.08 <.0001
IGFBP3 12 6.5637 0.6506 104 10.09 <.0001
IGFBP3 22 5.7611 0.9598 104 6.00 <.0001
Calbb 11 6.6712 0.5413 104 12.32 <.0001
Calbb 12 6.7867 0.8136 104 8.34 <.0001
Race*IGFBP3 1 11 5.3205 0.8356 104 6.37 <.0001
Race*IGFBP3 1 12 5.9448 0.6934 104 8.57 <.0001
Race*IGFBP3 1 22 4.9255 0.8333 104 5.91 <.0001
Race*IGFBP3 2 11 10.4036 1.2474 104 8.34 <.0001
Race*IGFBP3 2 12 7.1826 0.9830 104 7.31 <.0001
Race*IGFBP3 2 22 6.5968 1.7143 104 3.85 0.0002
IGF1*Calbb 1 11 6.9285 0.8086 104 8.57 <.0001
IGF1*Calbb 1 12 6.2440 1.3022 104 4.79 <.0001
IGF1*Calbb 2 11 8.3677 0.6599 104 12.68 <.0001
IGF1*Calbb 2 12 6.3715 1.0568 104 6.03 <.0001
IGF1*Calbb 3 11 4.7174 0.8858 104 5.33 <.0001
IGF1*Calbb 3 12 7.7445 1.6558 104 4.68 <.0001
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Differences of Least Squares Means
Calb _ _ _ _ _ Standard
Effect hrt_sex Race IGF1 IGFBP3 B hrt_sex Race IGF1 IGFBP3 CalbB Estimate Error P1
Race 1 2 -2.6641 0.9098 0.0042
hrt_sex FN FY -0.2603 1.1386 1.0000
hrt_sex FN MN -3.3289 1.1443 0.0132
hrt_sex FY MN -3.0686 1.4215 0.0996
IGF1 1 2 -0.7833 0.9178 1.0000
IGF1 1 3 0.3553 1.2002 1.0000
IGF1 2 3 1.1387 1.1156 0.9294
IGFBP3 11 12 1.2983 0.9339 0.5022
IGFBP3 11 22 2.1009 1.1693 0.2259
IGFBP3 12 22 0.8026 1.0379 1.0000
Calbb 11 12 -0.1155 0.8830 0.8961
Race*IGFBP3 1 11 1 12 -0.6243 0.9361 1.0000
Race*IGFBP3 1 11 1 22 0.3950 1.0255 1.0000
Race*IGFBP3 1 11 2 11 -5.0831 1.4400 0.0054
Race*IGFBP3 1 12 1 22 1.0193 0.8678 1.0000
Race*IGFBP3 1 12 2 12 -1.2378 1.0959 1.0000
Race*IGFBP3 1 22 2 22 -1.6713 1.8924 1.0000
Race*IGFBP3 2 11 2 12 3.2209 1.5626 0.3762
Race*IGFBP3 2 11 2 22 3.8068 2.1130 0.6705
Race*IGFBP3 2 12 2 22 0.5859 1.8987 1.0000
IGF1*Calbb 1 11 1 12 0.6844 1.4387 1.0000
IGF1*Calbb 1 11 2 11 -1.4392 0.8778 0.9369
IGF1*Calbb 1 11 3 11 2.2111 1.1061 0.4338
IGF1*Calbb 1 12 2 12 -0.1275 1.5958 1.0000
IGF1*Calbb 1 12 3 12 -1.5005 2.0798 1.0000
IGF1*Calbb 2 11 2 12 1.9961 1.1692 0.8172
IGF1*Calbb 2 11 3 11 3.6503 0.9951 0.0036
IGF1*Calbb 2 12 3 12 -1.3730 1.9577 1.0000
IGF1*Calbb 3 11 3 12 -3.0272 1.8235 0.8991
1 With 104 df.
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Model for change in muscle volume with strength training:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race is subject’s race: 1 Caucasian or 2 African American
Age is subject’s age
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
mvtb is baseline muscle volume for training (exercising) leg















/outp=resids ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'females vs males' hrt_sex 0.5 0.5 -1/E;
estimate 'mean for females' height 167.57 age 64.14 bwpre 78.62 bmipre 27.89 mvtb
1468.25 intercept 1 hrt_sex 0.5 0.5 0/E;






Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
MVTB 1 106 2.77 0.0989
IGF1 2 106 1.04 0.3561
IGFBP3 2 106 0.09 0.9133
CalbB 1 106 3.60 0.0607
Age 1 106 1.14 0.2874
Race 1 106 1.06 0.3059
hrt_sex 2 106 1.70 0.1875
bmipre 1 106 0.02 0.8907
Height 1 106 0.02 0.9025




Estimate Error DF t Value Pr > |t|
females vs males -38.0975 23.4381 106 -1.63 0.1070
mean for females 106.15 14.1046 106 7.53 <.0001
Least Squares Means
Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B Estimate Error DF t Value Pr > |t|
Race 1 110.49 11.1311 106 9.93 <.0001
Race 2 127.22 13.8641 106 9.18 <.0001
hrt_sex FN 102.39 12.4963 106 8.19 <.0001
hrt_sex FY 109.92 22.2137 106 4.95 <.0001
hrt_sex MN 144.25 15.6256 106 9.23 <.0001
IGF1 1 106.06 13.8205 106 7.67 <.0001
IGF1 2 126.12 10.9311 106 11.54 <.0001
IGF1 3 124.39 14.7591 106 8.43 <.0001
IGFBP3 11 122.09 13.2685 106 9.20 <.0001
IGFBP3 12 119.59 11.3179 106 10.57 <.0001
IGFBP3 22 114.88 14.6880 106 7.82 <.0001
CalbB 11 133.08 10.2493 106 12.98 <.0001
CalbB 12 104.63 13.8383 106 7.56 <.0001
Differences of Least Squares Means
Calb _ _ _ _ _ Standard
Effect hrt_sex Race IGF1 IGFBP3 B hrt_sex Race IGF1 IGFBP3 CalbB Estimate Error P1
Race 1 2 -16.7266 16.2588 0.3059
hrt_sex FN FY -7.5310 22.4331 1.0000
hrt_sex FN MN -41.8630 22.7002 0.2040
hrt_sex FY MN -34.3320 28.8966 0.7125
IGF1 1 2 -20.0608 14.2409 0.4857
IGF1 1 3 -18.3347 17.7056 0.9084
IGF1 2 3 1.7261 15.5227 1.0000
IGFBP3 11 12 2.5065 14.6943 1.0000
IGFBP3 11 22 7.2093 17.3346 1.0000
IGFBP3 12 22 4.7028 14.6802 1.0000
CalbB 11 12 28.4556 15.0071 0.0607
1 With 106 df.
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Model for change in muscle quality with strength training:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race is subject’s race: 1 Caucasian or 2 African American
Age is subject’s age
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
mqb is baseline muscle quality (strength per muscle volume) for training leg
mqc is change in muscle quality for trained leg
113
proc mixed data=one covtest scoring=10 convh=1E-5 covtest;












/outp=resids ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'females vs males' hrt_sex 0.5 0.5 -1/E;
estimate 'mean for females' mqb 16.74 height 167.62 bwpre 78.59 bmipre 27.92 age
64.51 intercept 1 hrt_sex 0.5 0.5 0/E;





Type 3 Tests of Fixed Effects
Num De
Effect DF DF F Value Pr > F
MQB 1 97 28.39 <.0001
Age 1 97 3.59 0.0610
Race 1 97 3.90 0.0511
Height 1 97 1.59 0.2102
bwpre 1 97 1.03 0.3130
IGF1 2 97 0.37 0.6930
IGFBP3 2 97 0.41 0.6632
CalbB 1 97 0.15 0.6980
IGF1*CalbB 2 97 3.07 0.0509
hrt_sex 2 97 1.71 0.1871




Estimate Error DF t Value Pr > |t|
females vs males -0.7121 0.5911 97 -1.20 0.2312
mean for females 2.7837 0.4174 97 6.67 <.0001
Least Squares Means
Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B Estimate Error DF t Value Pr > |t|
Race 1 2.5774 0.3268 97 7.89 <.0001
Race 2 3.4675 0.4152 97 8.35 <.0001
hrt_sex FN 2.4911 0.3707 97 6.72 <.0001
hrt_sex FY 3.0791 0.6678 97 4.61 <.0001
hrt_sex MN 3.4972 0.3884 97 9.00 <.0001
IGF1 1 3.1891 0.4809 97 6.63 <.0001
IGF1 2 3.1755 0.3384 97 9.38 <.0001
IGF1 3 2.7027 0.5220 97 5.18 <.0001
IGFBP3 11 2.8610 0.4115 97 6.95 <.0001
IGFBP3 12 3.2426 0.3547 97 9.14 <.0001
IGFBP3 22 2.9638 0.4414 97 6.72 <.0001
CalbB 11 2.9288 0.3096 97 9.46 <.0001
CalbB 12 3.1160 0.4443 97 7.01 <.0001
IGF1*CalbB 1 11 3.2783 0.4531 97 7.23 <.0001
IGF1*CalbB 1 12 3.1000 0.7950 97 3.90 0.0002
IGF1*CalbB 2 11 3.6860 0.3676 97 10.03 <.0001
IGF1*CalbB 2 12 2.6650 0.5332 97 5.00 <.0001
IGF1*CalbB 3 11 1.8222 0.4821 97 3.78 0.0003
IGF1*CalbB 3 12 3.5831 0.8809 97 4.07 <.0001
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Differences of Least Squares Means
Calb _ _ _ _ _ Standard
Effect hrt_sex Race IGF1 IGFBP3 B hrt_sex Race IGF1 IGFBP3 CalbB Estimate Error P1
Race 1 2 -0.8901 0.4507 0.0511
hrt_sex FN FY -0.5880 0.6854 1.0000
hrt_sex FN MN -1.0061 0.5636 0.2322
hrt_sex FY MN -0.4181 0.7848 1.0000
IGF1 1 2 0.01362 0.5221 1.0000
IGF1 1 3 0.4865 0.6741 1.0000
IGF1 2 3 0.4729 0.5730 1.0000
IGFBP3 11 12 -0.3816 0.4628 1.0000
IGFBP3 11 22 -0.1028 0.5160 1.0000
IGFBP3 12 22 0.2788 0.4360 1.0000
CalbB 11 12 -0.1872 0.4809 0.6980
IGF1*CalbB 1 11 1 12 0.1783 0.8658 1.0000
IGF1*CalbB 1 11 2 11 -0.4078 0.4858 1.0000
IGF1*CalbB 1 11 3 11 1.4561 0.5887 0.1359
IGF1*CalbB 1 12 2 11 -0.5860 0.8087 1.0000
IGF1*CalbB 1 12 2 12 0.4350 0.9362 1.0000
IGF1*CalbB 1 12 3 12 -0.4831 1.1874 1.0000
IGF1*CalbB 2 11 2 12 1.0210 0.6171 0.9117
IGF1*CalbB 2 11 3 11 1.8638 0.5228 0.0054
IGF1*CalbB 2 12 3 11 0.8428 0.6871 1.0000
1 With 97 df
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APPENDIX G
Final Statistical Models and Results for Percent Change with Strength Training
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APPENDIX G: FINAL STATISTICAL MODELS AND RESULTS FOR
PERCENT CHANGE WITH STRENGTH TRAINING
Model for relative percent change in muscle strength with strength training:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race: 1 Caucasian or 2 African American
Age
sex: 1 male or 2 female
hrt_sex is hormone replacement variable: MN is male, FN is females not on hormone
replacement therapy, FY is females on hormone replacement therapy
Height
bwpre is baseline body weight
bmipre is baseline body mass index
RMTLPREKG is baseline muscle strength for training leg
pctchange is the relative percent change in muscle strength with strength training
118
proc mixed data=one covtest;













/ outp=resids ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'male vs female' hrt_sex 1 1 -2/divisor=2;
estimate 'mean for females' rmtlprekg 24.77 height 167.62 age 64.11 bwpre 78.21
bmipre 27.79 intercept 1 hrt_sex 0.5 0.5 0/E;






Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
RMTLPREKG 1 104 33.67 <.0001
Race 1 104 10.72 0.0014
Height 1 104 1.06 0.3062
IGF1 2 104 0.14 0.8682
IGFBP3 2 104 0.69 0.5030
Calbb 1 104 0.11 0.7399
Age 1 104 3.29 0.0726
bwpre 1 104 0.03 0.8559
hrt_sex 2 104 3.75 0.0268
bmipre 1 104 0.06 0.8059
Race*IGFBP3 2 104 4.35 0.0153




Label Estimate Error DF t Value Pr > |t|
male vs female -10.5686 4.9487 104 -2.14 0.0351
mean for females 27.4827 3.0802 104 8.92 <.0001
Least Squares Means
Standard
Effect hrt_sex Race IGF1 IGFBP3 Calbb Estimate Error DF t Value Pr > |t|
Race 1 24.6361 2.4421 104 10.09 <.0001
Race 2 37.3639 3.4519 104 10.82 <.0001
hrt_sex FN 24.8662 2.8453 104 8.74 <.0001
hrt_sex FY 30.0882 4.7664 104 6.31 <.0001
hrt_sex MN 38.0457 3.5821 104 10.62 <.0001
IGF1 1 30.8396 3.4648 104 8.90 <.0001
IGF1 2 32.2410 2.8164 104 11.45 <.0001
IGF1 3 29.9195 4.1252 104 7.25 <.0001
IGFBP3 11 34.0902 3.3341 104 10.22 <.0001
IGFBP3 12 30.1448 2.7804 104 10.84 <.0001
IGFBP3 22 28.7651 4.1018 104 7.01 <.0001
Calbb 11 30.3720 2.3133 104 13.13 <.0001
Calbb 12 31.6281 3.4769 104 9.10 <.0001
Race*IGFBP3 1 11 22.8375 3.5710 104 6.40 <.0001
Race*IGFBP3 1 12 29.6551 2.9632 104 10.01 <.0001
Race*IGFBP3 1 22 21.4158 3.5609 104 6.01 <.0001
Race*IGFBP3 2 11 45.3429 5.3306 104 8.51 <.0001
Race*IGFBP3 2 12 30.6346 4.2009 104 7.29 <.0001
Race*IGFBP3 2 22 36.1143 7.3261 104 4.93 <.0001
IGF1*Calbb 1 11 30.7326 3.4554 104 8.89 <.0001
IGF1*Calbb 1 12 30.9465 5.5650 104 5.56 <.0001
IGF1*Calbb 2 11 37.8550 2.8200 104 13.42 <.0001
IGF1*Calbb 2 12 26.6271 4.5160 104 5.90 <.0001
IGF1*Calbb 3 11 22.5283 3.7852 104 5.95 <.0001
IGF1*Calbb 3 12 37.3107 7.0761 104 5.27 <.0001
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Differences of Least Squares Means
_ _ _ _ _Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 Calbb hrt_sex Race IGF1 IGFBP3 b Estimate Error P1
Race 1 2 -12.7278 3.8880 0.0014
hrt_sex FN FY -5.2220 4.8658 0.8571
hrt_sex FN MN -13.1796 4.8902 0.0246
hrt_sex FY MN -7.9576 6.0748 0.5793
IGF1 1 2 -1.4015 3.9221 1.0000
IGF1 1 3 0.9201 5.1289 1.0000
IGF1 2 3 2.3216 4.7676 1.0000
IGFBP3 11 12 3.9454 3.9911 0.9756
IGFBP3 11 22 5.3251 4.9971 0.8670
IGFBP3 12 22 1.3798 4.4354 1.0000
Calbb 11 12 -1.2561 3.7734 0.7399
Race*IGFBP3 1 11 1 12 -6.8175 4.0002 0.8217
Race*IGFBP3 1 11 1 22 1.4217 4.3826 1.0000
Race*IGFBP3 1 11 2 11 -22.5053 6.1538 0.0036
Race*IGFBP3 1 12 1 22 8.2392 3.7085 0.2565
Race*IGFBP3 1 12 2 12 -0.9795 4.6832 1.0000
Race*IGFBP3 1 22 2 22 -14.6984 8.0873 0.6480
Race*IGFBP3 2 11 2 12 14.7083 6.6776 0.2682
Race*IGFBP3 2 11 2 22 9.2286 9.0298 1.0000
Race*IGFBP3 2 12 2 22 -5.4797 8.1141 1.0000
IGF1*Calbb 1 11 1 12 -0.2139 6.1481 1.0000
IGF1*Calbb 1 11 2 11 -7.1224 3.7512 0.5436
IGF1*Calbb 1 11 3 11 8.2044 4.7269 0.7704
IGF1*Calbb 1 12 2 12 4.3194 6.8196 1.0000
IGF1*Calbb 1 12 3 12 -6.3642 8.8881 1.0000
IGF1*Calbb 2 11 2 12 11.2279 4.9966 0.2403
IGF1*Calbb 2 11 3 11 15.3267 4.2525 0.0045
IGF1*Calbb 2 12 3 12 -10.6836 8.3663 1.0000
IGF1*Calbb 3 11 3 12 -14.7824 7.7927 0.5454
1 With 104 df
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Model for relative percent change in muscle volume with strength training:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC
heterozygotes, 11 is CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is
the D-allele carriers
Race: 1 is Caucasian or 2 is African American
Age is the subject’s age
hrt_sex is hormone replacement therapy status variable: MN is male, FN
is females not on hormone replacement therapy, FY is females on hormone
replacement therapy
Height is the subject’s height
bwpre is baseline body weight
bmipre is baseline body mass index
MVTB is baseline muscle volume for training (exercising) leg
pctchange is the relative change in muscle volume with strength
training
proc mixed data=one;











/outp=resids ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'females vs males' hrt_sex 0.5 0.5 -1/E;
estimate 'mean for females' height 167.57 age 64.14 bwpre 78.62 bmipre 27.89 mvtb
1468.25 intercept 1 hrt_sex 0.5 0.5 0/E;







Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
MVTB 1 106 1.32 0.2535
IGF1 2 106 1.45 0.2382
IGFBP3 2 106 0.01 0.9887
CalbB 1 106 4.38 0.0388
Age 1 106 1.47 0.2281
Race 1 106 0.74 0.3919
hrt_sex 2 106 2.09 0.1293
bmipre 1 106 0.31 0.5806
Height 1 106 0.77 0.3830
bwpre 1 106 0.30 0.5835
Least Squares Means
Standard
Label Estimate Error DF t Value Pr > |t|
females vs males -2.8997 1.6460 106 -1.76 0.0810
mean for females 7.0891 0.9905 106 7.16 <.0001
Least Squares Means
Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B Estimate Error DF t Value Pr > |t|
Race 1 7.5640 0.7817 106 9.68 <.0001
Race 2 8.5455 0.9737 106 8.78 <.0001
hrt_sex FN 6.7344 0.8776 106 7.67 <.0001
hrt_sex FY 7.4420 1.5600 106 4.77 <.0001
hrt_sex MN 9.9879 1.0974 106 9.10 <.0001
IGF1 1 6.9332 0.9706 106 7.14 <.0001
IGF1 2 8.4307 0.7677 106 10.98 <.0001
IGF1 3 8.8003 1.0365 106 8.49 <.0001
IGFBP3 11 8.1383 0.9318 106 8.73 <.0001
IGFBP3 12 8.0686 0.7948 106 10.15 <.0001
IGFBP3 22 7.9574 1.0315 106 7.71 <.0001
CalbB 11 9.1574 0.7198 106 12.72 <.0001
CalbB 12 6.9521 0.9718 106 7.15 <.0001
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Differences of Least Squares Means
Calb _ _ _ _ _Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B hrt_sex Race IGF1 IGFBP3 B Estimate Error P1
Race 1 2 -0.9816 1.1418 0.3919
hrt_sex FN FY -0.7076 1.5754 1.0000
hrt_sex FN MN -3.2535 1.5942 0.1314
hrt_sex FY MN -2.5459 2.0294 0.6372
IGF1 1 2 -1.4976 1.0001 0.4119
IGF1 1 3 -1.8672 1.2434 0.4086
IGF1 2 3 -0.3696 1.0901 1.0000
IGFBP3 11 12 0.06971 1.0320 1.0000
IGFBP3 11 22 0.1809 1.2174 1.0000
IGFBP3 12 22 0.1111 1.0310 1.0000
CalbB 11 12 2.2054 1.0539 0.0388
1 With 106 df
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Model for relative percent change in muscle quality with strength training:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC
heterozygotes, 11 is CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is
the D-allele carriers
Race: 1 is Caucasian or 2 is African American
Age is the subject’s age
hrt_sex is hormone replacement variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement
therapy
Height is the subject’s height
bwpre is baseline body weight
bmipre is baseline body mass index
mqb is baseline muscle quality (strength per muscle volume) for
training leg
logdifference is the difference between the logarithms for baseline
muscle quality and muscle quality after strength training
125
proc mixed data=one covtest scoring=10 convh=1E-5 covtest;













/outp=resids ddfm=kr htype=3 solution;
*hrt_sex FN FY MN;
estimate 'females vs males' hrt_sex 0.5 0.5 -1/E;
estimate 'mean for females' mqb 16.74 height 167.62 bwpre 78.59 bmipre 27.92 age
64.51 intercept 1 hrt_sex 0.5 0.5 0/E;






Type 3 Tests of Fixed Effects
Num Den
Effect DF DF F Value Pr > F
MQB 1 95 57.45 <.0001
Age 1 95 2.30 0.1323
Race 1 95 6.26 0.0141
Height 1 95 2.58 0.1117
bwpre 1 95 1.61 0.2078
IGF1 2 95 0.19 0.8250
IGFBP3 2 95 0.14 0.8711
CalbB 1 95 0.64 0.4241
IGF1*CalbB 2 95 4.56 0.0128
hrt_sex 2 95 1.28 0.2834
bmipre 1 95 1.00 0.3187




Label Estimate Error DF t Value Pr > |t|
females vs males -0.01407 0.01362 95 -1.03 0.3042
mean for females 0.07357 0.009649 95 7.62 <.0001
Least Squares Means
Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B Estimate Error DF t Value Pr > |t|
hrt_sex FN 0.06757 0.008609 95 7.85 <.0001
hrt_sex FY 0.07967 0.01539 95 5.18 <.0001
hrt_sex MN 0.08769 0.009179 95 9.55 <.0001
Race 1 0.06449 0.007559 95 8.53 <.0001
Race 2 0.09213 0.01009 95 9.13 <.0001
IGF1 1 0.08306 0.01116 95 7.44 <.0001
IGF1 2 0.07849 0.008375 95 9.37 <.0001
IGF1 3 0.07337 0.01210 95 6.06 <.0001
IGFBP3 11 0.07852 0.01003 95 7.83 <.0001
IGFBP3 12 0.07491 0.008624 95 8.69 <.0001
IGFBP3 22 0.08149 0.01223 95 6.66 <.0001
CalbB 11 0.07385 0.007159 95 10.32 <.0001
CalbB 12 0.08277 0.01041 95 7.95 <.0001
IGF1*CalbB 1 11 0.08266 0.01050 95 7.87 <.0001
IGF1*CalbB 1 12 0.08345 0.01840 95 4.54 <.0001
IGF1*CalbB 2 11 0.09202 0.008691 95 10.59 <.0001
IGF1*CalbB 2 12 0.06497 0.01302 95 4.99 <.0001
IGF1*CalbB 3 11 0.04686 0.01110 95 4.22 <.0001
IGF1*CalbB 3 12 0.09988 0.02057 95 4.86 <.0001
Race*IGFBP3 1 11 0.05793 0.01132 95 5.12 <.0001
Race*IGFBP3 1 12 0.07613 0.008785 95 8.67 <.0001
Race*IGFBP3 1 22 0.05941 0.01086 95 5.47 <.0001
Race*IGFBP3 2 11 0.09912 0.01585 95 6.26 <.0001
Race*IGFBP3 2 12 0.07369 0.01313 95 5.61 <.0001
Race*IGFBP3 2 22 0.1036 0.02111 95 4.91 <.0001
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Differences of Least Squares Means
Calb _ _ _ _ _Calb Standard
Effect hrt_sex Race IGF1 IGFBP3 B hrt_sex Race IGF1 IGFBP3 B Estimate Error P1
hrt_sex FN FY -0.01210 0.01580 1.0000
hrt_sex FN MN -0.02012 0.01306 0.3798
hrt_sex FY MN -0.00802 0.01804 1.0000
Race 1 2 -0.02764 0.01105 0.0141
IGF1 1 2 0.004565 0.01212 1.0000
IGF1 1 3 0.009685 0.01566 1.0000
IGF1 2 3 0.005120 0.01381 1.0000
IGFBP3 11 12 0.003609 0.01205 1.0000
IGFBP3 11 22 -0.00296 0.01475 1.0000
IGFBP3 12 22 -0.00657 0.01304 1.0000
CalbB 11 12 -0.00892 0.01111 0.4241
IGF1*CalbB 1 11 1 12 -0.00079 0.01999 1.0000
IGF1*CalbB 1 11 2 11 -0.00936 0.01124 1.0000
IGF1*CalbB 1 11 3 11 0.03580 0.01369 0.0936
IGF1*CalbB 1 12 2 12 0.01849 0.02161 1.0000
IGF1*CalbB 1 12 3 12 -0.01643 0.02771 1.0000
IGF1*CalbB 2 11 2 12 0.02705 0.01232 0.5823
IGF1*CalbB 2 11 3 11 0.04515 0.01447 0.0036
IGF1*CalbB 2 12 3 12 -0.03491 0.02417 1.0000
IGF1*CalbB 3 11 3 12 -0.05302 0.02251 0.1854
Race*IGFBP3 1 11 1 12 -0.01820 0.01222 1.0000
Race*IGFBP3 1 11 1 22 -0.00148 0.01351 1.0000
Race*IGFBP3 1 11 2 11 -0.04119 0.01887 0.2835
Race*IGFBP3 1 12 1 22 0.01673 0.01112 1.0000
Race*IGFBP3 1 12 2 12 0.002440 0.01420 1.0000
Race*IGFBP3 1 12 2 22 -0.02743 0.02200 1.0000
Race*IGFBP3 1 22 2 22 -0.04416 0.02300 0.5202
Race*IGFBP3 2 11 2 12 0.02542 0.02036 1.0000
Race*IGFBP3 2 11 2 22 -0.00445 0.02676 1.0000
Race*IGFBP3 2 12 2 22 -0.02987 0.02368 1.0000
1 With 95 df
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APPENDIX H
Frequency Tables for Genotype Groups for Gene by Gene and Gene by Race
Interactions
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APPENDIX H: FREQUENCY TABLES FOR GENOTYPE GROUPS FOR GENE
BY GENE AND GENE BY RACE INTERACTIONS
Table of frequencies for IGF1 and PPP3R1 genotype groups for change in muscle
strength with strength training
PPP3R1 Genotype Group




192 Homozygotes 28 8
192 Heterozygotes 49 13
Noncarriers of the 192 Allele 19 5
Table of frequencies for IGFBP3 and Race groups for change in muscle strength
with strength training
Race
IGFBP3 Genotype Group African
American
Caucasian
AA Homozygotes 10 22
AC Heterozygotes 15 43
CC Homozygotes 5 27
Table of frequencies for IGF1 and PPP3R1 genotype groups for change in muscle
quality with strength training
PPP3R1 Genotype Group




192 Homozygotes 26 6
192 Heterozygotes 44 13
Noncarriers of the 192 Allele 19 5
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APPENDIX I
Genotype data tables and figures for baseline muscle phenotypes and for changes in
muscle phenotypes with strength training
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APPENDIX I: GENOTYPE DATA TABLES AND FIGURES FOR BASELINE MUSCLE PHENOTYPES AND FOR
CHANGES IN MUSCLE PHENOTYPES WITH STRENGTH TRAINING
Table 7. Physical characteristics for IGF1 192 homozygotes (n = 32-36), IGF1 192 heterozygotes (n = 57-62), and IGF1





Noncarriers of the 192
Allele (n = 24-26)1
Baseline After ST Baseline After ST Baseline After ST
Age 62 (6) -- 65 (9) -- 64 (9) --
Height (cm) 169 (9) -- 166 (8) -- 170 (9) --
Weight (kg) 77.9 (14.0) 78.1 (14.2) 77.5 (14.1) 77.7 (14.4) 80.5(15.4) 80.6 (15.7)
Body Fat (%) 33.9 (7.7) 33.6 (7.5) 33.9 (7.8) 33.6 (7.9) 33.3 (7.4) 32.5 (6.9)
FFM (kg) 51.6 (11.7) 51.7 (11.3) 50.9 (10.2) 51.3 (10.3) 53.8(11.7) 54.5 (11.9)
1 RM (kg) 24 ± 1.1 26 ± 0.9 27 ± 1.2
MV (cm3) 1440 ± 36 1480 ± 29 1490 ± 39

















Values are means (SD) FFM = Fat Free Mass MV = Muscle Volume MQ = Muscle Quality
Values for 1 RM, MV, and Q are least square means ± SE 1 RM = Knee extension one repetition maximum
1Sample size variability was due to missing data for muscle phenotypes
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Table 8. Physical characteristics for IGFBP3 AA homozygotes (n = 29-32), IGFBP3 AC heterozygotes (n = 55-61), and







Baseline After ST Baseline After ST Baseline After ST
Age 63 (10) -- 65 (8) -- 65 (7) --
Height (cm) 166 (10) -- 167 (8) -- 170 (9) --
Weight (kg) 78.5 (16.3) 78.8 (16.6) 77.4(12.8) 77.6 (13.2) 79.4(15.1) 79.4 (15.2)
Body Fat (%) 34.1 (7.4) 33.7 (7.6) 34.2 (8.4) 33.8 (8.2) 32.9 (6.5) 32.3 (6.4)
FFM (kg) 51.8 (12.5) 52.2 (12.7) 50.8 (9.9) 51.2 (9.8) 53.1 (11.2) 53.5 (11.1)
1 RM (kg) 24 ± 1.1 24 ± 1.0 28 ± 1.4
MV (cm3) 1470 ± 35 1450 ± 30 1500 ± 39

















Values are means (SD) FFM = Fat Free Mass MV = Muscle Volume MQ = Muscle Quality
Values for 1 RM, MV, and Q are least square means ± SE 1 RM = Knee extension one repetition maximum
1Sample size variability was due to missing data for muscle phenotypes
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Table 9. Physical characteristics for PPP3R1 II homozygotes (n = 89-96) and PPP3R1 D-allele carriers (n = 24-26) at





Baseline After ST Baseline After ST
Age 65 (8) -- 62 (9) --
Height (cm) 168 (9) -- 167 (6) --
Weight (kg) 78.7 (15.1) 78.8 (15.3) 76.3(10.8) 76.9 (11.3)
Body Fat (%) 33.6 (7.7) 33.1 (7.6) 34.5 (7.4) 34.3 (7.4)
FFM (kg) 52.1 (11.5) 52.5 (11.5) 49.8(8.4) 50.4 (8.6)
1 RM (kg) 24 ± 0.8 27 ± 1.2
MV (cm3) 1460 ± 27 1490 ± 36
MQ (kg/cm3)*10-3 16.6 ± 0.47 17.4 ± 0.64
Male/Female 44-47/45-49 -- 9-10/15-17 --
African
Americans/Caucasians
16-18/73-79 -- 12-14/12-13 --
Values are means (SD) FFM = Fat Free Mass MV = Muscle Volume MQ = Muscle Quality
Values for 1 RM, MV, and Q are least square means ± SE 1 RM = Knee extension one repetition maximum
1Sample size variability was due to missing data for muscle phenotypes
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Table 10. Change in muscle strength with strength training for IGF1 192 homozygotes (n = 36), IGF1 192
heterozygotes






192 Allele (n = 24)
Age 62 (6) 65 (9) 64 (9)
Height (cm) 169 (9) 166 (8) 170 (9)
Weight (kg) 77.9 (14.0) 77.5 (14.1) 80.5 (15.4)
Baseline Body Fat (%) 33.9 (7.7) 33.9 (7.8) 33.3 (7.4)
Baseline FFM (kg) 51.6 (11.7) 50.9 (10.2) 53.8(11.7)
Baseline 1 RM (kg)











Values are means (SD)
Values for ∆ 1 RM are least square means ± SE
FFM = Fat Free Mass
1 RM = Knee extension one repetition maximum
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Table 11. Change in muscle strength with strength training for IGFBP3 AA homozygotes (n = 32), IGFBP3 AC







Age 63 (10) 65 (8) 65 (7)
Height (cm) 166 (10) 167 (8) 170 (9)
Baseline Weight (kg) 78.5 (16.3) 77.4 (12.8) 79.4 (15.1)
Baseline Body Fat (%) 34.1 (7.4) 34.2 (8.4) 32.9 (6.5)
Baseline FFM (kg) 51.8 (12.5) 50.8 (9.9) 53.1 (11.2)
Baseline 1 RM (kg) 24 ± 1.1 24 ± 1.0 28 ± 1.4
∆ 1 RM (kg) 7.9 ± 0.78 6.6 ± 0.65 5.8 ± 0.96




Values are means (SD)
Values for ∆ 1 RM are least square means ± SE
FFM = Fat Free Mass
1 RM = Knee extension one repetition maximum
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Table 12. Change in muscle strength with strength training for PPP3R1 II homozygotes (n = 96) and PPP3R1 D-allele





Age 65 (8) 62 (9)
Height (cm) 168 (9) 167 (6)
Baseline Weight (kg) 78.7 (15.1) 76.3 (10.8)
Baseline Body Fat (%) 33.6 (7.7) 34.5 (7.4)
Baseline FFM (kg) 52.1 (11.5) 49.8 (8.4)
Baseline 1 RM (kg) 24 ± 0.8 27 ± 1.2





Values are means (SD)
Values for ∆ 1 RM are least square means ± SE
FFM = Fat Free Mass
1 RM = Knee extension one repetition maximum
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Table 13. Change in muscle volume with strength training for IGF1 192 homozygotes (n = 35), IGF1 192 heterozygotes






192 Allele (n = 26)
Age 63 (6) 65 (9) 64 (9)
Height (cm) 168 (9) 167 (8) 169 (9)
Baseline Weight (kg) 77.7 (14.4) 78.5 (15.0) 80.2 (15.0)
Baseline Body Fat (%) 33.8 (7.7) 33.9 (7.9) 33.3 (7.4)
Baseline FFM (kg) 51.5 (12.0) 51.5 (10.7) 53.2 (11.4)
Baseline MV (cm3) 1440 ± 36 1480 ± 29 1490 ± 39
∆MV (cm3) 110 ± 14 130 ± 11 120 ± 15




Values are means (SD)
Values for ∆MV are least square means ± SE
FFM = Fat Free Mass
MV = Muscle Volume
138
Table 14. Change in muscle volume for IGFBP3 AA homozygotes (n = 30), IGFBP3 AC heterozygotes (n = 61), and







Age 64 (10) 65 (8) 65 (7)
Height (cm) 165 (9) 167 (8) 171 (8)
Baseline Weight (kg) 78.4 (16.4) 77.9 (13.9) 80.5 (14.8)
Baseline Body Fat (%) 34.1 (7.7) 34.1 (8.2) 33.0 (6.6)
Baseline FFM (kg) 51.6 (12.7) 51.1 (10.6) 53.7 (10.9)
Baseline MV (cm3) 1470 ± 35 1450 ± 30 1500 ± 39
∆MV (cm3) 120 ± 13 120 ± 11 110 ± 15




Values are means (SD)
Values for ∆MV are least square means ± SE
FFM = Fat Free Mass
MV = Muscle Volume
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Table 15. Change in muscle volume with strength training for PPP3R1 II homozygotes (n = 94) and PPP3R1 D-allele





Age 64 (8) 63 (8)
Height (cm) 168 (9) 166 (6)
Baseline Weight (kg) 79.0 (15.6) 77.1 (10.9)
Baseline Body Fat (%) 33.6 (7.8) 34.6 (7.3)
Baseline FFM (kg) 52.3 (11.7) 50.3 (8.8)
Baseline MV (cm3) 1460 ± 27 1490 ± 36





Values are means (SD)
Values for ∆MV are least square means ± SE
FFM = Fat Free Mass
MV = Muscle Volume
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Table 16. Change in muscle quality with strength training for IGF1 192 homozygotes (n = 32), IGF1 192 heterozygotes






192 Allele (n = 24)
Age 63 (6) 66 (9) 64 (9)
Height (cm) 168 (9) 167 (8) 170 (9)
Baseline Weight (kg) 78.3 (14.3) 77.9 (13.9) 80.5 (15.4)
Baseline Body Fat (%) 34.1 (8.0) 34.2 (7.9) 33.3 (7.4)
Baseline FFM (kg) 51.7 (12.1) 50.9 (10.0) 53.8 (11.7)
Baseline MQ
(kg/cm3)*10-3
16.2 ± 0.63 17.3 ± 0.52 17.5 ± 0.67
∆MQ (kg/cm3)*10-3 3.2 ± 0.48 3.2 ± 0.34 2.7 ± 0.52




Values are means (SD)
Values for ∆MQ are least square means ± SE
FFM = Fat Free Mass
MQ = Muscle Quality
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Table 17. Change in muscle quality with strength training for IGFBP3 AA homozygotes (n = 29), IGFBP3 AC







Age 63 (10) 65 (8) 65 (7)
Height (cm) 165 (10) 167 (8) 170 (8)
Baseline Weight (kg) 78.2 (16.7) 77.8 (12.7) 80.5 (14.8)
Baseline Body Fat (%) 33.9 (7.7) 34.6 (8.4) 33.0 (6.6)
Baseline FFM (kg) 51.8 (12.9) 50.7 (9.9) 53.7 (10.9)
Baseline MQ
(kg/cm3)*10-3
16.1 ± 0.61 16.5 ± 0.55 18.5 ± 0.77
2.9 ± 0.41 3.2 ± 0.35 3.0 ± 0.44∆MQ(kg/cm3)*10-3




Values are means (SD)
Values for ∆MQ are least square means ± SE
FFM = Fat Free Mass
MQ = Muscle Quality
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Table 18. Change in muscle quality with strength training for PPP3R1 II homozygotes (n = 89)





Age 65 (8) 63 (8)
Height (cm) 168 (9) 166 (6)
Baseline Weight (kg) 79.0 (15.1) 76.9 (11.0)
Baseline Body Fat (%) 33.8 (7.8) 34.8 (7.5)
Baseline FFM (kg) 52.2 (11.5) 50.0 (8.6)
Baseline MQ
(kg/cm3)*10-3
16.6 ± 0.47 17.4 ± 0.64





Values are means (SD)
Values for ∆MQ are least square means ± SE
FFM = Fat Free Mass
MQ = Muscle Quality
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Age 62 (6) 61 (9) 66 (9) 63 (9) 65 (9) 62 (8)
Height (cm) 169 (9) 168 (7) 166 (9) 167 (7) 171 (10) 164 (4)
Baseline Weight (kg) 77.9 (14.6) 78.0 (12.8) 78.1 (14.8) 74.9 (10.8) 81.3 (16.9) 77.4 (8.4)
Baseline Body Fat (%) 35.1 (7.4) 29.7 (7.6) 33.3 (7.9) 36.5 (7.3) 32.4 (7.9) 36.9 (4.1)
Baseline FFM (kg) 50.8 (12.8) 54.2 (6.1) 51.8 (10.4) 47.5 (9.4) 55.1 (12.5) 48.9 (7.0)
Baseline 1 RM (kg) 22 ± 1.3 29 ± 2.2 25 ± 1.0 27 ± 1.6 26 ± 1.4 25 ± 2.7
∆ 1 RM (kg) 6.9 ± 0.81 6.2 ± 1.30 8.4 ± 0.66* 6.4 ± 1.06 4.7 ± 0.89 7.7 ± 1.66
Male/Female 12/16 4/4 24/25 4/9 11/8 1/4
African
Americans/Caucasians
2/26 2/6 9/40 7/6 6/13 4/1
Values are means (SD) 192/192 = IGF1 192 Homozygotes
Values for ∆ 1 RM are least square means ± SE 192/- = IGF1 192 Heterozygotes
FFM = Fat Free Mass -/- = IGF1 non-carriers if the 192 allele
1 RM = Knee extension one repetition maximum
* Significantly greater than PPP3R1 II and IGF1 -/-, P < 0.05
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Age 60 (7) 62 (6) 62 (8) 64 (11) 65 (8) 67 (7) 59 (11) 67 (10) 62 (6)
Height (cm) 169 (12) 167 (8) 172 (5) 163 (8) 167 (8) 169 (10) 170 (10) 169 (9) 170 (11)


















Baseline Body Fat (%) 32.2 (8.4) 35.5 (7.8) 32.2(6.3) 34.8 (7.0) 34.1(9.4) 32.6 (6.1) 35.0 (8.6) 32.3 (7.1) 34.3 (8.2)
Baseline FFM (kg) 55.1(15.0) 49.1(11.1) 53.4(8.3) 49.9(11.5) 50.7(8.9) 52.1(11.1) 52.9(13.1) 53.3(10.1) 55.2(15.20
Baseline 1 RM (kg) 24 ± 2.0 24 ± 1.6 30 ± 2.8 23 ± 1.4 25 ± 1.4 30 ± 2.3 18 ± 3.5 25 ± 1.7 29 ± 2.5
∆ 1 RM (kg) 7.2 ± 1.54 6.7 ± 1.19 7.9±2.16 8.8 ± 0.96 7.5±0.95 6.8 ± 1.68 8.6 ± 2.39 5.9 ± 1.16 6.2 ± 1.75
Male/Female 4/5 7/12 5/3 7/12 11/15 10/7 2/2 6/7 4/3
African
Americans/Caucasians
1/8 3/16 0/8 8/11 7/19 1/16 1/3 5/8 4/3
Values are means (SD) AA = IGFBP3 AA Homozygotes 192/192 = IGF1 192 Homozygotes
Values for ∆ 1 RM are least square means ± SE AC = IGFBP3 AC Heterozygotes 192/- = IGF1 192 Heterozygotes
FFM = Fat Free Mass CC = IGFBP3 CC Homozygotes -/- = IGF1 non-carriers of the 192
allele
1 RM = Knee extension one repetition maximum
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Age 65 (10) 58 (6) 64 (7) 65 (10) 65 (8) 64 (6)
Height (cm) 166 (11) 164 (6) 167 (8) 170 (7) 170 (9) 165 (3)
Baseline Weight (kg) 79.7 (16.7) 74.4 (14.6) 77.1 (13.7) 79.2 (8.2) 80.4 (15.9) 72.5 (4.3)
Baseline Body Fat (%) 33.3 (7.4) 33.9 (8.0) 34.6 (8.8) 34.5 (7.1) 32.5 (6.2) 35.8 (8.7)
Baseline FFM (kg) 53.3 (13.4) 48.9 (10.1) 50.2 (10.3) 51.7 (6.8) 54.1 (11.4) 46.4 (8.3)
Baseline 1 RM (kg) 24 ± 1.5 23 ± 1.8 23 ± 1.1 26 ± 1.6 26 ± 1.4 32 ± 2.8
∆ 1 RM (kg) 8.3 ± 1.03 7.5 ± 1.46 6.6 ± 0.74 6.8 ± 1.11 6.0 ± 1.07 7.6 ± 2.02
Male/Female 12/13 3/7 17/26 5/7 18/10 1/3
African
Americans/Caucasians
5/20 6/4 8/35 6/6 4/24 1/3
Values are means (SD) AA = IGFBP3 AA Homozygotes
Values for ∆ 1 RM are least square means ± SE AC = IGFBP3 AC Heterozygotes
FFM = Fat Free Mass CC = IGFBP3 CC Homozygotes
1 RM = Knee extension one repetition maximum
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Age 62 (5) 65 (8) 65 (9) 63 (9) 65 (9) 61 (7)
Height (cm) 168 (9) 166 (7) 167 (9) 167 (7) 171 (10) 164 (4)
Baseline Weight (kg) 76.5 (14.7) 82.2 (12.9) 79.5 (15.9) 74.9 (10.8) 81.4 (16.4) 76.0 (8.2)
Baseline Body Fat (%) 35.0 (7.5) 29.3 (7.7) 33.2 (8.0) 36.5 (7.3) 32.8 (8.0) 36.7 (3.7)
Baseline FFM (kg) 50.0 (12.7) 57.4 (5.4) 52.7 (10.8) 47.5 (9.4) 54.8 (12.2) 48.2 (6.5)
Baseline MV (cm3) 1450 ± 48 1500 ± 79 1490 ± 37 1510 ± 56 1460 ± 45 1450 ± 99
∆MV (cm3) 90 ± 24 60 ± 30 130 ± 14 120 ± 21 140 ± 17 100 ± 34
Male/Female 11/17 5/2 24/22 4/9 11/9 1/5
African
Americans/Caucasians
2/26 2/5 9/37 7/6 7/13 5/1
Values are means (SD) 192/192 = IGF1 192 Homozygotes
Values for ∆MV are least square means ± SE 192/- = IGF1 192 Heterozygotes
FFM = Fat Free Mass -/- = IGF1 non-carriers of the 192 allele
MV = Muscle Volume
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Age 62 (8) 63 (5) 64 (7) 64 (11) 65 (8) 66 (7) 61 (10) 67 (10) 62 (6)
Height (cm) 168 (13) 167 (8) 171 (5) 163 (8) 167 (8) 171 (8) 168 (10) 169 (9) 169 (10)
Baseline Weight (kg) 81.2(21.1) 75.4(13.1) 80.9(10.3) 75.6(16.0) 80.0(14.8) 79.7(14.3) 81.2(12.3) 78.9(13.4) 81.5(20.0)
Baseline Body Fat (%) 31.6 (9.6) 35.2 (7.5) 31.9 (6.7) 34.3 (6.8) 34.2 (9.4) 32.7 (6.4) 36.2 (8.0) 32.3 (7.1) 34.4 (7.7)
Baseline FFM (kg) 55.6(16.4) 49.0(11.3) 54.8 (7.9) 49.6(11.6) 52.1(10.3) 53.0(10.5) 52.0(11.5) 53.3(10.1) 53.9(14.6)
Baseline MV (cm3) 1450 ± 70 1390 ± 48 1560 ± 85 1480 ± 44 1440 ± 42 1570 ± 69 1430 ± 86 1500 ± 53 1490 ± 69
∆MV (cm3) 60 ± 29 80 ± 22 90 ± 38 150 ±16 110 ± 16 90 ± 28 130 ± 32 130 ± 20 110 ± 26
Male/Female 3/4 8/13 5/2 7/12 12/14 9/5 2/3 6/7 4/4
African
Americans/Caucasians
1/6 3/18 0/7 8/11 7/19 1/13 2/3 5/8 5/3
Values are means (SD) AA = IGFBP3 AA Homozygotes 192/192 = IGF1 192 Homozygotes
Values for ∆MV are least square means ± SE AC = IGFBP3 AC Heterozygotes 192/- = IGF1 192 Heterozygotes
FFM = Fat Free Mass CC = IGFBP3 CC Homozygotes -/- = IGF1 non-carriers of the 192
allele
MV = Muscle volume
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Age 66 (10) 59 (6) 64 (7) 67 (9) 64 (7) 62 (6)
Height (cm) 166 (11) 164 (6) 167 (8) 169 (7) 172 (8) 165 (3)
Baseline Weight (kg) 79.7 (17.1) 75.2 (15.2) 77.1 (15.0) 80.8 (8.2) 82.3 (15.6) 71.8 (4.0)
Baseline Body Fat (%) 34.2 (7.5) 33.8 (8.5) 34.0 (8.5) 34.7 (6.9) 32.4 (6.5) 35.7 (7.5)
Baseline FFM (kg) 52.6 (13.6) 49.5 (10.6) 50.7 (11.2) 52.7 (7.7) 55.3 (10.9) 46.0 (7.3)
Baseline MV (cm3) 1490 ± 45 1450 ± 61 1430 ± 34 1450 ± 53 1470 ± 47 1580 ± 79
∆MV(cm3) 120 ± 16 130 ± 23 140 ± 12 90 ± 20 130 ± 16 100 ± 30
Male/Female 9/12 3/6 20/29 6/6 17/7 ¼
African
Americans/Caucasians
5/16 6/3 9/40 6/6 4/20 2/3
Values are means (SD) AA = IGFBP3 AA Homozygotes
Values for ∆MV are least square means ± SE AC = IGFBP3 AC Heterozygotes
FFM = Fat Free Mass CC = IGFBP3 CC Homozygotes
MV= Muscle Volume
149



























Age 62 (6) 65 (8) 66 (8) 63 (9) 65 (8) 62 (8)
Height (cm) 168 (9) 167 (7) 166 (9) 167 (7) 171 (10) 164 (4)
Weight (kg) 77.7 (14.6) 81.0 (13.7) 78.8 (14.7) 74.9 (10.8) 81.3 (16.9) 77.4 (8.4)
Body Fat (%) 35.2 (7.7) 29.4 (8.4) 33.5 (8.0) 36.5 (7.3) 32.4 (7.9) 36.9 (4.1)
FFM (kg) 50.6 (13.0) 56.3 (4.9) 51.9 (10.1) 47.5 (9.4) 55.1 (12.5) 48.9 (7.0)
Baseline MQ (kg/cm3)*10-3 15.7 ± 0.68 17.3 ± 1.21 17.0 ± 0.57 17.6 ± 0.85 17.2 ± 0.73 17.4 ± 1.35
∆MQ (kg/cm3)*10-3 3.3 ± 0.45 3.1 ± 0.80 3.7 ± 0.37* 2.7 ± 0.53 1.8 ± 0.48 3.6 ± 0.88
Male/Female 11/15 4/2 22/22 4/9 11/8 1/4
African
Americans/Caucasians
2/24 1/5 8/36 7/6 6/13 4/1
Values are means (SD) 192/192 = IGF1 192 Homozygotes
Values for ∆MV are least square means ± SE 192/- = IGF1 192 Heterozygotes
FFM = Fat Free Mass -/- = IGF1 non-carriers of the 192 allele
MQ = Muscle Quality
* Significantly greater than PPP3R1 II and IGF1 -/-, P < 0.05
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Age 62 (8) 63 (5) 64 (7) 65 (11) 66 (8) 66 (2) 59 (11) 67 (10) 62 (60
Height (cm) 168 (13) 167 (8) 171 (5) 163 (8) 167 (8) 170 (8) 170 (10) 169 (9) 170 (11)
Baseline Weight (kg) 81.2(21.1) 76.2(12.9) 80.9(10.3) 76.4(16.1) 78.4(12.6) 79.0(14.1) 80.9(14.2) 78.9(13.4) 83.2(20.9)
Baseline Body Fat (%) 31.6 (9.6) 36.0 (7.7) 31.9 (6.7) 34.5 (7.0) 34.8 (9.5) 32.8 (6.2) 35.0 (8.6) 32.3 (7.1) 34.3 (8.3)





















∆MQ (kg/cm3)*10-3 3.5 ± 0.85 2.6 ± 0.77 4.5 ± 1.20 2.8 ± 0.51 3.7 ± 0.53 3.9 ± 0.88 3.7 ± 1.26 2.7 ± 0.61 3.7 ± 0.92
Male/Female 3/4 7/11 5/2 7/11 10/14 9/6 2/2 6/7 4/3
African
Americans/Caucasians
1/6 2/16 0/7 8/10 6/18 1/14 1/3 5/8 4/3
Values are means (SD) AA = IGFBP3 AA Homozygotes 192/192 = IGF1 192 Homozygotes
Values for ∆MQ are least square means ± SE AC = IGFBP3 AC Heterozygotes 192/- = IGF1 192 Heterozygotes
FFM = Fat Free Mass CC = IGFBP3 CC Homozygotes -/- = IGF1 non-carriers of the 192
allele MQ = Muscle Quality
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Age 66 (11) 59 (6) 65 (7) 67 (9) 65 (7) 64 (6)
Height (cm) 166 (11) 164 (6) 167 (9) 169 (7) 171 (9) 165 (3)
Baseline Weight (kg) 79.6 (17.5) 75.2 (15.2) 77.3 (13.6) 80.0 (8.1) 81.7 (15.5) 72.5 (4.3)
Baseline Body Fat (%) 33.9 (7.5) 33.8 (8.5) 34.4 (8.8) 35.3 (6.9) 32.5 (6.4) 35.8 (8.7)
Baseline FFM (kg) 52.8 (13.9) 49.5 (10.6) 50.5 (10.5) 51.7 (7.2) 54.9 (10.9) 46.4 (8.3)
Baseline MQ
(kg/cm3)*10-3
15.9 ± 0.83 15.3 ± 1.23 16.1 ± 0.62 17.4 ± 0.95 18.0 ± 0.81 19.8 ± 1.53
∆MQ (kg/cm3)*10-3 3.3± 0.52 2.4 ± 0.75 3.0 ± 0.39 3.2 ± 0.61 2.9 ± 0.53 4.6 ± 0.98
Male/Female 9/11 3/6 18/26 5/6 17/8 1/3
African
Americans/Caucasians
4/16 6/3 8/36 5/6 4/21 1/3
Values are means (SD) MQ = Muscle Quality CC = IGFBP3 CC Homozygotes
Values for ∆MQ are least square means ± SE AA = IGFBP3 AA Homozygotes






































Figure 5 Baseline Muscle Strength for Race by
IGFBP3 Genotype Groups












































Figure 6 Baseline Muscle Quality for Race by
IGFBP3 Genotype Groups

































Figure 7 Percent Change in Muscle Strength with Strength
Training by Race and Insulin-like Growth Factor Binding
Protein 3 (IGFBP3) Genotype Group












































































Figure 8 Relative Change in Muscle Quality by Race and
Insulin-like Growth Factor Binding Protein 3 (IGFBP3)
Genotype Group
P = 0.076 for interaction




















Figure 9 Change in Muscle Volume with Strength Training for Insulin-like Growth





















Figure 10 Change in Muscle Volume with Strength Training for Insulin-like





















































Figure 11 Change in Muscle Quality with Strength Training for Insulin-



























Models and Results for Calculating Percent Variability
160
APPENDIX J: MODELS AND RESULTS FOR CALCULATING PERCENT
VARIABILITY
Model for calculating percent variability for change in muscle strength with
strength training attributable to genotypes:
RMTLPREKG is baseline muscle strength
rmdkg is change in muscle strength with strength training
igf1 is subject’s insulin-like growth factor 1 genotype
igfbp3 is subject’s insulin-like growth factor binding protein 3 genotype
calbb is subject’s calcineurin B (PPP3R1) genotype
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
hrt_sex is subject’s hormone replacement status
proc means data=one n css;
var rmdkg;
quit;
proc mixed data=one method=type3 covtest boxplot;













/ ddfm=sat solution residuals;







Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square Error F Value Pr > F
DF
RMTLPREKG 1 3.614304 3.614304 104 0.31 0.5789
Race 1 99.966343 99.966343 104 8.57 0.0042
Height 1 8.642697 8.642697 104 0.74 0.3912
IGF1 2 15.800191 7.900095 104 0.68 0.5101
IGFBP3 2 40.699811 20.349906 104 1.75 0.179
Calbb 1 0.199613 0.199613 104 0.02 0.8961
Age 1 16.368561 16.368561 104 1.40 0.2388
bwpre 1 1.644461 1.644461 104 0.14 0.7080
hrt_sex 2 100.878464 50.439232 104 4.33 0.0157
bmipre 1 1.967392 1.967392 104 0.17 0.6821
Race*IGFBP3 2 56.527655 28.263828 104 2.42 0.0935
IGF1*Calbb 2 63.061851 31.530925 104 2.70 0.0716
Residual 104 1212.521814 11.658864 . . .
Covariance Parameter Estimates
Standard Z
Cov Parm Estimate Error Value Pr Z
Residual 11.6589 1.6168 7.21 <.0001
Fit Statistics
-2 Res Log Likelihood 622.0
AIC (smaller is better) 624.0
AICC (smaller is better) 624.1
BIC (smaller is better) 626.7
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Solution for Fixed Effects
Standard
Effect hrt_sex Race IGF1 IGFBP3 Calbb Estimate Error t Value Pr > |t|1
Intercept -23.2374 43.4170 -0.54 0.5936
RMTLPREKG -0.03551 0.06378 -0.56 0.5789
Race 1 -1.6713 1.8924 -0.88 0.3792
Race 2 0 . . .
Height 0.2197 0.2552 0.86 0.3912
IGF1 1 -1.5005 2.0798 -0.72 0.4723
IGF1 2 -1.3730 1.9577 -0.70 0.4847
IGF1 3 0 . . .
IGFBP3 11 3.8068 2.1130 1.80 0.0745
IGFBP3 12 0.5859 1.8987 0.31 0.7583
IGFBP3 22 0 . . .
Calbb 11 -3.0272 1.8235 -1.66 0.0999
Calbb 12 0 . . .
Age -0.05539 0.04675 -1.18 0.2388
bwpre -0.1025 0.2730 -0.38 0.7080
hrt_sex FN -3.3289 1.1443 -2.91 0.0044
hrt_sex FY -3.0686 1.4215 -2.16 0.0332
hrt_sex MN 0 . . .
bmipre 0.3096 0.7536 0.41 0.6821
Race*IGFBP3 1 11 -3.4118 2.3587 -1.45 0.1511
Race*IGFBP3 1 12 0.4335 2.0994 0.21 0.8368
Race*IGFBP3 1 22 0 . . .
Race*IGFBP3 2 11 0 . . .
Race*IGFBP3 2 12 0 . . .
Race*IGFBP3 2 22 0 . . .
IGF1*Calbb 1 11 3.7116 2.3102 1.61 0.1112
IGF1*Calbb 1 12 0 . . .
IGF1*Calbb 2 11 5.0233 2.1604 2.33 0.0220
IGF1*Calbb 2 12 0 . . .
IGF1*Calbb 3 11 0 . . .
IGF1*Calbb 3 12 0 . . .
1with 104 DF
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Model for calculating percent variability for change in muscle volume with strength
training attributable to genotypes:
mvtb is baseline muscle volume
mvca is change in muscle volume with strength training
igf1 is subject’s insulin-like growth factor 1 genotype
igfbp3 is subject’s insulin-like growth factor binding protein 3 genotype
calbb is subject’s calcineurin B (PPP3R1) genotype
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
hrt_sex is subject’s hormone replacement status
proc means data=one n css;
var mvca;
quit;
proc mixed data=one method=type3 covtest boxplot;



















Type 3 Analysis of Variance
Sum of Error
Source DF Squares Mean Square DF F Value Pr > F
MVTB 1 11072 11072 106 2.77 0.0989
IGF1 2 8332.125558 4166.062779 106 1.04 0.3561
IGFBP3 2 725.618650 362.809325 106 0.09 0.9133
CalbB 1 14365 14365 106 3.60 0.0607
Age 1 4566.843505 4566.843505 106 1.14 0.2874
Race 1 4228.496532 4228.496532 106 1.06 0.3059
hrt_sex 2 13588 6794.016230 106 1.70 0.1875
bmipre 1 75.755552 75.755552 106 0.02 0.8907
Height 1 60.254168 60.254168 106 0.02 0.9025
bwpre 1 127.297106 127.297106 106 0.03 0.8587
Residual 106 423504 3995.322087 . . .
Covariance Parameter Estimates
Standard Z
Cov Parm Estimate Error Value Pr Z
Residual 3995.32 548.80 7.28 <.0001
Fit Statistics
-2 Res Log Likelihood 1254.4
AIC (smaller is better) 1256.4
AICC (smaller is better) 1256.4
BIC (smaller is better) 1259.1
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Solution for Fixed Effects
Standard
Effect hrt_sex Race IGF1 IGFBP3 CalbB Estimate Error t Value Pr > |t|1
Intercept 171.39 462.22 0.37 0.7115
MVTB 0.06110 0.03670 1.66 0.0989
IGF1 1 -18.3347 17.7056 -1.04 0.3028
IGF1 2 1.7261 15.5227 0.11 0.9117
IGF1 3 0 . . .
IGFBP3 11 7.2093 17.3346 0.42 0.6783
IGFBP3 12 4.7028 14.6802 0.32 0.7493
IGFBP3 22 0 . . .
CalbB 11 28.4556 15.0071 1.90 0.0607
CalbB 12 0 . . .
Age -0.8738 0.8173 -1.07 0.2874
Race 1 -16.7266 16.2588 -1.03 0.3059
Race 2 0 . . .
hrt_sex FN -41.8630 22.7002 -1.84 0.0680
hrt_sex FY -34.3320 28.8966 -1.19 0.2375
hrt_sex MN 0 . . .
bmipre 1.0920 7.9300 0.14 0.8907
Height -0.3215 2.6177 -0.12 0.9025
bwpre -0.5302 2.9702 -0.18 0.85
Residual . .
1 with 106 DF
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Model for calculating percent variability for change in muscle quality with strength
training attributable to genotypes:
mqb is baseline muscle volume
mqc is change in muscle volume with strength training
igf1 is subject’s insulin-like growth factor 1 genotype
igfbp3 is subject’s insulin-like growth factor binding protein 3 genotype
calbb is subject’s calcineurin B (PPP3R1) genotype
bwpre is subject’s baseline body weight
bmipre is subject’s baseline body mass index
hrt_sex is subject’s hormone replacement status
proc means data=one n css;
var mqc;
quit;
proc mixed data=one method=type3 covtest boxplot;




















Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square DF F Value Pr > F
MQB 1 94.083090 94.083090 97 28.39 <.0001
Age 1 11.907632 11.907632 97 3.59 0.0610
Race 1 12.927397 12.927397 97 3.90 0.0511
Height 1 5.273079 5.273079 97 1.59 0.2102
bwpre 1 3.409480 3.409480 97 1.03 0.3103
IGF1 2 2.440301 1.220151 97 0.37 0.6930
IGFBP3 2 2.733374 1.366687 97 0.41 0.6632
CalbB 1 0.502028 0.502028 97 0.15 0.6980
IGF1*CalbB 2 20.358235 10.179117 97 3.07 0.0509
hrt_sex 2 11.301844 5.650922 97 1.71 0.1871
bmipre 1 1.977592 1.977592 97 0.60 0.4417
Residual 97 321.457894 3.313999 . .
Covariance Parameter Estimates
Standard Z
Cov Parm Estimate Error Value Pr Z
Residual 3.3140 0.4759 6.96 <.0001
Fit Statistics
-2 Res Log Likelihood 457.7
AIC (smaller is better) 459.7
AICC (smaller is better) 459.7
BIC (smaller is better) 462.3
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Solution for Fixed Effects
Standard
Effect hrt_sex Race IGF1 IGFBP3 CalbB Estimate Error t Value Pr > |t|1
Intercept -14.3454 24.2313 -0.59 0.5552
MQB -0.3414 0.06407 -5.33 <.0001
Age -0.04674 0.02466 -1.90 0.0610
Race 1 -0.8901 0.4507 -1.98 0.0511
Race 2 0 . . .
Height 0.1821 0.1444 1.26 0.2102
bwpre -0.1522 0.1501 -1.01 0.3130
IGF1 1 -0.4831 1.1874 -0.41 0.6850
IGF1 2 -0.9181 1.0069 -0.91 0.3641
IGF1 3 0 . . .
IGFBP3 11 -0.1028 0.5160 -0.20 0.8425
IGFBP3 12 0.2788 0.4360 0.64 0.5240
IGFBP3 22 0 . . .
CalbB 11 -1.7609 0.9628 -1.83 0.0705
CalbB 12 0 . . .
IGF1*CalbB 1 11 1.9392 1.3021 1.49 0.1397
IGF1*CalbB 1 12 0 . . .
IGF1*CalbB 2 11 2.7819 1.1229 2.48 0.0150
IGF1*CalbB 2 12 0 . . .
IGF1*CalbB 3 11 0 . . .
IGF1*CalbB 3 12 0 . . .
hrt_sex FN -1.0061 0.5636 -1.79 0.0774
hrt_sex FY -0.4181 0.7848 -0.53 0.5955
hrt_sex MN 0 . . .
bmipre 0.3207 0.4152 0.77 0.4417
1 with 97 DF
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APPENDIX K
Calculations for Percent Variability for all Genotypes and each Gene by Gene
Interaction of Interest
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APPENDIX K: CALCULATIONS FOR PERCENT VARIABILITY FOR ALL
GENOTYPES AND EACH GENE BY GENE INTERACTION OF INTEREST
To determine the percent variability of the muscle phenotype attributable to each
genotype and each gene by gene interaction of interest, r2 was determined from the Type
III sums of squares.




r2 = SSM/SST = SSM/(SSM +SSE)
For this model only random (due to error) and genetic effects of interest were included,
so the model sums of squares included all genotypes and those gene by gene interactions
which were significant or exhibited a trend. Covariates were not included in the model
because they should not play a role because they are being controlled for. Example: BMI
would not be expected to contribute to the change in muscle strength with strength
training (if it does it is controlled for by using as a covariate).
So if there was a significant IGF1*PPP3R1 interaction or a trend towards a significant
interaction the r2 terms would be the following:
r2IGF1average = SSIGF1/(SSIGF1 + SSIGFBP3 + SSPPP3R1 + SSIGF1*PPP3R1 + Error (or SSresidual)) 
 
r2IGFBP3average = SSIGFBP3/(SSIGF1 + SSIGFBP3 + SSPPP3R1 + SSIGF1*PPP3R1 + Error (or
SSresidual)) 
 
r2PPP3R1average = SSPPP3R1/(SSIGF1 + SSIGFBP3 + SSPPP3R1 + SSIGF1*PPP3R1 + Error (or
SSresidual)) 
 
r2IGF1*PPP3R1average = SSIGF1*PPP3R1/(SSIGF1 + SSIGFBP3 + SSPPP3R1 + SSIGF1*PPP3R1 + Error (or
SSresidual)) 
 
However, for each gene involved in a significant or trend towards a significant interaction
some of the sums of squares is contributed by the sums of squares for the interaction. It
is not possible to determine this contribution so it was estimated that each gene involved
in an interaction contributed half of the percent variability.
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For change in muscle strength with strength training. There were trends for a
significant interaction gene by gene interaction for IGF1 by PPP3R1 (P = 0.0716)






SSRESIDUAL (ERROR) = 1212.52
r2IGF1AVG = 15.80/(15.80+40.70+0.20+63.06+56.53+1212.52) = 15.80/1388.81 = 1.14%
r2IGFBP3AVG = 40.70/1388.81 = 2.93%
r2PPP3R1AVG = 0.20/1388.81 = 0.01%
r2IGF1*PPP3R1 = 63.06/1388.81 = 4.54%
r2IGFBP3*Race = 56.53/1388.81 = 4.07%
r2IGF1 ~ 4.54/2 + 1.14 ~ 3.41%
r2IGFBP3 ~ 4.07/2 + 2.93 ~ 4.97%
r2PPP3R1 ~ 4.54/2 + 0.01 ~ 2.28%
For change in muscle volume with strength training. There was a trend for a




SSRESIDUAL (ERROR) = 423504
r2IGF1 = 8332/(8332+726+14365+423504) = 8332/446927 = 1.86%
r2IGFBP3 = 726/446927 = 0.16%
r2PPP3R1 = 14365/446927 = 3.21%
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For change in muscle quality with strength training. There was a trend for a





SSRESIDUAL (ERROR) = 321.46
r2IGF1AVG = 2.44/(2.44+2.73+0.50+20.36+321.46) = 2.44/347.49= 0.70%
r2IGFBP3AVG = 2.73/347.49 = 0.79%
r2PPP3R1AVG = 0.50/347.49 = 0.14%
r2IGF1*PPP3R1 = 20.36/347.49 = 5.86%
r2IGF1 ~ 5.86/2 + 0.70 ~ 3.63%
r2IGFBP3 = 0.79%
r2PPP3R1 ~ 5.86/2 + 0.14 ~ 3.07%
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APPENDIX L
Models and Results for Total Gene Effects for Analyses in Which a Trend for a
Significant Interaction Occurred
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APPENDIX L: MODELS AND RESULTS FOR TOTAL GENE EFFECTS FOR
ANALYSES IN WHICH A TREND FOR A SIGNIFICANT INTERACTION
OCCURRED
Model for change in strength with strength training for IGF1:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race: 1 Caucasian or 2 African American
Age is subject’s age
sex: 1 male or 2 female
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is baseline body weight
bmipre is baseline body mass index
/*analysis for gene effect for IGF1 for change in muscle strength*/
/*full model*/
proc means data=one n css;
var rmdkg;
quit;
proc mixed data=one method=type3 covtest boxplot;





















proc means data=one n css;
var rmdkg;
quit;
proc mixed data=one method=type3 covtest boxplot;




















Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
RMTLPREKG 1 3.614304 3.614304
Race 1 99.966343 99.966343
Height 1 8.642697 8.642697
IGF1 2 15.800191 7.900095
IGFBP3 2 40.699811 20.349906
Calbb 1 0.199613 0.199613
Age 1 16.368561 16.368561
bwpre 1 1.644461 1.644461
hrt_sex 2 100.878464 50.439232
bmipre 1 1.967392 1.967392
Race*IGFBP3 2 56.527655 28.263828
IGF1*Calbb 2 63.061851 31.530925
Residual 104 1212.521814 11.658864
Constrained Model:
Sum of
Source DF Squares Mean Square
RMTLPREKG 1 4.825644 4.825644
Race 1 80.303996 80.303996
Height 1 10.189801 10.189801
Calbb 1 6.328011 6.328011
Age 1 17.423118 17.423118
bwpre 1 4.571200 4.571200
hrt_sex 2 128.552162 64.276081
bmipre 1 5.734234 5.734234
IGFBP3 2 53.554319 26.777160
Race*IGFBP3 2 65.893174 32.946587
Residual 108 1382.954162 12.805131
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Model for change in strength with strength training for IGFBP3:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race: 1 Caucasian or 2 African American
Age is subject’s age
sex: 1 male or 2 female
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is baseline body weight
bmipre is baseline body mass index
/*analysis for gene effect for IGFBP3 for change in muscle strength*/
/*full model*/
proc means data=one n css;
var rmdkg;
quit;
proc mixed data=one method=type3 covtest boxplot;





















proc means data=one n css;
var rmdkg;
quit;
proc mixed data=one method=type3 covtest boxplot;




















Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
RMTLPREKG 1 3.614304 3.614304
Race 1 99.966343 99.966343
Height 1 8.642697 8.642697
IGF1 2 15.800191 7.900095
IGFBP3 2 40.699811 20.349906
Calbb 1 0.199613 0.199613
Age 1 16.368561 16.368561
bwpre 1 1.644461 1.644461
hrt_sex 2 100.878464 50.439232
bmipre 1 1.967392 1.967392
Race*IGFBP3 2 56.527655 28.263828
IGF1*Calbb 2 63.061851 31.530925
Residual 104 1212.521814 11.658864
Constrained Model:
Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
RMTLPREKG 1 11.868777 11.868777
Race 1 120.215997 120.215997
Height 1 6.103380 6.103380
Calbb 1 0.847680 0.847680
Age 1 40.082231 40.082231
bwpre 1 0.747230 0.747230
hrt_sex 2 127.353545 63.676773
bmipre 1 0.986788 0.986788
IGF1 2 45.420302 22.710151
IGF1*Calbb 2 35.524215 17.762107
Residual 108 1289.747279 11.942104
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Model for change in strength with strength training for PPP3R1:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B (PPP3R1) genotype, 11 is the II homozygotes, 12 is the D-
allele carriers
Race: 1 Caucasian or 2 African American
Age is subject’s age
sex: 1 male or 2 female
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is baseline body weight
bmipre is baseline body mass index
/*analysis for gene effect for PPP3R1 for change in muscle strength*/
/*full model*/
proc means data=one n css;
var rmdkg;
quit;
proc mixed data=one method=type3 covtest boxplot;





















proc means data=one n css;
var rmdkg;
quit;
proc mixed data=one method=type3 covtest boxplot;




















Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
RMTLPREKG 1 3.614304 3.614304
Race 1 99.966343 99.966343
Height 1 8.642697 8.642697
IGF1 2 15.800191 7.900095
IGFBP3 2 40.699811 20.349906
Calbb 1 0.199613 0.199613
Age 1 16.368561 16.368561
bwpre 1 1.644461 1.644461
hrt_sex 2 100.878464 50.439232
bmipre 1 1.967392 1.967392
Race*IGFBP3 2 56.527655 28.263828
IGF1*Calbb 2 63.061851 31.530925
Residual 104 1212.521814 11.658864
Constrained Model:
Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
RMTLPREKG 1 5.860671 5.860671
Race 1 96.472287 96.472287
Height 1 4.166675 4.166675
Age 1 23.396079 23.396079
bwpre 1 0.370524 0.370524
hrt_sex 2 120.701509 60.350754
bmipre 1 0.638072 0.638072
IGF1 2 108.328174 54.164087
IGFBP3 2 20.301794 10.150897
Race*IGFBP3 2 30.520656 15.260328
Residual 107 1280.953999 11.971533
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Model for change in muscle quality with strength training for IGF1:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B genotype, 11 is the II homozygotes, 12 is the D-allele carriers
Race: 1 Caucasian or 2 African American
Age is subject’s age
sex: 1 male or 2 female
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is baseline body weight
bmipre is baseline body mass index
/*analysis for gene effect for IGF1 for change in muscle quality*/
/*full model*/
proc means data=one n css;
var mqc;
quit;
proc mixed data=one method=type3 covtest boxplot;




















proc means data=one n css;
var mqc;
quit;
proc mixed data=one method=type3 covtest boxplot;



















Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
MQB 1 94.083090 94.083090
Age 1 11.907632 11.907632
Race 1 12.927397 12.927397
Height 1 5.273079 5.273079
bwpre 1 3.409480 3.409480
IGF1 2 2.440301 1.220151
IGFBP3 2 2.733374 1.366687
CalbB 1 0.502028 0.502028
hrt_sex 2 11.301844 5.650922
bmipre 1 1.977592 1.977592
IGF1*CalbB 2 20.358235 10.179117
Residual 97 321.457894 3.313999
Constrained Model:
Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
MQB 1 110.944409 110.944409
Age 1 13.963383 13.963383
Race 1 9.836652 9.836652
Height 1 5.764891 5.764891
bwpre 1 5.110641 5.110641
IGFBP3 2 3.449142 1.724571
CalbB 1 0.432539 0.432539
hrt_sex 2 19.036949 9.518474
bmipre 1 3.420044 3.420044
Residual 101 367.281512 3.636451
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Model for change in muscle quality with strength training for PPP3R1:
IGF1 is the IGF1 genotype, 1 is 192 homozygote, 2 is 192 heterozygotes,
3 is non-carriers of the 192 allele
IGFBP3 is the IGFBP3 genotype, 11 is AA homozygotes, 12 is AC heterozygotes, 11 is
CC homozygotes
Calbb is the calcineurin B (PPP3R1) genotype, 11 is the II homozygotes, 12 is the D-
allele carriers
Race: 1 Caucasian or 2 African American
Age is subject’s age
sex: 1 male or 2 female
hrt_sex is hormone replacement therapy status variable: MN is male, FN is females not
on hormone replacement therapy, FY is females on hormone replacement therapy
Height is subject’s height
bwpre is baseline body weight
bmipre is baseline body mass index
/*analysis for gene effect for PPP3R1 for change in muscle quality*/
/*full model*/
proc means data=one n css;
var mqc;
quit;
proc mixed data=one method=type3 covtest boxplot;




















proc means data=one n css;
var mqc;
quit;
proc mixed data=one method=type3 covtest boxplot;



















Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
MQB 1 94.083090 94.083090
Age 1 11.907632 11.907632
Race 1 12.927397 12.927397
Height 1 5.273079 5.273079
bwpre 1 3.409480 3.409480
IGF1 2 2.440301 1.220151
IGFBP3 2 2.733374 1.366687
CalbB 1 0.502028 0.502028
hrt_sex 2 11.301844 5.650922
bmipre 1 1.977592 1.977592
IGF1*CalbB 2 20.358235 10.179117
Residual 97 321.457894 3.313999
Constrained Model:
Type 3 Analysis of Variance
Sum of
Source DF Squares Mean Square
MQB 1 93.612824 93.612824
Age 1 11.802626 11.802626
Race 1 14.629462 14.629462
Height 1 3.356136 3.356136
bwpre 1 2.330282 2.330282
IGFBP3 2 6.204668 3.102334
IGF1 2 25.151528 12.575764
hrt_sex 2 13.155892 6.577946
bmipre 1 1.279626 1.279626
Residual 100 342.562523 3.425625
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APPENDIX M
Calculation for Total Gene Effects for Analyses in Which a Trend for a Significant
Interaction Occurred
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APPENDIX M: CALCULATION FOR TOTAL GENE EFFECTS FOR
ANALYSES IN WHICH A TREND FOR A SIGNIFICANT INTERACTION
OCCURRED
To determine the significance of the total gene effect for change in muscle phenotype the
full model sums of squares (with all gene effects and error term) was compared with the
constrained model sums of squares (in which all gene effects of interest were removed).
The difference in sums of squares for the error term for these two models was the
contribution to the sums of squares due to that particular gene effect. This difference in
sums of squares was divided by the degrees of freedom for that gene effect (the
difference in degrees of freedom for the error terms for the full and constrained models).
The mean square for the gene effect was then calculated as the quotient of the sums of
squares due to the gene effect divided by the degrees of freedom for the gene effect. The
F-ratio was then calculated as the ratio of the mean square for the gene effect and the
mean square for the error term for the full model. The level of significance was tested
using F tables with the numerator degrees of freedom (df1 in tables) equal to the degrees
of freedom for the gene effect and the denominator degrees of freedoms (df2 in tables) as
the error term degrees of freedom.
Effects of IGF1 genotype on change in muscle strength with ST:
For full model:
Error sums of squares = 1212.52
Mean Square = 11.66
Degrees of freedom = 104
For constrained model (without sums of squares for IGF1 and IGF1*PPP3R1):
Error sums of squares = 1382.95
Mean Square = 12.81
Degrees of freedom = 108
Differences in sums of squares for two models = 1382.95 – 1212.52 = 170.43
Degrees of freedom due to IGF1 gene effects = 108 – 104 = 4
Mean Square for IGF1 gene effects = 170.43/4 = 42.61
F = 42.61/11.66 = 3.61
df1 = 4
df2 = 104
Using F tables P < 0.01 (F = 3.51 for df1 = 4 and df2 = 100 for P = 0.01)
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Effects of IGFBP3 genotype on change in muscle strength with ST:
For full model:
Error sums of squares = 1212.52
Mean Square = 11.66
Degrees of freedom = 104
For constrained model (without sums of squares for IGFBP3 and IGFBP3*Race):
Error sums of squares = 1289.74
Mean Square = 11.94
Degrees of freedom = 108
Differences in sums of squares for two models = 1289.74 – 1212.52 = 77.22
Degrees of freedom due to IGFBP3 gene effects = 108 – 104 = 4
Mean Square for IGFBP3 gene effects = 77.22/4 = 19.31
F = 19.31/11.66 = 1.66
df1 = 4
df2 = 104
Using F tables P > 0.05 (F = 2.46 for df1 = 4 and df2 = 100 for P = 0.05) so non-
significant
Effects of PPP3R1 genotype on change in muscle strength with ST:
For full model:
Error sums of squares = 1212.52
Mean Square = 11.66
Degrees of freedom = 104
For constrained model (without sums of squares for PPP3R1 and PPP3R1*IGF1):
Error sums of squares = 1280.95
Mean Square = 11.97
Degrees of freedom = 107
Differences in sums of squares for two models = 1280.95 – 1212.52 = 68.43
Degrees of freedom due to PPP3R1 gene effects = 107 – 104 = 3
Mean Square for PPP3R1 gene effects = 68.43/3 = 22.81




Using F tables P > 0.05 (F = 2.70 for df1 = 3 and df2 = 100 for P = 0.05) so non-
significant
Effects of IGF1 genotype on change in muscle quality with ST:
For full model:
Error sums of squares = 321.46
Mean Square = 3.31
Degrees of freedom = 97
For constrained model (without sums of squares for IGF1 and IGF1*PPP3R1):
Error sums of squares = 367.28
Mean Square = 3.64
Degrees of freedom = 101
Differences in sums of squares for two models = 367.28 – 321.46 = 45.82
Degrees of freedom due to IGF1 gene effects = 101 – 97 = 4
Mean Square for IGF1 gene effects = 45.82/4 = 11.46
F = 11.46/3.31 = 3.46
df1 = 4
df2 = 97
Using F tables P < 0.05 (F = 2.46 for df1 = 4 and df2 = 100 for P = 0.05)
Effects of PPP3R1 genotype on change in muscle quality with ST:
For full model:
Error sums of squares = 321.46
Mean Square = 3.31
Degrees of freedom = 97
For constrained model (without sums of squares for IGF1 and IGF1*PPP3R1):
Error sums of squares = 342.56
Mean Square = 3.43
Degrees of freedom = 100
Differences in sums of squares for two models = 342.56 – 321.46 = 21.10
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Degrees of freedom due to PPP3R1 gene effects = 100 – 97 = 3
Mean Square for PPP3R1 gene effects = 21.10/3 = 7.03
F = 7.03/3.31 = 2.12
df1 = 3
df2 = 97
Using F tables P > 0.05 (F = 2.70 for df1 = 3 and df2 = 100 for P = 0.05) so non-
signficant
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Effects of aging on the components of sarcopenia
Potential mechanisms of sarcopenia
Strength training as an intervention for sarcopenia
Genetic influences on phenotypes related to sarcopenia
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APPENDIX N: LITERATURE REVIEW
The following review of literature provides background information relevant to the
understanding of the influence of insulin-like growth factor pathway genes on the muscle
phenotype adaptations to ST. This review will focus on the following topics: 1) Causes
and consequences of sarcopenia, 2) Effects of aging on the components of sarcopenia, 3)
Potential mechanisms of sarcopenia, 4) Strength training (ST) as an intervention for
sarcopenia, 5) Genetic influences on muscle phenotypes related to sarcopenia, and 6)
Physiology of IGF1 pathway gene polymorphisms.
Causes and consequences of sarcopenia: Sarcopenia is a Greek word literally
meaning “loss of flesh”, which was first coined by Rosenberg in 1989 (223). It refers to
the loss of skeletal muscle mass with aging that further results in loss of skeletal muscle
function, including loss of strength, muscle quality, and power (134, 149). There are
many factors occurring naturally with aging that may contribute to the loss of muscle size
and function. However, there is a relatively large inter-individual variability in the
magnitude of loss in muscle mass and muscle function with age, as well as the factors
that explain these losses. Some of these factors include: decreases in alpha motor
neurons, motor units, protein synthesis, expression of myosin heavy chains, and a rise in
catabolic stimuli, including cytokines (e.g. IL-6 and TNF-α) (33, 150, 242). Hormonal
and growth factors include, reduction in the levels of sex steroids and impairments in the
growth hormone (GH)/insulin-like growth factor (IGF) pathway (152, 244, 277). There
are also environmental factors, such as nutrition and physical inactivity that can have a
profound influence on sarcopenia (167).
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The first study to define and determine the prevalence of sarcopenia in a large
group of individuals was the New Mexico study reported by Baumgartner et al. (20).
These investigators defined sarcopenia as occurring in an individual whose muscle mass
was ≥ 2 standard deviations below the mean appendicular muscle mass for young healthy
adults. Using dual-energy x-ray absorptiometry (DXA) to measure appendicular muscle
mass, Baumgartner et al. (20) found in elderly Hispanic and Caucasian males and females
that the prevalence of sarcopenia increased from 13 to 24% of persons aged 65-70 years
to over 50% of those older than 80 years. In addition, sarcopenic women had 3.6 times
higher rates of disability, and sarcopenic men had 4.1 times higher disability rates
compared with study participants with normal muscle mass. In another study in which
DXA was used to measure muscle mass, Iannuzzi-Sucich et al. (105) reported that the
prevalence of sarcopenia was 22.6% for women aged 64-93 years and 26.8% for men
aged 64-92 years. These authors also reported that the prevalence of sarcopenia for
women and men older than 80 years was 31% and 45%, respectively.
In addition to these studies, the losses of muscle mass and muscle function due to
sarcopenia have been well-documented in cross-sectional and longitudinal studies (68,
114, 132, 141, 147), and have many significant health consequences ranging from
decreased functional ability to increased mortality. These consequences include:
increased risk of falls (142, 144), hip fractures (9), bone mineral density loss (243), and
physical disability (276). Loss of strength is often related to dysfunction in the elderly
(18, 189, 204) and is a powerful predictor of future disability, especially in women (204).
Loss of muscle mass with age may also lead to glucose intolerance (25). Finally, it has
been shown that sarcopenia is associated with increased mortality (158, 159, 231). Miller
197
et al. (161) showed that corrected arm muscle area is a better predictor of long term
mortality than BMI, which is often used as a predictor of mortality in older adults. Also,
several studies have reported an association between low muscle strength and increased
mortality rates (79, 133, 205). For example, Metter et al. (158) reported that both hand
grip strength and change in grip strength were predictors of mortality, independent of
physical activity or muscle mass.
Using the standard criteria for sarcopenia, Baumgartner et al. (20) estimated the
prevalence of sarcopenia to be about 9 million in the U.S. (20). With an aging society, it
is estimated that the incidence of sarcopenia will increase significantly, resulting in major
increases in health care cost. In the United States, census data reported that there were 35
million Americans over the age of 65. By 2015, this number is projected to increase to
46 million (U.S. Census Bureau, 2000). Consequently, health care costs will increase for
the elderly. In 2001, projects spending totaled 103 billion for nursing home stays, and by
2010, this will increase by 77% to 183 billion (Health Care Financing Administration,
2000). Because society is aging, it is imperative to address this disease process through
a better understanding of its causes, prevalence, and treatment.
Effects of aging on the components of sarcopenia: Muscle mass and strength
reach a peak between 40 and 50 yrs of age and remain relatively stable until the sixth
decade. After age 50 an accelerated decline in muscle strength (~12-14%/decade) usually
occurs (132, 141, 157), while muscle mass declines at a rate of ~ 6%/decade (147).
These losses in muscle strength and muscle mass result in a loss of muscle function of ~
40% by the 8th decade of life, often resulting in disability and morbidity, and possibly
even mortality (158, 161).
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The decline in muscle mass with age is strongly correlated with strength, and the
losses associated with aging (76, 207). However, depending on the measurement method
used, it has been reported that muscle mass declines at a slower rate with aging than
muscle strength (154). Various measurement techniques have been used to estimate
losses in muscle mass with age (e.g. ultra-sound, computed tomography scans [CT],
magnetic resonance imaging [MRI], 40K counting, creatinine excretion, DXA, and
hydrodensiometry), however, little information is available from direct measurement of
muscle mass. A post-mortem examination of cadavers would allow for a more direct
measurement of muscle mass and would overcome certain ethical and logistical
problems.
Metter et al. (158) estimated fat-free mass (FFM) via creatinine excretion in ~ 950
subjects from the Baltimore Longitudinal Study on Aging (BLSA) and found that FFM
loss of ~ 33% occurs during the adult life span. Lexell et al. (138) employed a whole
muscle post-mortem examination to quantify size of whole muscle, number of fibers, and
fiber size to measure total age-related changes in muscle. For this study, these
investigators examined autopsied cross-sections of whole vastus lateralis muscle from 43
previously healthy men between the ages of 15 and 83 years. The results showed that
sarcopenia begins around the age of 25 years and accelerates thereafter. These
investigators reported that this muscle decline is caused mainly by a decrease in fiber
number, with no preferential loss of any particular fiber type, and to a lesser degree by a
loss of fiber size, mostly of type II fibers. Further supporting evidence for these findings
was provided by Overend et al. (184) who performed CT scans on thigh muscles of
young and older men and found that comparisons of relative leg muscle strength in these
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subjects may be misleading due to the decreases in muscle tissue associated with aging.
These authors stressed that appropriate measurement of muscle size and cross-sectional
area (CSA) needed to be performed prior to making such comparisons. More recently,
Trappe et al. (270) reported that in men and women each of the four muscles comprising
the quadriceps, atrophy similarly with aging, such that CSA in elderly subjects is ~ 27%
lower than in younger subjects as measured by CT.
Age-related declines in muscle strength are related to changes in number of motor
units, altered muscle pennation angle, fiber type grouping, loss of muscle fibers,
decreased expression of myosin heavy chain (MHC) proteins, and increases in connective
tissue and fat infiltration (12, 124, 130, 138). The age-related decline in muscle strength
has been demonstrated by several cross-sectional and longitudinal studies, which have
shown that there is considerable loss of muscle strength beginning after the 50s for men,
and somewhat earlier for women (141, 147). However, investigations that examine aging
effects often employ cross-sectional designs. These studies cannot establish cause and
effect relationships, but only associations between variables and are confounded by
factors such as diet, physical activity, or generational differences when comparing
subjects of different ages and/or generations. Even when using longitudinal data to
assess age-related changes, these confounding factors may still persist. Despite the
methodological constraints with cross-sectional studies, these studies can provide
important contributions to the literature, especially when using large sample sizes and
when combined with other studies.
Using cross-sectional data from the BLSA, in which grip strength was measured
in 847 men aged 20-89 years, Kallman et al. (118) reported that muscle strength is
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highest in the 30s and subsequently declines in a curvilinear fashion after the age of 40.
After the 80s strength declined by ~37%. On the other hand, longitudinal analysis of
these data showed that ~15% of the subjects over age 60 years demonstrated no strength
decline during an ~ 9 year follow-up. These results suggest that there is a significant
inter-individual variability in age-related strength losses. A follow-up report from the
BLSA suggested that concentric, eccentric, and isometric knee and elbow flexor and
extensor strength declines with aging, when ~ 650 men and women aged 20-93 years
were examined (141). In addition, Era et al. (61) reported the isometric strength levels in
five muscle groups for men in their 30s, 50s, and 70s. The results showed significant
age-related differences between these age groups for isometric handgrip, elbow flexion,
knee extension, trunk extension and flexion strength that was similar to the BLSA results
reported by Kallman et al. (118). Both studies examined strength differences over a
similar portion of the adult life span. Arm flexor and extensor data show that the age-
related declines in arm strength are similar to the declines that occur in leg strength, but
these declines begin at a later age. To investigate the relationship between muscle
strength, age, and body composition, Frontera et al. (76), in an earlier cross-sectional
study, measured isokinetic strength of the elbow and knee extensors and flexors in 200
healthy, 45-78 year old men and women. They measured peak torque for the knee at 60
and 240 degrees/s and for the elbow at 60 and 180 degrees/s. Strength in all muscle
groups at both testing speeds was significantly lower (15.5-26.7%) in the 65-78 year old
age group compared with the 45-54 year old age group. However, when strength was
adjusted for FFM, age-associated differences among age groups were not significant in
all muscle groups, except in the knee extensors at high velocity (240 degrees/s). These
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results support the hypothesis that age-related declines in muscle mass are at least
partially responsible for the losses in muscle strength. This conclusion also confirms an
earlier report by Borges (26), who measured maximal isometric and isokinetic knee
extension and flexion muscle torque at slow, medium, and fast velocities (12, 90, 150
degrees/s) in ~140 healthy men and women from 20-70 years of age. Both isokinetic and
isometric torque were lower with increased age for both sexes. Isokinetic torque
decreased significantly between 20 and 30 years of age in men and between 40 and 50
years of age in women. A significant decrease in torque was also observed between the
ages of 60 and 70 years in both men and women. There was a significant decrease in
maximum isometric torque between 60 and 70 years in both sexes. Peak torque was
significantly correlated with body mass, height, and body surface area in these subjects.
Cross-sectional data at the muscle fiber level provide additional support for these
results. In this regard, Frontera et al. (78) reported a 35% reduction in type II muscle
fiber force production in older men (~ 75 yrs) compared to younger men. In addition,
Trappe et al. (267) reported in a cross-sectional study that older women had 25-40% less
power in single fibers than young women, old men, and young men. These results
showed that older women have attenuated force production in single skeletal muscle
fibers.
These findings suggest that the decline in whole muscle strength is at least
partially caused by the decrease in force generating capacity of individual muscle fibers
with aging. However, if older subjects are unable to maximally recruit existing motor
units, then limited force production of muscle fibers may be a limiting factor. Maximal
voluntary contraction with twitch interpolation provides evidence that elderly subjects
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can fully and maximally contract their musculature (43, 102, 126), although one report
found that less than full activation (as low as 69%) of musculature occurred in older
adults (250). On the other hand, Jakobi et al. (109) reported that with sufficient attempts,
elderly men can fully activate their elbow flexors and extensors, as well as younger men,
even if an impairment previously existed. These findings highlight a design flaw in many
previous studies that assessed muscle strength without providing an adequate
familiarization period prior to strength testing.
Due to logistical difficulties and expenses, longitudinal studies are not as common
as cross-sectional investigations. Furthermore, longitudinal studies are subject to other
problems, such as loss to follow-up and observations that are often not equally spaced.
However, longitudinal designs are preferable for assessing the effects of aging.
Typically, longitudinal studies on sarcopenia report a more rapid rate of decline in muscle
strength than do cross-sectional studies. For example, Bassey and Harries (19) reported
that in men and women > 65 years, strength declined ~2% per year. However, a four-
year follow-up on 620 survivors showed that grip strength had declined by 12% in men
and by 19% in women, and these strength losses were significantly related to age (19).
These authors also found a significant decline in physical activity and functional capacity
in these subjects. These findings were supported by Sowers et al. (248), who found
almost 9% of women had at least a 6% loss (>2.5 kg) of lean mass over a three-year
observation period in African American and Caucasian women aged 34-58 years. This
loss of muscle mass was associated with decreased physical functioning as determined by
slower walking velocity and decreased leg strength. Further support is offered by
Aniansson et al. (8), who reported that over a seven-year period, between the age of 70
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and 75, there was a significant decline in knee extensor, elbow extensor and flexor
strength in both men and women, with a larger decrease occurring in isokinetic as
compared with isometric strength. Men with a higher level of physical activity had
greater isokinetic muscle strength in the knee flexors and extensors than those men with
lower activity level. Seven-year follow-up results showed a body mass decrease of 6%
and a quadriceps muscle strength decrease of 10-22% over this period (7). During this
time span there was also a reduction in fast-twitch fiber area in the quadriceps. Seven-
year follow-up data from this cohort showed that in these active elderly men between the
ages of 76 to 80 years, isokinetic strength at 30 degrees/s decreased significantly at a rate
of 2-3% per year (6). Both type I and type II fiber areas significantly increased during
this time, which was interpreted as a compensatory adaptation for the loss of motor units
that occur with aging (6).
These findings were supported by Rantanen et al. (203) in a study which
investigated age-related changes in strength over a 5-year period in ~100 men and ~185
women with baseline age of 75 years. They found a substantial inter-individual
variability in the percent change in strength over the five-year period ranging from a 4%
increase in knee extension strength in men and women to a 16% decrease in hand grip
strength in women. Reduced grip strength was more extensive in women than men. The
more active men in this study maintained their trunk extension strength better than
sedentary men. In women who decreased their activity levels over the five-year period,
the rate of decline in grip and elbow flexion strength was 32% and 27% respectively,
which was greater than other similarly aged subjects who either remained sedentary or
were more active. The more active women retained their knee extension strength at a
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higher level than the other groups. Those subjects who died before their follow-up tests
exhibited poorer strength at baseline, indicating the possibility that low muscle strength is
a predictor of mortality. The results from this study also suggest that participation in
everyday physical tasks (i.e. household work, walking, and gardening), which are also the
most common physically demanding activities of older people, may be essential for
maintaining strength at a sufficient level to maintain functional ability. This conclusion
is supported by other findings that examined muscle strength thresholds that are
associated with compromised performance or ambulatory tasks. For example, cross-
sectional data from the BLSA (131) indicated that with increasing knee extensor peak
torque, gait time decreases, then plateaus at higher strength levels (> 130 Nm for normal
gait, and > 190 Nm for faster gait). In a more recent study, it was reported that subjects
with isometric leg extension peak torque to body weight ratio < 3.0 Nm/kg are at a
substantial risk for impaired function in chair rise, gait speed, and stair ascent and descent
tasks (193).
The above findings by Rantanen et al. (203) concur with more recent findings
by Frontera et al. (75), who investigated age-associated changes in skeletal muscle mass
and function over a 12 year span. For this study, isokinetic strength of the knee and
elbow flexors and extensors were measured in twelve healthy, older (~65 yrs), sedentary
men. Both knee and elbow flexor and extensor strength declined from 20 to 30% at slow
and fast velocities. These subjects also had an ~ 16% loss in quadriceps cross-sectional
area (CSA), as assessed by CT scans. Linear regression analysis showed that strength at
baseline and changes in CSA over time were independent predictors of strength after 12
years. In addition, vastus lateralis muscle biopsies showed a 30% reduction of type I
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fiber percentage, but showed no change in mean area of either fiber type. These authors
suggested that the preferential loss of type I fibers was surprising in light of previous
findings suggesting no change in fiber-type distribution with age (196) and may be
explained by methodological shortcomings (139) or coexpression of myosin heavy chain
isoforms (5). In spite of these potential issues, Frontera et al. (75) concluded that a loss
in muscle CSA is a major contributor to the decrease in muscle strength with advancing
age, and together with muscle strength at baseline, accounts for ~90% of the variability in
strength during the 12-year period. These findings are supported by other recent data that
showed a smaller mid-thigh CSA and greater fat infiltration in the muscle are associated
with lower strength (175) and functional ability in older men and women (279).
Muscle quality (MQ), sometimes referred to as specific tension or strength per
unit of muscle, also appears to be influenced by age. MQ considers neuromuscular
effects and is considered a better estimate of skeletal muscle function than overall fat-free
mass (FFM). MQ declines both at the whole muscle (147) and single muscle fiber level
(78). Early studies provided conflicting results. Young et al. (290) reported no
difference in MQ of the knee extensors of older women compared to younger controls
when strength was measured isometrically. Young et al. (291) also reported that, in
contrast to the findings in women, older men showed a 19% lower MQ than younger
men. Lynch et al. (147) reported a difference in leg MQ between young and older adults,
and that arm MQ decreased to a similar extent in men and women. However, leg MQ
declined approximately 20% more than arm MQ with increasing age in women. Frontera
et al. (78) studied single muscle fibers in younger and older men and women and reported
a difference in muscle fiber quality in men, with fibers from young men having greater
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capacity for force production than fibers from older men. More recently in a cross-
sectional study comprised of ~2600 men and women between the ages of 70-79, Newman
et al. (175) found that upper and lower extremity MQ decreased with increasing age.
Thus, these data show that MQ decreases with age, but the magnitude of this decline
seems to depend on sex and the muscle group studied.
Potential mechanisms of sarcopenia: There has been no single cause identified
that explains the decline of muscle size and function that occurs with aging. However,
there are many interrelated factors that appear to contribute to sarcopenia. These
include: loss of alpha motor neurons and motor units, declines in testosterone, estrogen,
growth hormone, IGF-1, protein synthesis rate, changes in myosin heavy chain (MHC)
gene expression, and an elevation in catabolic stimuli including cytokines. The total
number of central nervous system and muscle neurons decreases with age (31, 219), and
in particular those neurons of the fast motor unit (51, 52). Muscle contractile and
mitochondrial protein synthesis rates decline with aging (12, 173, 220, 221), as do whole
body muscle protein synthesis rates, and MHC levels (12, 95). Also, hormone levels,
including testosterone, estrogen, growth hormone, IGF-1 (16, 93, 191), have been shown
to decrease with age. Finally, catabolic stimuli, including cytokines, have been shown to
increase with aging (230).
Strength training (ST) as an intervention for sarcopenia: Strength training (ST)
has been shown to be the most effective and safest intervention for the prevention of
sarcopenia in the elderly (24, 101, 195). ST has been shown to increase muscle strength
and muscle mass substantially in the elderly in as little as 8 wks (65). Several training
studies have shown the efficacy of ST in increasing muscle strength and muscle mass in
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men and women aged 50-98 yrs (29, 64, 65, 77, 108). Additionally, the muscle
adaptations due to ST have been shown to positively affect functional ability in elderly
men and women (30, 234).
Most studies have shown that ST increases muscle strength ~25 to 45% in the
elderly (64, 108, 121, 135, 268). At least one study has shown that ST can increase
muscle strength in individuals up to the age of 98 yrs (65). Sullivan et al. (255) reported
strength increases of 74% in recuperating nursing home patients whose mean age was 83
yrs. Most studies have suggested that there is little or no effect of age in the muscle
strength response to ST. However, Lemmer et al. (135) reported slightly, but not
significantly greater strength gains (34%) in 20-30 year old men and women compared to
65-75 year old men and women (28%). However, there was no age difference in the
response of muscle volume to the same ST program (108). These data suggest that in
response to ST, elderly muscle adapts similarly as younger muscle in response to
progressive muscle overload.
Dependent on the method of measurement, intensity of the training program, and
possibly the age and sex of the subjects, total body muscle mass generally increases in
response to ST, however the range in training studies has been from no significant
increase to a 41% increase (33, 77). The discrepancy in these results may in large part be
due to the difference in techniques used (hydrostatic weighing and K-40 counting or
creatinine excretion), which have specific assumptions for estimating lean tissue mass.
Furthermore, it is likely that the whole body lean tissue, assessed by these techniques,
would not change much in a short-term study based on the findings of the change in
actual muscle volume.
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Change in muscle volume or CSA allows for the measurement of the specific
muscle being stimulated and allows the differentiation of muscle, bone, and fat. Muscle
volume or CSA is typically measured by computed tomography (CT) or magnetic
resonance imaging (MRI). Several studies have shown that ST increases muscle CSA in
the elderly by ~ 8% with the range from studies being 3-23% (65, 77, 84, 217). Studies
which have measured muscle volume with ST instead of CSA, to determine changes in
muscle size, have shown similar or greater increases in the muscle due to ST (108, 123,
265).
However, at the myofiber level, the increases in fiber size with ST are at least
10%, but often more than 30%. This may be due to the fact that MRI and CT
measurements include connective and other tissues which do not change with ST. Both
type I and type II fibers increase in size with ST (29, 34, 64, 77, 137). Trappe et al. (269)
found increases in fiber area of 20% in type I fibers and 13% in type II fibers in elderly
men after 12 wks of ST. Force increased by 35% in type II fibers and by 20% in type I
fibers. Shortening velocity increased 75% in MHC I and 45% in MHC IIa. Additionally,
power increased 56% in both fiber types combined. In a similar study in older women
following 12 wks of ST, fiber diameter increased by 24% in type I fibers and did not
change in type IIa fibers. Force increased by 33% in type I and 14% in type II fibers.
Shortening velocity was unaltered in both fiber types following training, yet power
increased 50% in type I and 25% in type II fibers (270).
Many of the non-muscle-mass components of strength loss are reversed with
strength training (88, 122). For example, Welle et al. (284) studied the effect of ST on
MQ (3-RM strength/muscle CSA) in young and older subjects. Their older subjects
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exhibited a 32% increase in MQ of knee extensors, which was not significantly different
from the increase in young subjects. Hakkinen et al. (87) found similar MQ
improvements in older men and women in response to ST when muscle strength was
assessed with an isometric test. In another study, Welle et al. (284) found that the
increase in specific tension (3-RM strength/CSA) following 3 months of resistance
training in young (22-31 yrs) and older (62-72 yrs) individuals was similar for elbow
flexion (~20%) and knee extension (~35%), but was more than double in older subjects
for knee flexion. Reeves et al. (209) found that ST increased vastus lateralis muscle-
specific force by 19% in older men and women (mean age 74.3 ± 3.5 yr). Finally, studies
by Ivey et al. (108) and Tracy et al. (265) have demonstrated an increase in MQ
following ST. In response to a 9 wk ST program, Tracy et al. (265) reported a 14 and
16% increase in MQ (quantified by 1-RM and muscle volume) for older men and women,
respectively.
Genetic influences on muscle phenotypes related to sarcopenia: Results from
heritability studies, genome wide scans, and candidate gene studies have suggested the
presence of a genetic influence on baseline and ST-induced muscle phenotypes. Several
heritability studies have shown the influence of genetics on fat-free mass (FFM) at
baseline. Bouchard et al. (27) estimated the transmissible variance of familial
resemblance for FFM to be 40-50% in subjects from the Quebec Family Study. Other
studies performed on monozygotic (MZ) and dizygotic (DZ) twin pairs have shown that
the heritability in lean body mass ranges from 52-80% (10, 176, 239). In a recent study,
Huygens et al. (103) reported that up to > 90% of the variance in baseline muscle mass is
heritable in young male twins.
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Several family studies, using parent-child and sib-sib correlations, have shown
transmission coefficients for isometric strength (handgrip and arm pull) to vary between
0.20 and 0.60. Heritability estimates have been higher in twins and vary between 0.60
and 0.80. Jones et al. (112) used young MZ and DZ twins to determine the heritability of
maximal isometric elbow extension force at 100° (180° = straight arm). These authors
estimated the heritability to be 83%. In young adult male twins, Thomis et al. (262)
found that additive genetic factors explained 66-78% of the variance in maximal
isometric torque depending on the angle of measurement. Thomis et al. (261)
investigated the influence of genetic factors on static and dynamic strength in young male
MZ and DZ twins. They found that the genetic factor contribution to the variability in
eccentric arm flexor strength was 62-82%, and 29-65% in concentric arm flexor strength.
Tiainen et al. (263) investigated genetic components for maximal isometric handgrip,
knee extension, and ankle plantar flexion strength in MZ and DZ twins aged 63-76 yr
from the Finnish Twin Study. These authors reported that genetics accounted for 14% of
the variance in handgrip strength and 31% of the variance in knee strength for these
twins. Previous studies among older twins reported that genetics accounted for 22-52%
of the variance in grip strength (10, 36, 72, 208). Arden et al. (10) reported a heritability
of 46% for leg extensor strength in MZ and DZ postmenopausal women twins. In a more
recent twins study, Huygens et al. (103) reported an ~ 60% heritability in baseline knee,
trunk, and elbow isokinetic strength.
Variability of response to a standardized strength training protocol suggests that
heritability may influence the response of muscle phenotypes to strength training,
although probably accounting for a smaller percent of the variance in muscle phenotypes
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than at baseline. For example, in 65-75 year old men and women, the responses to a
standardized strength training protocol varied from 5-59% for increases in muscle
strength and 1-20% for increases in muscle volume (108, 135). Thomis et al. (260)
investigated the heritability of changes in arm strength after 10 weeks of strength training
in young male MZ and DZ twins. These researchers found evidence for a genotype by
training interaction for one-repetition maximum (1RM) strength and isometric strength
with MZ intra-pair correlations of 0.46 and 0.30, respectively. These researchers found
that 20% of the variation in post-training 1RM strength, isometric strength, and
concentric moment at 120 degrees/sec was explained by training-specific genetic factors
that were independent from genetic factors that explained variation in the pre-training
phenotype (30-77%).
Few studies have been reported using genome-wide scans or linkage studies to
identify genes or gene regions that may influence muscle phenotypes at baseline or after
ST. Chagnon et al. (37) performed a genome-wide search for genes related to body
composition and its changes after a 20-wk endurance-exercise training program. These
researchers found evidence of significant linkage with changes in FFM and the IGF-1
gene. Huygens et al. (103) explored the potential role of the myostatin pathway in
relation to muscle strength and estimated muscle CSA in humans using linkage analysis
with a candidate gene approach. Linkage patterns were observed between knee extension
and flexion peak torque with markers corresponding to the myostatin gene, the CDKN1A
gene, and the MYOD1 gene with a maximum LOD score of 2.63 reported for the
myostatin gene.
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In contrast to the limited data available from genome-wide scans on the influence
of genes on muscle phenotypes, there have been many candidate gene studies, including
several studies on the IGF1 and myostatin genes (as suggested by linkage studies) on
baseline muscle phenotypes. For example, Sun et al. (256) found that the polymorphism
in the promoter region of the IGF1 gene displayed association and linkage with baseline
FFM and the change in FFM due to endurance exercise training. Roth et al. (227)
investigated the influence of the interleukin-6 -174 (G/C) promoter polymorphism on
FFM in men and women aged 21-92 yrs. These investigators found a significantly lower
total FFM for men in the C/C genotype group compared with those in the G/G genotype
group, as well as significantly lower FFM of the lower limbs compared with the G/G
group. Roth et al. (225) also reported that the C174T polymorphism in the ciliary
neurotrophic factor receptor gene significantly influenced FFM in men and women aged
20-90 yrs. In another study, Roth’s group reported that the FokI polymorphism was
significantly associated with total and appendicular FFM in elderly men (210). Finally,
Walsh et al. (280) from Roth’s lab, reported that the CAG repeat polymorphism in exon 1
of the human androgen receptor gene was significantly associated with FFM in men aged
19-90 yrs. For this polymorphism, those men with a greater CAG repeat number had
greater total FFM than those with fewer CAG repeats.
There have been several candidate gene studies which have investigated the
influence of these genes on baseline muscle strength. Geusens et al. (81) reported
significant differences in quadriceps muscle strength (23%) between vitamin D receptor
BsmI genotype groups in nonobese women older than 70 years. Grundberg et al. (85)
investigated the influence of the poly adenosine (A) repeat and the BsmI single
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nucleotide polymorphisms in the vitamin D receptor on muscle strength and body
composition in healthy 20-39 yr old women. These investigators found that individuals
with shorter poly A repeat (ss) and/or absence of the linked BsmI restriction site (BB)
had greater hamstring strength compared with women with a longer poly A repeat (LL)
and/or presence of the linked BsmI restriction site (bb). Van Pottelbergh et al. (274)
examined whether in community-dwelling men over 70 yrs, a polymorphic binding site
of the Sp1 transcription factor in the gene encoding for the alpha1 chain of type I
collagen (COL1A1 Sp1) was associated with muscle strength. They found that the
presence of the s allele for this gene was associated with lower grip strength and biceps
strength in the dominant arm, with the difference between ss and SS genotype groups of
21% and 30%, respectively. Roth et al. (226) investigated the relationship between
ciliary neurotrophic factor (CNTF) genotype and muscle strength in men and women
aged 20-90 yrs. They reported that individuals heterozygous for the CNTF null (A allele)
mutation (G/A) exhibited significantly higher concentric peak torque of the knee
extensors and knee flexors at 3.14 rad/sec than G/G homozygotes. Also, MQ of the knee
extensors (peak torque at 3.14 rad/sec/muscle mass) was significantly greater in G/A
heterozygotes. In subjects 60 years and older, A/A homozygotes demonstrated
significantly lower eccentric peak torque at 0.52 rad/sec for both knee extensors and knee
flexors compared to G/G and G/A genotype groups. These data indicated that individuals
exhibiting the G/A genotype possess significantly greater muscular strength and MQ at
relatively fast contraction speeds than do G/G individuals. Sayer et al. (235) studied the
influence of the ApaI marker polymorphism in the insulin-like growth factor 2 (IGF2)
gene on handgrip strength in older men and women. These investigators observed that
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this polymorphism was significantly associated with grip strength in men, accounting for
1% of the variance in grip strength between G/G and A/A men. Schrager et al. (237)
investigated the influence of this same polymorphism on FFM and muscle strength in
men and women at several different time points across the adult age span. They reported
that isokinetic arm strength (peak torque shortening) at the first time point was lower in
ApaI A/A genotype men than in G/G men. With aging, G/G men had a significantly
greater rate of loss in FFM compared to A/A men. Compared to G/G women, A/A
women had lower total body FFM, lower isokinetic arm (peak torque lengthening and
shortening) and leg (peak torque shortening) strength at the first time point, and lower
values at age 35 for these muscle phenotypes. This difference between the genotype
groups was maintained at age 65 and across the adult age span. Finally, Clarkson et al.
(41) investigated the influence of the R577X polymorphism of the ACTN3 gene on
baseline muscle phenotypes in 355 women and 247 men aged 18 to 40 yrs and reported
that this polymorphism accounted for about 2% of baseline MVC.
There are only a limited number of studies that have reported the influence of
candidate genes on muscle phenotype response to any exercise training modality and an
even fewer number using ST (41, 69, 107, 127, 211). Sun et al. (256) investigated the
influence of the microsatellite marker in the insulin-like growth factor-1 (IGF1) gene and
body composition phenotypes before and after 20 weeks of aerobic exercise training in
the HERITAGE Family Study. They found significant differences in baseline FFM
among IGF1 genotype groups (192 bp homozygotes, heterozygotes, and noncarriers).
There were also significant differences between IGF1 genotype groups in the change in
FFM with training, with 192 bp homozygotes gaining only half the amount of FFM
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compared with the other two IGF1 genotype groups. However, this type of training
modality is not ideal for increasing FFM. Folland et al. (69) investigated the influence of
ACE genotype on the quadriceps’ strength response to 9 weeks of isometric or dynamic
ST in healthy males. These investigators found a significant interaction between ACE
genotype and isometric strength with greater strength gains in those with the D allele, and
more specifically the ID genotype. Reichman et al. (211) reported that two
polymorphisms in the interleukin-15 receptor-alpha gene (IL15RA) were associated with
the muscle hypertrophic response to ST in young men and women. These authors found
that a single nucleotide polymorphism in exon 7 of IL15RA was strongly associated with
muscle hypertrophy and accounted for 7.1% of the variation. In addition, they found that
a polymorphism in exon 4 of the IL15RA gene was also independently associated with
muscle hypertrophy and accounted for an additional 3.5% of the variation in hypertrophy
in response to 10 wks of ST. One potential weakness of this study was that changes in
muscle mass were assessed using circumference measurements. Clarkson et al. (41)
investigated the influence of the R577X polymorphism on the elbow flexor/extensor
strength response to 12-wk standardized elbow flexor/extensor resistance training
program of the nondominant arm. These authors found that this polymorphism was
associated with the elbow flexor/extensor strength response to ST in women, but not in
men. In women, this polymorphism accounted for ~ 2% of the gain in 1-RM strength.
Finally, Kostek et al. (127) studied the influence of the dinucleotide CA repeat
polymorphism near the promoter region of the IGF1 gene on muscle phenotype responses
to ST in Caucasians. These authors found that carriers of the 192 allele (192
homozygotes + 192 heterozygotes) gained significantly more strength with ST than those
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with no 192 allele. Each of these previous candidate gene studies had the limitation of
either no direct measurement of muscle tissue (69, 211), very small samples sizes (69,
107, 127), or only considered a single candidate gene (41, 69, 107, 127, 211).
Physiology of IGF-1 pathway gene polymorphisms: The IGF1 gene, that
encodes for the IGF-1 protein, is located on human chromosome 12 (12q22-q24.1) (168)
and consists of 88,066 base pairs. This gene contains two known promoters, six exons,
and five introns (247). Depending on the tissue of origin and transcriptional splicing the
mRNA typically contains 153 amino acids and is eventually translated into a 70 amino
acid protein with three disulfide bridges (140). The mRNA can produce at least three
different transcripts, two of which are expressed in skeletal muscle (17, 153, 229, 254,
288).
The somatomedin hypothesis was developed from early experiments which
investigated somatic growth caused by the pituitary gland. Results from these
experiments suggested that growth hormone (GH) causes somatic growth indirectly by
modulating levels of mediating growth factors, designated as somatomedin substance (46,
170, 233). This somatomedin substance regulated by GH was purified from rat serum
and designated as insulin-like growth factor-1 (IGF-1) (213). This substance was termed
“insulin-like” because of its ability to stimulate glucose uptake into fat and muscle cells,
as well as its homology in amino acid sequence with insulin (202, 213). The primary
structural difference between insulin and IGF-1 is that IGF-1 retains the C chain that is
cleaved from proinsulin during post-transcriptional processing (213). Upon discovery of
IGF-1, the somatomedin hypothesis was refined to suggest that GH secreted by the
pituitary would target the liver to secrete IGF-1, which would then act on bodily tissues
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to stimulate growth and provide feedback to the pituitary to control the level of GH
secretion. However, D’Ercole et al. (45) first indicated the somatomedin hypothesis was
incomplete when they discovered that explants of fetal mouse tissue maintained in serum-
free media showed higher levels of IGF-1 in the culture medium as compared with
extracts of the tissues themselves: liver, intestine, heart, brain, kidney, and lung. Other
studies also showed that various tissues express IGF-1 and that this tissue-specific IGF-1
could be affected by and also act independent of plasma GH (145, 146, 216).
Nevertheless, the direct effect of GH on non-hepatic tissues remained in question and it
was subsequently shown that GH could affect tissues by stimulating local production of
IGF-1 or by acting directly on tissues to cause growth (83). The latter process occurred
without a mediating factor, but the resulting growth was not as dramatic as when IGF-1
was involved.
Action of IGF-1. IGF-1 displays numerous diverse functions during both
embryonic development and postnatal growth. Studies have shown that mice carrying
null mutations in the IGF1 gene are born small and grow poorly postnatally (11, 197).
Naturally occurring mutations in the IGF1 gene are rare. It has been reported that only a
single patient, with both intrauterine and postnatal growth retardation, has been found
who had a deletion of the IGF1 gene (287). The complete physiological functions of
IGF-1 are beyond the scope of this review. Therefore, a brief background of IGF-1
action will be given with specific emphasis on skeletal muscle.
IGF-1 exerts some of its influence as an endocrine hormone circulating in the
blood stream until reaching its target tissue. Unlike insulin, IGF-1 in the circulation is
bound by one of six known insulin-like growth factor binding proteins (IGFBPs) (113).
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These binding proteins act as carriers of IGF-1 to transport it out of circulation and
prolong the half-life by protecting it from proteolytic degradation. In addition to their
role in circulation, IGFBPs are often expressed in target tissues where they act to regulate
IGF-1 function further. IGFBPs have been shown to augment and attenuate IGF-1 action
depending on the target tissue (206).
The IGFBP is cleaved by proteases, releasing IGF-1, which can then bind to a
tissue’s insulin or IGF-1 receptor. The insulin and IGF-1 receptors structures are up to
~85% homologous, however, IGF-1 has a greater affinity for the IGF-1 receptor. Upon
binding of IGF-1, the IGF-1 receptor undergoes rapid phosphorylation to activate
tyrosine kinases (136, 253). These tyrosine kinases interact with intermediate signaling
proteins, insulin receptor substrate (IRS-1), and src homology containing proteins (Shc),
resulting in a complex and versatile modulation of cellular transcription and translation
(67).
The activation of IRS-1 by IGF-1 binding to the IGF-1 receptor results in the
activation of phosphatidylinositol 3-kinase (PI 3-K). The PI 3-K pathway has been
shown to mediate skeletal muscle hypertrophy in mammalian muscle (169, 186). In
addition, studies have shown that the binding of IGF-1 to its receptor signals the opening
of a cell’s calcium channels (48), releasing calcium into the cell to be bound by
calmodulin, activating calcineurin, which can in turn stimulate muscle hypertrophy (172,
240).
The IGF-1 receptor has been shown to play many roles including: mediating
amino acid uptake in muscle as well as decrease protein degradation, stimulating
proliferation and differentiation of myocytes, and increasing DNA synthesis in muscle
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satellite cells and regulating gene expression for proteins involved in growth and
metabolism, including the c-fos and c-jun genes (40, 53, 62, 183, 294). Mice lacking the
IGF-1 receptor die immediately after birth due to respiratory failure and severe growth
deficiency (45% of normal) (143). Also a transgenic mouse study showed that IGF-1
mediates its proliferative and differentiative effects via the IGF-1 receptor (199).
Both gene knockout and transgenic animal studies have demonstrated the
importance of IGF-1 in muscle development (96, 143, 171). In muscle, IGF-1 has been
shown to stimulate satellite cell proliferation (38), increase amino acid uptake (155),
suppress proteolysis (13), increase thymidine incorporation (82), stimulate myogenic
differentiation (66), and stimulate myogenesis (236), and unlike other mitogenic factors,
IGF-1 will separately stimulate both proliferation and differentiation of muscle cells in
culture (200). Transgenic mice overexpressing the IGF1 gene show enhanced myotube
formation as well as increased mRNA levels of myogenic factors, Myo D and myogenin,
and elevated mRNA for contractile proteins (42) and, in addition, demonstrate protection
from the normal loss of muscle mass and strength that occurs with senescence and
undergo muscle regeneration from cardiotoxin-induced muscle damage (171).
Overexpression of IGF-1 in transgenic mice has also been shown to prevent muscle
alterations in the neuromuscular junction, preserve spinal cord motor neuron innervation
in the muscle, and decrease the loss of type IIb muscle fibers (156), as well as accelerate
muscle and motor neuron regeneration after sciatic nerve crush injury (201). The
regeneration or preservation of neural innervation is likely to be a causative factor in
preventing muscle strength and mass loss with age.
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Circulating IGF-1 and exercise. IGF-1 is produced by various tissues including
skeletal muscle, however, the majority of the circulating form of IGF-1 is produced in the
liver. Several studies have investigated the relation of circulating IGF-1 and exercise and
have found an increase in circulating IGF-1 up to 20 minutes after high intensity cycling
(35) and forearm resistance exercise (60). Nevertheless, ST studies did not show an
increase in circulating IGF-1 (128, 179, 180), but did change levels of potential
modulators of IGF-1 action, including IGFBP-2, IGFBP-3, and acid labile subunit (180).
In contrast, it was reported that high intensity aerobic training (59) and eccentric exercise
(14) increased muscle IGF-1 and muscle IGF1 mRNA, respectively, but did not affect
circulating levels of IGF-1. The results of these studies suggest that circulating IGF-1
levels are likely to play a minimal role in the response to exercise, but that locally
expressed IGF-1 impact is more dramatic. The exact time course for the change in
muscle IGF1 gene expression and protein translation will require further study.
Furthermore, Sjogren et al. (245) reported that liver specific deletion of the IGF1 gene
produced mice that lacked the circulating form of IGF-1, yet displayed normal growth.
These results suggest that the endocrine form of IGF-1 may not be important for muscle
growth or maintenance in adult humans.
Autocrine/paracrine role of IGF-1 in aging muscle. Circulating levels of GH and
IGF-1, as well as levels of IGF-1 in muscle, decrease with age (275). This decline begins
in the thirties and results in a 40% decrease by the age of 80. It is thought that the
decrease in circulating levels of IGF-1 specifically is a causal factor in the decline in
muscle function that occurs with aging. Compounding or possibly causing this decline is
the reduction with age of the autocrine/paracrine form of IGF-1 produced by muscle.
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The IGF1 gene can express multiple isoforms, derived from alternative splicing,
depending on the tissue of origin and the stimulus. The predominant circulating isoform
of IGF-1, produced by the liver due to GH stimulation, has been termed IGF-1Eb and is
produced by splicing out exon one and thus utilizes the exon two promoter. Skeletal
muscle expresses two known isoforms of the IGF1 gene when it is subjected to stretch or
mechanical stimulation. The first muscle isoform is termed IGF-1Ea (229) and is
initiated at the exon 2 promoter similar to the liver form, however in IGF-1Ea, exon 5 is
removed by alternative splicing. Overexpression of this isoform in transgenic mice
resulted in pronounced muscle hypertrophy and older mice displayed signs of protection
against the normal loss of muscle mass associated with aging (171). Musaro et al. (171)
concluded that overexpression of IGF-1Ea could preserve muscle architecture and the
age-independent regenerative capacity of muscle.
The second IGF-1 isoform expressed in muscle, termed mechano-growth factor
(MGF) or IGF-1Ec, is a splice variant resulting from a novel splice acceptor site in the
intron preceding exon 6 and is generated in muscle subjected to stretch and overload
(288). Structurally, the MGF mRNA differs from its liver counterpart because of the
presence of a 49-base pair insert on the carboxyl end of the protein, which is derived
from exon 5 of the IGF1 gene. This isoform is not glycosylated, therefore, it is expected
to have a shorter half-life than the liver IGF and is therefore likely to be designed to act in
an autocrine/paracrine, rather than in a systemic fashion. Animal studies have shown
significant upregulation of MGF with muscle stimulation (153, 288). Other studies have
shown that locally produced IGF-1 can stimulate muscle hypertrophy through activation
of satellite cells and increased protein synthesis rates (1, 98, 240, 289). In humans,
222
several studies have shown an increase in muscle IGF-1 with a single bout of resistance
exercise (14, 64, 198), even in frail elders (64), although the specific IGF-1 isoform was
not determined. However, reports from two studies have suggested that MGF mRNA
and MGF protein levels will be increased less with muscle stimulation in older rats (185)
and humans (89) than in those who are younger. These results suggest a reduced capacity
of older muscle to be stimulated by resistance exercise. However, Hameed et al. (90) did
report ~170% increase in MGF mRNA after 5 weeks of ST in elderly men.
Results from previous studies clearly show that ST induces local expression of
IGF-1 and it is likely that this locally expressed IGF-1 is mediating many of the
hypertrophic effects observed in skeletal muscle. However, as previously mentioned,
there is significant variability observed in the strength and hypertrophic responses of
skeletal muscle to ST. Additionally, the increases in IGF-1 mRNA that occur in response
to resistance exercise have been shown to range from 2-864% (91), and a variation for
IGF-1 increase with ST of ~137% has been observed in the elderly (64, 90). These
results suggest that genetics could be affecting this response. Indeed, studies have shown
that circulating levels of IGF-1 are almost completely under genetic control in healthy
twin children and the variability in circulating levels in the elderly is estimated to be ~
63% under genetic control (99, 119). To date, no studies have examined the heritability
of IGF1 muscle expression. An autosomal genome wide search for genes related to FFM
and its changes with exercise training revealed that a polymorphism in the IGF1
promoter region displayed significant linkage with changes in FFM (37). Additionally,
this same polymorphism was shown to be associated and in linkage with baseline FFM
and with the change in FFM resulting from aerobic exercise training (256). More
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importantly, this polymorphism has been shown to influence the changes in strength with
ST in Caucasian older men and women (127).
IGF1 CA dinucleotide repeat polymorphism. The IGF1 polymorphism identified
in a genome wide scan and most association studies is the CA dinucleotide repeat
polymorphism near the promoter region of the IGF1 gene in humans (283). Studies in
rats and humans of a similar CA repeat near a promoter region have shown this repeat to
influence gene expression (2, 228). The CA dinucleotide repeat polymorphism near the
promoter region of the IGF1 gene typically contains between 16 and 22 CA repeats and
this polymorphism is commonly referred to by the base pair length of the amplified DNA
fragment (e.g. 192 bp). The 192 allele (19 CA repeats at nucleotide position 1087-1127
in the human IGF-1 DNA sequence Genbank accession number AY260957, RS#
10665874) of the IGF1 promoter gene polymorphism has been investigated in various
contexts. Genotyping of this polymorphism is typically separated into three groups: 192
homozygotes, 192 heterozygotes, and noncarriers of the 192 allele. It has not been
determined whether the 192 polymorphism is causally related to changes in IGF-1
function, yet, the 192 allele is the most prevalent allele in the majority of the populations
studied to date. Although this polymorphism has not been proven to be functional, it has
been proven to be a potential marker for disease-related phenotypes and possibly IGF-1
expression levels. Also, this polymorphism has been shown to influence muscle strength
in Caucasians.
Rosen et al. (222) first implicated this polymorphism in influencing serum levels
of IGF-1 and bone mineral density in older men and women. These investigators
reported that 192 homozygotes had lower serum levels of IGF-1, and in a group of older
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men, 192 homozygotes had a disproportionately high incidence of idiopathic osteoporosis
(222). Since this report other groups have investigated the influence of the 192 allele on
circulating IGF-1 levels with some studies showing decreased (71, 212), increased (125,
162, 215, 273), or no difference unless combined with oral contraceptive use (111, 292).
Although results are inconclusive for the effect of the 192 polymorphism on IGF-1 levels,
it seems possible that the IGF1 192 gene polymorphism may affect skeletal muscle-
related phenotypes because of previous results showing positive associations of this
polymorphism with FFM (37, 256) and with the change in muscle strength with ST (127).
If the 192 allele itself is not functional it would appear to be at least a valid marker for
phenotypes related to IGF-1 expression. Therefore, the possibility exists that the 192
polymorphism is in linkage disequilibrium with a functional polymorphism in the IGF1
gene.
Physiology of IGFBP-3. Almost all IGFs released from tissue are bound with high
affinity and specificity by IGFBPs. There have been at least six IGFBPs identified and
they are designated IGFBP-1 to IGFBP-6. IGFBPs have several important functions,
including: limiting the bioavailability of free IGFs to bind to IGF receptors, preventing
IGF-induced hypoglycemia, regulating the transport of IGFs between intra- and
extravascular space, enhancing the actions of IGFs by forming a slow-releasing pool of
IGFs, affecting cellular proliferation/death via IGFBP receptors, and potentiating or
inhibiting IGF action.
IGFBP-3 is a member of the family of IGFBPs. It has been reported that IGFBP-
3 carries most of the 90% of IGFs in circulation which is bound by IGFBPs (22).
Regulation of IGFBP3 gene expression is complex and tissue specific. GH, insulin, and
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insulin-like growth factors are hormones important in the regulation of IGFBP3
expression (21, 259, 278), as are agents that induce growth inhibition/apoptosis, such as
p53 (32), retinoic acid (86, 151), vitamin D (177), antiestrogens (104), antiandrogens
(178), transforming growth factor-β (86, 181), and tumor necrosis factor-α (232). Also, it
has been reported that IGFBP-3 levels are inversely associated with cigarette smoking
(117). In addition, it has been reported that African Americans have lower circulating
levels of IGFBP-3 than Caucasians (192, 272). As is the case with IGF-1, IGFBP-3
concentrations in the blood decline with age (115, 116, 293).
Because it is a major carrier of IGFs in circulation, IGFBP-3 appears to play an
important role in the growth of tissues in early development. However, the role of
IGFBP-3 in tissue growth in adults, especially in skeletal muscle, is not as clear. There is
evidence that IGFBP-3 is present in skeletal muscle and that it may be a modulator of the
autocrine/paracrine effect of IGFs expressed in skeletal muscle (4, 15, 249, 295). It has
also been shown that increased secretion of IGFBP-3 in a primary adult human skeletal
muscle cell model can be stimulated by IGF-1 (70).
IGFBP3 promoter region -202 polymorphism. The IGFBP3 gene, which encodes
for the IGFBP-3 protein, is highly conserved among species and is present on
chromosome 7p14-p12 (58). Twin studies have shown that about half of the intra-
individual variability in circulating IGFBP-3 levels is genetically determined (94). Deal
et al. (47) detected five polymorphic sites on the IGFBP3 gene, and identified the -202
locus in the promoter region of this gene as significantly influencing age-adjusted
circulating IGFBP-3 concentration. For this polymorphism, the wild-type adenine allele
is replaced with the variant cytosine allele with an allele frequency of 40% in those
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subjects tested. These investigators found that A homozygotes had higher levels of
circulating IGFBP-3 than AC heterozygotes who had higher circulating levels of IGFBP-
3 than C homozygotes. Also, these authors reported significantly higher promoter
activity for the A allele compared with the C allele in an in vitro study. This finding was
consistent with the relationship observed between genotype and circulating IGFBP-3 
levels. In addition, these investigators reported that body mass index (BMI) and height
interacted with the -202 polymorphism to influence circulating IGFBP-3 levels, such that
tall individuals or individuals with a BMI of 27 or greater had levels of circulating
IGFBP-3 that were significantly higher when they possessed at least one A allele.
Other studies that have investigated the influence of this polymorphism on cancer
risk have also shown that the A allele was associated with higher levels of IGFBP-3 (111,
210, 246). However, it was also reported that the -202 polymorphism interacted with
body size indicators, ethnicity, use of aspirin/NSAIDS (246), and oral contraceptive
status (111) to influence IGFBP-3 levels.
Physiology of calcineurin and its link with IGF-1. Calcineurin is a Ca2+/calmodulin-
dependent protein phosphatase, which plays a key role in mediating hypertrophic
response. Calcineurin consists of a 58- to 59-kD catalytic subunit, designated as
calcineurin A (CnA), and a 19-kD Ca2+-binding regulatory subunit, designated as
calcineurin B (281). There are 2 major isoforms, alpha and beta, of CnA encoded by
separate genes located on different human chromosomes. A third isoform, A-gamma, is
unique to the testis. Calcineurin B consists of only one isoform designated as alpha
isoform 1. Calcineurin is highly expressed in muscle tissue at levels ten times higher
than most other tissues. Calcineurin is activated by sustained increase in basal Ca2+
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concentration (44). Once activated, calcineurin dephosphorylates the nuclear factor of
activated T-cell (NFAT) families or members of other transcriptional factor families,
such as myocyte enhancer factor 2 (MEF2). These activated transcription factors
translocate to the nucleus and then play an important role in the subsequent
transcriptional activation of genes involved in hypertrophy (54, 55, 285) or genes which
influence other muscle phenotypes (39, 165, 174, 188).
The role that calcineurin plays in cardiac muscle appears to be more clear than the
role it plays in skeletal muscle. Several investigators have reported that calcineurin
stimulates cardiac hypertrophy (92, 166, 214). Molkentin et al. (166) reported that
transgenic mice overexpressing constitutively active calcineurin or NFAT3 develop
cardiac hypertrophy. Other investigators have reported increased calcineurin activity in
hearts of patients with different forms of hypertrophy including: iodiopathic
cardiomyopathy (92), aortic stenosis, and hypertrophic obstructive cardiomyopathy
(214).
The role of calcineurin in skeletal muscle is not as clear as its role in cardiac
muscle. There have been several reports which have suggested that calcineurin may play
a role in skeletal muscle hypertrophy (54, 55, 163, 172, 240, 257), while results from
other studies have suggested that calcineurin is involved in skeletal muscle fiber-type
conversion (39, 165, 174, 188, 241, 257). Still others have reported that calcineurin plays
a role in myogenic differentiation (50, 73, 74). In a transgenic mice study, Talmadge et
al. (257) reported that calcineurin activation can influence skeletal muscle phenotype
(fiber-type), and that the specific influence of calcineurin activation on the phenotypic
and mass characteristics of a muscle, is dependent upon the original phenotypic state of
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the muscle. Therefore, calcineurin appears to play some role in influencing skeletal
muscle phenotypes (mass and fiber type).
Several in vivo studies have supported a role for calcineurin activation in
promoting skeletal muscle growth. For example, Bigard et al. (23) reported that
inhibition of calcineurin with cyclosporine A (CsA) significantly reduced the growth of
both the slow/type I soleus muscle and fast/type II plantaris muscle in normal,
ambulatory rats (23). CsA also slowed the growth of mouse plantaris muscle during
overload hypertrophy (54) and reduced or prevented soleus and plantaris growth after a
period of unloading and atrophy (163). Similarly, overexpression of a muscle-specific,
constitutively active calcineurin caused an increase in soleus muscle, but produced a
decrease in plantaris muscle mass in ambulatory mice (257). Also Dunn et al. (55)
showed in mice that overload-induced hypertrophy and fast-to-slow contractile protein
transitions were prevented in muscle fibers expressing a peptide which bound
calcium/calmodulin complexes and inhibited their signaling to calmodulin-dependent
enzymes such as calcineurin.
In contrast to these results, some investigators have presented findings against a
role for calcineurin activation in promoting muscle growth. Serrano et al. (241) reported
that growth in soleus muscle fibers that were regenerating after injection with toxin was
not affected by the calcineurin activity inhibitors, CsA or FK506 (241). Other studies
reported that expression of a muscle-specific, constitutively active calcineurin had no
effect on muscle fiber size or mass in soleus or plantaris muscles (174), whereas, null-
mutant mice for the CnAα isoform showed an increase in fiber number in soleus muscle,
but no change in fiber size or number in plantaris muscle (187). To some extent, the
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apparent conflict in results as far as calcineurin’s role in promoting muscle growth may
be due to differences in dosing with calcineurin inhibitors (both amount as well as length
of dosing), where relatively small doses are ineffective at inhibiting muscle growth, as
discussed in a review article (160). Similar explanations concerning calcineurin dose
dependency may underlie differences in findings on calcineurin-overexpressing animals.
Other factors which may explain the discrepancy in results are differences in gender,
species, or even strain of animals tested, as well as differences in muscle type studied and
differences in the mechanism regulating the increase in muscle size depending on the
specific type (hypertrophy, maintenance, regeneration) or stimulus for muscle growth.
In a another study concerning the role of calcineurin in muscle growth,
researchers generated and analyzed null mutants and muscle-targeted, conditional
mutants for specific isoforms (188). One line targeted the ß-isoform of CnA and
produced a reduction of ~ 50% in total calcineurin activity in muscle. In a second line, a
conditional, muscle-specific null mutation of PPP3R1 (PPP3R11-LoxP(fl/fl)-MLC-cre
mice) produced a > 80% reduction in muscle calcineurin activity. Somatic deletion of
CnAβ resulted in a significant reduction in fiber number and muscle mass relative to
wild-type mice. However, for PPP3R11-LoxP(fl/fl)-MLC-cre mice there were no
differences in fiber number and muscle mass relative to wild-type mice. This difference
may be explained by the fact that CsA treatments would affect calcineurin activity in all
muscle cells at all stages of development, whereas activity of calcineurin in PPP3R11-
LoxP(fl/fl)-MLC-cre mice would be affected only in cells that express myosin light chain
1f. Because myosin light chain 1f expression is initiated after early stages of myogenic
cell proliferation and differentiation (148), early myogenic cells in the conditional
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mutants would be expected to express wild-type levels of calcineurin. Alternatively,
CnAβ mutants would be calcineurin deficient throughout myogenesis, which would lead
to a reduction in myogenic cells, and ultimately to a reduction in the number of muscle
fibers, based on evidence suggesting that calcineurin promotes myogenic cell
proliferation and early differentiation (73, 74).
Parsons et al. (188) reported that activation of muscle calcineurin may contribute
to muscle fiber growth in at least some muscles and under some experimental conditions.
After IGF-1 treatments, both CnAβ-null mutants and wild-type mice showed similar
increases in plantaris and soleus muscle mass. However, the significant increase in
plantaris muscle caused by IGF-1 treatment of wild-type mice was not observed in
PPP3R11-LoxP(fl/fl)-MLC-cre mice, although soleus muscle mass increase did occur.
This finding implicates the calcineurin that is expressed specifically in muscle in the
adaptive response to IGF-1 stimulation. However, an explanation for the lack of a similar
response in CnAβ mutants has yet to be established. However, the greater loss of
calcineurin activity in PPP3R11-LoxP(fl/fl)-MLC-cre mice than in CnAβ-null mutants
suggests that the differences may reflect the magnitudes of calcineurin activity.
Further insight into the role of calcineurin on muscle growth during overload may
be provided by comparisons of effects of different perturbations on calcineurin activity.
Dunn et al. (54) reported that growth of plantaris muscle during overload by synergist
ablation for 4 wk was reduced ~ 45% by CsA treatments, which decrease calcineurin
activity by 65% (57). Similarly, CnAβ-null mutants in which calcineurin activity was
reduced by ~50%, showed a 54% reduction in the increase in plantaris muscle mass
during 6 wk of overload (188). However, plantaris muscle in PPP3R11-LoxP(fl/fl)-
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MLC-cre mice, in which there was a > 80% reduction in muscle calcineurin activity,
experienced only a trend for a 21% reduction in muscle growth.
In addition to its possible role in influencing hypertrophy in response to overload,
studies have suggested that calcineurin plays a role in skeletal muscle differentiation.
Friday et al. (73) found that differentiation of skeletal muscle myoblasts was inhibited at
the first (commitment) stage by treatment with either CsA or expression of CAIN, a
physiological inhibitor of calcineurin. These authors concluded that myogenesis is
initiated by a calcineurin-dependent pathway. Also Delling et al. (50) concluded from
studies using both adenovirus-mediated gene transfer of activated calcineurin protein and
calcineurin inhibitory peptide (CAIN) that the IGF-calcineurin-NFATc3 pathway
enhances myogenic differentiation.
Still other investigators have provided results suggesting a role of calcineurin in
activating slow type I muscle fiber gene programs (23, 39, 54, 241). In PPP3R11-
LoxP(fl/fl)-MLC-cre mice experiencing overload, fiber switching to a slower phenotype
was impaired (188), and systemic null mutation of either calcineurin Aα or Aβ resulted in
a reduction in the proportion of slow/type I fibers in healthy, ambulatory mice (187).
Likewise, it has been reported that overexpression of calcineurin in skeletal muscle
produces a shift toward a slower phenotype (174, 257). This calcineurin-activated switch
to a slower phenotype may play an important role in the muscle phenotype responses to
strength training in adults due to observations from several investigators, that the
consequence of resistance training is a conversion of some fiber types from less to more
metabolically efficient, such as from type II d/x to IIa (56, 106, 129, 251, 252). Thus, if
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calcineurin does indeed play a role in fiber-type switching it could play a very important
role in the muscle phenotype responses to strength training.
Although its exact role in skeletal muscle is unclear, calcineurin does appear to
influence skeletal muscle phenotype response to muscle stimulation. Calcineurin may
activate different classes of transcription factors and co-activators (MEF2, GATA)
depending on the type of calcium signal (prolonged, low amplitude or high-amplitude) on
the muscle cell (182) to produce different responses (hypertrophy, fiber-type switching,
etc). One study has even shown that calcineurin may regulate satellite cell fusion during
muscle fiber hypertrophy via the NFATc2 transcription factor (100).
Reports have suggested that calcineurin is linked with IGF-1 in a mechanical
signaling pathway to influence skeletal muscle cell phenotypes (172, 240). Another
report also suggested an IGF-calcineurin-NFATc3 link for influencing myogenic
differentiation (50). Mechanical loading causes a rapid transient increase of IGF-1
release by muscle cells (190). The binding of IGF-1 to its receptor on muscle cells can
subsequently stimulate L-type calcium channel activity to increase cytosolic calcium
(48). Cytosolic calcium then binds to calmodulin, which then activates calcineurin.
Activated calcineurin dephosphorylates NFAT or other transcription factors resulting in
the translocation of transcription factors into the nucleus, where they bind to the
transcription factor response elements to enhance the expression of specific genes to
influence muscle phenotypes. In vitro studies in mice skeletal muscle cells showed that
the IGF-1-induced hypertrophy of these cells could be prevented by inhibition of
calcineurin activity (172, 240). Experimental manipulations that cause increased
mechanical loads on muscle have been shown to produce increases in muscle mass that
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can be attenuated by reductions in calcineurin activity (54, 163, 188). For example,
calcineurin inhibition during rat muscle overload, caused by synergist ablation,
significantly reduced the hypertrophic response of this muscle, and prevented the 20-fold
increase in the number of slow, myosin heavy chain-I-expressing fibers (slow/type I
fibers) that occurred in overloaded muscle, in which calcineurin was not inhibited (54).
Besides the IGF-1-calcineurin mechanical signaling pathway, there have been
reports of other IGF-1-stimulated signaling pathways that may play a role in skeletal
muscle hypertrophy, including the PI3K/Akt/mTOR pathway (186, 218, 241). Even
though it is likely that there are multiple pathways involved in the IGF-1-mediated
muscle phenotype response to ST, there appears to be sufficient evidence supporting an
important role for an IGF-1-calcineurin mechanical signaling pathway in skeletal muscle
phenotype responses to ST.
Calcineurin B promoter region 5-base pair insertion/deletion (I/D) polymorphism.
There have been few reports on the influence of polymorphisms of the calcineurin gene
and the genes encoding for its subunits on protein levels, activity level of calcineurin, and
other phenotypes. For example, Poirier et al. (194) investigated the influence of
calcineurin polymorphisms and polymorphisms of related genes on cardiac hypertrophy.
These authors reported that the nuclear factor NFATC4 gene, activated by calcineurin,
influenced the individual cardiac hypertrophic response. More specifically, a Gly/Ala
substitution at position 160 of the NFATC4 protein (G160A) was associated with left
ventricular mass and wall thickness (194). However, these authors did not report the
influence of any calcineurin polymorphisms on cardiac hypertrophy response.
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We are aware of only one report on any polymorphisms in genes encoding for
calcineurin or its subunits, which was for a polymorphism in the gene encoding for the
regulatory subunit of calcineurin, calcineurin B (258). The gene that encodes for
calcineurin B is located on human chromosome 2p16-p15 (281). This gene encodes for
calcineurin B in all tissues except the testis, and it is highly conserved at the level of both
protein and DNA sequences in eukaryotes.
Tang et al. (258) identified and investigated the influence of the 5-base pair (bp)
insertion/deletion (I/D) polymorphism in the promoter region of the calcineurin B
(PPP3R1) gene on traditional left ventricular hypertrophy and inappropriately high left
ventricular mass in severe hypertensive Caucasian and African American men and
women. These authors reported that this polymorphism influenced inappropriately high
left ventricular mass in severe hypertensives, with those individuals possessing a D allele
at increased risk for developing inappropriately high left ventricular mass. This 5-bp
deletion is predicted to eliminate a consensus Nkx-2 transcription binding sight and
disrupt an AseI restriction site (258). These authors suggest that the Nkx-2
transcriptional binding site serves as an important binding site for a repressor or inhibitor
of PPP3R1 transcription, and the 5-bp deletion in this region removes the inhibition and
consequently promotes the expression of PPP3R1, leading to increased calcineurin
activity. Due to the influence that this polymorphism may have on hypertrophy in
cardiac muscle, and the fact that cardiac and skeletal muscle share common hypertrophic
pathways (182), it is possible that this polymorphism may influence hypertrophic
responses to mechanical overload in skeletal muscle as well. However, we are unaware
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of any previous cross-sectional or strength training reports on the influence of calcineurin
gene polymorphisms on skeletal muscle phenotypes.
In conclusion, loss of muscle mass and function due to sarcopenia may result in
loss of independence, disability, and even mortality in the elderly. ST has been shown to
be the most effective intervention in the prevention and treatment of sarcopenia, however,
significant inter-individual variability exists in the muscle phenotype response to ST,
suggesting a genetic influence. A small number of candidate genes have been identified
which appear to influence muscle phenotype responses to ST, including IGF1. However,
IGF-1 is linked with several downstream proteins that influence muscle hypertrophy. At
present, no studies have reported the influence of more than one gene, which is part of a
pathway of genes involved in muscle hypertrophy, on muscle response to ST. Therefore,
the need exists to investigate gene polymorphisms linked in a common pathway to better
understand genetic influences on muscle phenotype responses to ST, in order to better
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